Quinoline derivatives and their use in neurodegenerative diseases

ABSTRACT

The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.

RELATED APPLICATION

This application claims the benefit of U.S. Provisional application62/008,012, filed on Jun. 5, 2014, the content of which is incorporatedby reference in its entirety.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to quinoline compounds useful asantagonists of P2X7. The invention also provides pharmaceuticallyacceptable compositions comprising compounds of the present inventionand methods of using said compositions in the treatment of variousdisorders.

BACKGROUND OF THE INVENTION

The P2X7 receptor is a ligand-gated ion channel that belongs to thePurinergic Receptor Family. The receptor is expressed on many cell typesrelated to the immune and nervous systems. In the nervous system P2X7 isexpressed on microglia, oligodendrocytes and astrocytes. Briefactivation of the P2X7 receptor channel with its endogenous ligand ATPleads to several downstream events including the processing and releaseof the proinflammatory cytokine IL1-β from monocytes and macrophages.P2X7 activation also plays an important role in regulating the glutamaterelease/uptake in astrocytes.

P2X7 receptors are ionotropic receptors activated by ATP, which mayregulate neurotransmission in the CNS by activating presynaptic and/orpostsynaptic P2X7 receptors on central and peripheral neurons and glia(Deuchars S. A. et al., J. Neurosci. 21:7143-7152, (2001), Kanjhan R. etal., J. Comp. Neurol. 407:11-32 (1997), Le K. T. et al., Neuroscience83:177-190 (1998)). Activation of the P2X7 receptor on cells of theimmune system (macrophages, mast cells and lymphocytes) leads to releaseof interleukin-1β (IL-1β), giant cell formation, degranulation, andL-selectin shedding. ATP is able to increase local release and processof IL-1 in rats through a P2X7 receptor mediated mechanism followinglipopolysaccharide (LPS) intraperitoneal injections (Griffiths et al.,J. Immunology Vol. 154, pages 2821-2828 (1995); Solle et al., J. Biol.Chemistry, Vol. 276, pages 125-132, (2001)).

Antagonism of the P2X7 receptor is considered to be an attractivetherapeutic approach for the treatment of multiple sclerosis andAlzheimer's disease, due to its significant role in dampening the CNSinflammation and supporting neuroprotection.

SUMMARY OF THE INVENTION

It has now been found that compounds of this invention, andpharmaceutically acceptable compositions thereof, are effective asantagonists of P2X7. Such compounds have general formula I:

or a pharmaceutically acceptable salt thereof, wherein each of Ring A,Z, R¹, R², m, and n, is as defined and described in embodiments herein.

Compounds of the present invention, and pharmaceutically acceptablecompositions thereof, are useful for treating a variety of diseases,disorders or conditions, associated with P2X7 activity. Such diseases,disorders, or conditions include those described herein.

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS 1. General Description ofCompounds of the Invention

In certain embodiments, the present invention provides antagonists ofP2X7. In some embodiments, such compounds include those of the formulaedescribed herein, or a pharmaceutically acceptable salt thereof, whereineach variable is as defined and described herein.

2. Compounds and Definitions

Compounds of this invention include those described generally above, andare further illustrated by the classes, subclasses, and speciesdisclosed herein. As used herein, the following definitions shall applyunless otherwise indicated. For purposes of this invention, the chemicalelements are identified in accordance with the Periodic Table of theElements, CAS version, Handbook of Chemistry and Physics, 75^(th) Ed.Additionally, general principles of organic chemistry are described in“Organic Chemistry”, Thomas Sorrell, University Science Books,Sausalito: 1999, and “March's Advanced Organic Chemistry”, 5^(th) Ed.,Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001, theentire contents of which are hereby incorporated by reference.

The term “aliphatic” or “aliphatic group”, as used herein, means astraight-chain (i.e., unbranched) or branched, substituted orunsubstituted hydrocarbon chain that is completely saturated or thatcontains one or more units of unsaturation, or a monocyclic hydrocarbonor bicyclic hydrocarbon that is completely saturated or that containsone or more units of unsaturation, but which is not aromatic (alsoreferred to herein as “carbocycle” “cycloaliphatic” or “cycloalkyl”),that has a single point of attachment to the rest of the molecule.Unless otherwise specified, aliphatic groups contain 1-6 aliphaticcarbon atoms. In some embodiments, aliphatic groups contain 1-5aliphatic carbon atoms. In other embodiments, aliphatic groups contain1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groupscontain 1-3 aliphatic carbon atoms, and in yet other embodiments,aliphatic groups contain 1-2 aliphatic carbon atoms. In someembodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refersto a monocyclic C₃-C₇ hydrocarbon that is completely saturated or thatcontains one or more units of unsaturation, but which is not aromatic,that has a single point of attachment to the rest of the molecule.Exemplary aliphatic groups are linear or branched, substituted orunsubstituted C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl groups andhybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or(cycloalkyl)alkenyl.

The term “lower alkyl” refers to a C₁₋₄ straight or branched alkylgroup. Exemplary lower alkyl groups are methyl, ethyl, propyl,isopropyl, butyl, isobutyl, and tert-butyl.

The term “lower haloalkyl” refers to a C₁₋₄ straight or branched alkylgroup that is substituted with one or more halogen atoms.

The term “heteroatom” means one or more of oxygen, sulfur, nitrogen, orphosphorus (including, any oxidized form of nitrogen, sulfur, orphosphorus; the quaternized form of any basic nitrogen or; asubstitutable nitrogen of a heterocyclic ring, for example N (as in3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR⁺ (as inN-substituted pyrrolidinyl)).

The term “unsaturated”, as used herein, means that a moiety has one ormore units of unsaturation.

As used herein, the term “bivalent C₁₋₈ (or C₁₋₆) saturated orunsaturated, straight or branched, hydrocarbon chain”, refers tobivalent alkylene, alkenylene, and alkynylene chains that are straightor branched as defined herein.

The term “alkylene” refers to a bivalent alkyl group. An “alkylenechain” is a polymethylene group, i.e., —(CH₂)_(n)—, wherein n is apositive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from1 to 2, or from 2 to 3. A substituted alkylene chain is a polymethylenegroup in which one or more methylene hydrogen atoms are replaced with asubstituent. Suitable substituents include those described below for asubstituted aliphatic group.

The term “alkenylene” refers to a bivalent alkenyl group. A substitutedalkenylene chain is a polymethylene group containing at least one doublebond in which one or more hydrogen atoms are replaced with asubstituent. Suitable substituents include those described below for asubstituted aliphatic group. The term “alkynylene” refers to a bivalentalkynyl group. A substituted alkynylene chain is a group containing atleast one triple bond in which one or more hydrogen atoms are replacedwith a substituent. Suitable substituents include those described belowfor a substituted aliphatic group.

The term “halogen” means F, Cl, Br, or I.

The term “aryl” used alone or as part of a larger moiety as in“aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic andbicyclic ring systems having a total of five to fourteen ring members,wherein at least one ring in the system is aromatic and wherein eachring in the system contains three to seven ring members. The term “aryl”is used interchangeably with the term “aryl ring”. In certainembodiments of the present invention, “aryl” refers to an aromatic ringsystem. Exemplary aryl groups are phenyl, biphenyl, naphthyl, anthracyland the like, which optionally includes one or more substituents. Alsoincluded within the scope of the term “aryl”, as it is used herein, is agroup in which an aromatic ring is fused to one or more non-aromaticrings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, ortetrahydronaphthyl, and the like.

The terms “heteroaryl” and “heteroar-”, used alone or as part of alarger moiety, e.g., “heteroaralkyl”, or “heteroaralkoxy”, refer togroups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms;having 6, 10, or 14 π electrons shared in a cyclic array; and having, inaddition to carbon atoms, from one to five heteroatoms. The term“heteroatom” refers to nitrogen, oxygen, or sulfur, and includes anyoxidized form of nitrogen or sulfur, and any quaternized form of a basicnitrogen. Heteroaryl groups include, without limitation, thienyl,furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl,thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl,purinyl, naphthyridinyl, and pteridinyl. The terms “heteroaryl” and“heteroar-”, as used herein, also include groups in which aheteroaromatic ring is fused to one or more aryl, cycloaliphatic, orheterocyclyl rings, where the radical or point of attachment is on theheteroaromatic ring. Nonlimiting examples include indolyl, isoindolyl,benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl,benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl,quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl,phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl,tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one. Aheteroaryl group is optionally mono- or bicyclic. The term “heteroaryl”is used interchangeably with the terms “heteroaryl ring”, “heteroarylgroup”, or “heteroaromatic”, any of which terms include rings that areoptionally substituted. The term “heteroaralkyl” refers to an alkylgroup substituted by a heteroaryl, wherein the alkyl and heteroarylportions independently are optionally substituted.

As used herein, the terms “heterocycle”, “heterocyclyl”, “heterocyclicradical”, and “heterocyclic ring” are used interchangeably and refer toa stable 5- to 7-membered monocyclic or 7-10-membered bicyclicheterocyclic moiety that is either saturated or partially unsaturated,and having, in addition to carbon atoms, one or more, preferably one tofour, heteroatoms, as defined above. When used in reference to a ringatom of a heterocycle, the term “nitrogen” includes a substitutednitrogen. As an example, in a saturated or partially unsaturated ringhaving 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, thenitrogen is N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl),or ⁺NR (as in N-substituted pyrrolidinyl).

A heterocyclic ring can be attached to its pendant group at anyheteroatom or carbon atom that results in a stable structure and any ofthe ring atoms can be optionally substituted. Examples of such saturatedor partially unsaturated heterocyclic radicals include, withoutlimitation, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiophenylpyrrolidinyl, piperidinyl, pyrrolinyl, morpholinyl,tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl,oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl,thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle”,“heterocyclyl”, “heterocyclyl ring”, “heterocyclic group”, “heterocyclicmoiety”, and “heterocyclic radical”, are used interchangeably herein,and also include groups in which a heterocyclyl ring is fused to one ormore aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl,3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, wherethe radical or point of attachment is on the heterocyclyl ring. Aheterocyclyl group is optionally mono- or bicyclic. The term“heterocyclylalkyl” refers to an alkyl group substituted by aheterocyclyl, wherein the alkyl and heterocyclyl portions independentlyare optionally substituted.

As used herein, the term “partially unsaturated” refers to a ring moietythat includes at least one double or triple bond. The term “partiallyunsaturated” is intended to encompass rings having multiple sites ofunsaturation, but is not intended to include aryl or heteroarylmoieties, as herein defined.

As described herein, certain compounds of the invention contain“optionally substituted” moieties. In general, the term “substituted”,whether preceded by the term “optionally” or not, means that one or morehydrogens of the designated moiety are replaced with a suitablesubstituent. “Substituted” applies to one or more hydrogens that areeither explicit or implicit from the structure

refers to at least

and

refers to at least

Unless otherwise indicated, an “optionally substituted” group has asuitable substituent at each substitutable position of the group, andwhen more than one position in any given structure is substituted withmore than one substituent selected from a specified group, thesubstituent is either the same or different at every position.Combinations of substituents envisioned by this invention are preferablythose that result in the formation of stable or chemically feasiblecompounds. The term “stable”, as used herein, refers to compounds thatare not substantially altered when subjected to conditions to allow fortheir production, detection, and, in certain embodiments, theirrecovery, purification, and use for one or more of the purposesdisclosed herein.

Suitable monovalent substituents on a substitutable carbon atom of an“optionally substituted” group are independently deuterium; halogen;—(CH₂)₀₋₄R^(◯); —(CH₂)₀₋₄OR^(◯); —O(CH₂)₀₋₄R^(◯), —O—(CH₂)₀₋₄C(O)OR^(◯);—(CH₂)₀₋₄CH(OR^(◯))₂; —(CH₂)₀₋₄SR; —(CH₂)₀₋₄Ph, which are optionallysubstituted with R^(◯); —(CH₂)₀₋₄O(CH₂)₀₋₁Ph which is optionallysubstituted with R^(◯); —CH═CHPh, which is optionally substituted withR^(◯); —(CH₂)₀₋₄O(CH₂)₀₋₁-pyridyl which is optionally substituted withR^(◯); —NO₂; —CN; —N₃; —(CH₂)₀₋₄N(R^(◯))₂; —(CH₂)₀₋₄N(R^(◯))C(O)R^(◯);—N(R^(◯))C(S)R^(◯); —(CH₂)₀₋₄N(R^(◯))C(O)NR^(◯) ₂; —N(R^(◯))C(S)NR^(◯)₂; —(CH₂)₀₋₄N(R^(◯))C(O)OR^(◯); —N(R^(◯))N(R^(◯))C(O)R^(◯);—N(R^(◯))N(R^(◯))C(O)NR^(◯) ₂; —N(R^(◯))N(R^(◯))C(O)OR^(◯);—(CH₂)₀₋₄C(O)R^(◯); —C(S)R^(◯); —(CH₂)₀₋₄C(O)OR^(◯);—(CH₂)₀₋₄C(O)SR^(◯); —(CH₂)₀₋₄C(O)OSiR^(◯) ₃; —(CH₂)₀₋₄C(O)R^(◯);—OC(O)(CH₂)₀₋₄SR^(◯), SC(S)SR^(◯); —(CH₂)₀₋₄SC(O)R^(◯);—(CH₂)₀₋₄C(O)NR^(◯) ₂; —C(S)NR^(◯) ₂; —C(S)SR^(◯); —SC(S)SR^(◯),—(CH₂)₀₋₄OC(O)NR^(◯) ₂; —C(O)N(OR^(◯))R^(◯); —C(O)C(O)R^(◯);—C(O)CH₂C(O)R^(◯); —C(NOR^(◯))R^(◯); —(CH₂)₀₋₄SSR^(◯);—(CH₂)₀₋₄S(O)₂R^(◯); —(CH₂)₀₋₄S(O)₂OR^(◯); —(CH₂)₀₋₄S(O)₂R^(◯);—S(O)₂NR^(◯) ₂; —(CH₂)₀₋₄S(O)R^(◯); —N(R^(◯))S(O)₂NR^(◯) ₂;—N(R^(◯))S(O)₂R^(◯); —N(OR^(◯))R^(◯); —C(NH)NR^(◯) ₂; —P(O)₂R^(◯);—P(O)R^(◯) ₂; —OP(O)R^(◯) ₂; —OP(O)(OR^(◯))₂; SiR^(◯) ₃; —(C₁₋₄ straightor branched alkylene)O—N(R^(◯))₂; or —(C₁₋₄ straight or branchedalkylene)C(O)O—N(R^(◯))₂, wherein each R^(◯) is optionally substitutedas defined below and is independently hydrogen, C₁₋₆ aliphatic, —CH₂Ph,—O(CH₂)₀₋₁Ph, —NH(CH₂)₀₋₁Ph, —CH₂-(5-6 membered heteroaryl ring), or a5-6-membered saturated, partially unsaturated, or aryl ring having 0-4heteroatoms independently selected from nitrogen, oxygen, or sulfur, or,notwithstanding the definition above, two independent occurrences ofR^(◯), taken together with their intervening atom(s), form a3-12-membered saturated, partially unsaturated, or aryl mono- orbicyclic ring having 0-4 heteroatoms independently selected fromnitrogen, oxygen, or sulfur, which is optionally substituted as definedbelow.

Suitable monovalent substituents on R^(◯) (or the ring formed by takingtwo independent occurrences of R^(◯) together with their interveningatoms), are independently deuterium, halogen, —(CH₂)₀₋₂R^(●),-(haloR^(●)), —(CH₂)₀₋₂OH, —(CH₂)₀₋₂OR^(●), —(CH₂)₀₋₂CH(OR^(●))₂;—O(haloR^(●)), —CN, —N₃, —(CH₂)₀₋₂C(O)R^(●), —(CH₂)₀₋₂C(O)OH,—(CH₂)₀₋₂C(O)OR^(●), —(CH₂)₀₋₂SR^(●), —(CH₂)₀₋₂SH, —(CH₂)₀₋₂NH₂,—(CH₂)₀₋₂NHR^(●), —(CH₂)₀₋₂NR^(●) ₂, —NO₂, —SiR^(●) ₃, —OSiR^(●) ₃,—C(O)SR^(●), —(C₁₋₄ straight or branched alkylene)C(O)OR^(●), or—SSR^(●) wherein each R^(●) is unsubstituted or where preceded by “halo”is substituted only with one or more halogens, and is independentlyselected from C₁₋₄ aliphatic, —CH₂Ph, —O(CH₂)₀₋₁Ph, or a 5-6-memberedsaturated, partially unsaturated, or aryl ring having 0-4 heteroatomsindependently selected from nitrogen, oxygen, or sulfur. Suitabledivalent substituents on a saturated carbon atom of R^(●) include ═O and═S.

Suitable divalent substituents on a saturated carbon atom of an“optionally substituted” group include the following: ═O, ═S, ═NNR*₂,═NNHC(O)R*, ═NNHC(O)OR*, ═NNHS(O)₂R*, ═NR*, ═NOR*, —O(C(R*₂))₂₋₃O—, or—S(C(R*₂))₂₋₃S—, wherein each independent occurrence of R* is selectedfrom hydrogen, C₁₋₆ aliphatic which is substituted as defined below, oran unsubstituted 5-6-membered saturated, partially unsaturated, or arylring having 0-4 heteroatoms independently selected from nitrogen,oxygen, or sulfur. Suitable divalent substituents that are bound tovicinal substitutable carbons of an “optionally substituted” groupinclude: —O(CR*₂)₂₋₃O—, wherein each independent occurrence of R* isselected from hydrogen, C₁₋₆ aliphatic which is optionally substitutedas defined below, or an unsubstituted 5-6-membered saturated, partiallyunsaturated, or aryl ring having 0-4 heteroatoms independently selectedfrom nitrogen, oxygen, or sulfur.

Suitable substituents on the aliphatic group of R* include halogen,—R^(●), -(haloR^(●)), —OH, —OR^(●), —O(haloR^(●)), —CN, —C(O)OH,—C(O)OR^(●), —NH₂, —NHR^(●), —NR^(●) ₂, or —NO₂, wherein each R^(●) isunsubstituted or where preceded by “halo” is substituted only with oneor more halogens, and is independently C₁₋₄ aliphatic, —CH₂Ph,—O(CH₂)₀₋₄Ph, or a 5-6-membered saturated, partially unsaturated, oraryl ring having 0-4 heteroatoms independently selected from nitrogen,oxygen, or sulfur.

Suitable substituents on a substitutable nitrogen of an “optionallysubstituted” group include —R^(†), —NR^(†) ₂, —C(O)R^(†), —C(O)OR^(†),—C(O)C(O)R^(†), —C(O)CH₂C(O)R^(†), —S(O)₂R^(†), —S(O)₂NR^(†) ₂,—C(S)NR^(†) ₂, —C(NH)NR^(†) ₂, or —N(R^(†))S(O)₂R^(†); wherein eachR^(†) is independently hydrogen, C₁₋₆ aliphatic which is optionallysubstituted as defined below, unsubstituted —OPh, or an unsubstituted5-6-membered saturated, partially unsaturated, or aryl ring having 0-4heteroatoms independently selected from nitrogen, oxygen, or sulfur, or,notwithstanding the definition above, two independent occurrences ofR^(†), taken together with their intervening atom(s) form anunsubstituted 3-12-membered saturated, partially unsaturated, or arylmono- or bicyclic ring having 0-4 heteroatoms independently selectedfrom nitrogen, oxygen, or sulfur.

Suitable substituents on the aliphatic group of R^(†) are independentlyhalogen, —R^(●), -(haloR^(●)), —OH, —OR^(●), —O(haloR^(●)), —CN,—C(O)OH, —C(O)OR^(●), —NH₂, —NHR^(●), —NR^(●) ₂, or —NO₂, wherein eachR^(●) is unsubstituted or where preceded by “halo” is substituted onlywith one or more halogens, and is independently C₁₋₄ aliphatic, —CH₂Ph,—O(CH₂)₀₋₄Ph, or a 5-6-membered saturated, partially unsaturated, oraryl ring having 0-4 heteroatoms independently selected from nitrogen,oxygen, or sulfur.

In certain embodiments, the terms “optionally substituted”, “optionallysubstituted alkyl,” “optionally substituted”, “optionally substitutedalkenyl,” “optionally substituted alkynyl”, “optionally substitutedcarbocyclic,” “optionally substituted aryl”, “optionally substitutedheteroaryl,” “optionally substituted heterocyclic,” and any otheroptionally substituted group as used herein, refer to groups that aresubstituted or unsubstituted by independent replacement of one, two, orthree or more of the hydrogen atoms thereon with typical substituentsincluding, but not limited to:

-   -   —F, —Cl, —Br, —I, deuterium,    -   —OH, protected hydroxy, alkoxy, oxo, thiooxo,    -   —NO₂, —CN, CF₃, N₃,    -   —NH₂, protected amino, —NH alkyl, —NH alkenyl, —NH alkynyl, —NH        cycloalkyl, —NH-aryl, —NH-heteroaryl, —NH-heterocyclic,        -dialkylamino, -diarylamino, -diheteroarylamino,    -   —O-alkyl, —O-alkenyl, —O-alkynyl, —O-cycloalkyl, —O-aryl,        —O-heteroaryl, —O-heterocyclic,    -   —C(O)-alkyl, —C(O)-alkenyl, —C(O)-alkynyl, —C(O)-carbocyclyl,        —C(O)-aryl, —C(O)-heteroaryl, —C(O)-heterocyclyl,    -   —CONH₂, —CONH-alkyl, —CONH-alkenyl, —CONH-alkynyl,        —CONH-carbocyclyl, —CONH-aryl, —CONH-heteroaryl,        —CONH-heterocyclyl,    -   —OCO₂-alkyl, —OCO₂-alkenyl, —OCO₂-alkynyl, —OCO₂-carbocyclyl,        —OCO₂-aryl, —OCO₂-heteroaryl, —OCO₂-heterocyclyl, —OCONH₂,        —OCONH-alkyl, —OCONH-alkenyl, —OCONH-alkynyl,        —OCONH-carbocyclyl, —OCONH-aryl, —OCONH-heteroaryl,        —OCONH-heterocyclyl,    -   —NHC(O)-alkyl, —NHC(O)-alkenyl, —NHC(O)-alkynyl,        —NHC(O)-carbocyclyl, —NHC(O)-aryl, —NHC(O)-heteroaryl,        —NHC(O)-heterocyclyl, —NHCO₂-alkyl, —NHCO₂-alkenyl,        —NHCO₂-alkynyl, —NHCO₂-carbocyclyl, —NHCO₂-aryl,        —NHCO₂-heteroaryl, —NHCO₂-heterocyclyl, —NHC(O)NH₂,        —NHC(O)NH-alkyl, —NHC(O)NH-alkenyl, —NHC(O)NH-alkenyl,        —NHC(O)NH-carbocyclyl, —NHC(O)NH-aryl, —NHC(O)NH-heteroaryl,        —NHC(O)NH-heterocyclyl, NHC(S)NH₂, —NHC(S)NH-alkyl,        —NHC(S)NH-alkenyl, —NHC(S)NH-alkynyl, —NHC(S)NH-carbocyclyl,        —NHC(S)NH-aryl, —NHC(S)NH-heteroaryl, —NHC(S)NH-heterocyclyl,        —NHC(NH)NH₂, —NHC(NH)NH-alkyl, —NHC(NH)NH-alkenyl,        —NHC(NH)NH-alkenyl, —NHC(NH)NH-carbocyclyl, —NHC(NH)NH-aryl,        —NHC(NH)NH-heteroaryl, —NHC(NH)NH-heterocyclyl, —NHC(NH)-alkyl,        —NHC(NH)-alkenyl, —NHC(NH)-alkenyl, —NHC(NH)-carbocyclyl,        —NHC(NH)-aryl, —NHC(NH)-heteroaryl, —NHC(NH)-heterocyclyl,    -   —C(NH)NH-alkyl, —C(NH)NH-alkenyl, —C(NH)NH-alkynyl,        —C(NH)NH-carbocyclyl, —C(NH)NH-aryl, —C(NH)NH-heteroaryl,        —C(NH)NH-heterocyclyl,    -   —S(O)-alkyl, —S(O)-alkenyl, —S(O)-alkynyl, —S(O)-carbocyclyl,        —S(O)-aryl, —S(O)-heteroaryl, —S(O)-heterocyclyl —SO₂NH₂,        —SO₂NH-alkyl, —SO₂NH-alkenyl, —SO₂NH-alkynyl,        —SO₂NH-carbocyclyl, —SO₂NH-aryl, —SO₂NH-heteroaryl,        —SO₂NH-heterocyclyl,    -   —NHSO₂-alkyl, —NHSO₂-alkenyl, —NHSO₂-alkynyl,        —NHSO₂-carbocyclyl, —NHSO₂-aryl, —NHSO₂-heteroaryl,        —NHSO₂-heterocyclyl,    -   —CH₂NH₂, —CH₂SO₂CH₃,    -   -mono-, di-, or tri-alkyl silyl,    -   -alkyl, -alkenyl, -alkynyl, -aryl, -arylalkyl, -heteroaryl,        -heteroarylalkyl, heterocycloalkyl, -cycloalkyl, -carbocyclic,        -heterocyclic, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy,        -methoxyethoxy, —SH, —S-alkyl, —S-alkenyl, —S-alkynyl,        —S-carbocyclyl, —S-aryl, —S-heteroaryl, —S-heterocyclyl, or        methylthiomethyl.

As used herein, the term “pharmaceutically acceptable salt” refers tothose salts which are, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response and the like, andare commensurate with a reasonable benefit/risk ratio. Pharmaceuticallyacceptable salts are well known in the art. For example, S. M. Berge etal., describe pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein byreference. Pharmaceutically acceptable salts of the compounds of thisinvention include those derived from suitable inorganic and organicacids and bases. Examples of pharmaceutically acceptable, nontoxic acidaddition salts are salts of an amino group formed with inorganic acidssuch as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuricacid and perchloric acid or with organic acids such as acetic acid,oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid ormalonic acid or by using other methods used in the art such as ionexchange. Other pharmaceutically acceptable salts include adipate,alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate,borate, butyrate, camphorate, camphorsulfonate, citrate,cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,formate, fumarate, glucoheptonate, glycerophosphate, gluconate,hemisulfate, heptanoate, hexanoate, hydroiodide,2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, laurylsulfate, malate, maleate, malonate, methanesulfonate,2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate,pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate,propionate, stearate, succinate, sulfate, tartrate, thiocyanate,p-toluenesulfonate, undecanoate, valerate salts, and the like.

Salts derived from appropriate bases include alkali metal, alkalineearth metal, ammonium and N⁺(C₁₋₄alkyl)₄ salts. Representative alkali oralkaline earth metal salts include sodium, lithium, potassium, calcium,magnesium, and the like. Further pharmaceutically acceptable saltsinclude, when appropriate, nontoxic ammonium, quaternary ammonium, andamine cations formed using counterions such as halide, hydroxide,carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and arylsulfonate.

Unless otherwise stated, structures depicted herein are also meant toinclude all isomeric (e.g., enantiomeric, diastereomeric, tautomers, andgeometric (or conformational)) forms of the structure; for example, theR and S configurations for each asymmetric center, Z and E double bondisomers, and Z and E conformational isomers. Therefore, singlestereochemical isomers as well as enantiomeric, diastereomeric, andgeometric (or conformational) mixtures of the present compounds arewithin the scope of the invention. Unless otherwise stated, alltautomeric forms of the compounds of the invention are within the scopeof the invention.

Additionally, unless otherwise stated, structures depicted herein arealso meant to include compounds that differ only in the presence of oneor more isotopically enriched atoms. For example, compounds having thepresent structures including the replacement of hydrogen by deuterium ortritium, or the replacement of a carbon by a ¹³C- or ¹⁴C-enriched carbonare within the scope of this invention. In some embodiments, the groupcomprises one or more deuterium atoms.

There is furthermore intended that a compound of the formula I includesisotope-labeled forms thereof. An isotope-labeled form of a compound ofthe formula I is identical to this compound apart from the fact that oneor more atoms of the compound have been replaced by an atom or atomshaving an atomic mass or mass number which differs from the atomic massor mass number of the atom which usually occurs naturally. Examples ofisotopes which are readily commercially available and which can beincorporated into a compound of the formula I by well-known methodsinclude isotopes of hydrogen, carbon, nitrogen, oxygen, phos-phorus,fluo-rine and chlorine, for example ²H, ³H, ¹³C, ¹⁴C, ¹⁵N, 180, 170,³¹P, ³²P, ³⁵S, ¹⁸F and ³⁶Cl, respectively. A compound of the formula I,a prodrug, thereof or a pharmaceutically acceptable salt of either whichcontains one or more of the above-mentioned isotopes and/or otherisotopes of other atoms is intended to be part of the present invention.An isotope-labeled compound of the formula I can be used in a number ofbeneficial ways. For example, an isotope-labeled compound of the formulaI into which, for example, a radioisotope, such as ³H or ¹⁴C, has beenincorporated, is suitable for medicament and/or substrate tissuedistribution assays. These radioisotopes, i.e. tritium (³H) andcarbon-14 (¹⁴C), are particularly preferred owing to simple preparationand excellent detectability. Incorporation of heavier isotopes, forexample deuterium (²H), into a compound of the formula I has therapeuticadvantages owing to the higher metabolic stability of thisisotope-labeled compound. Higher metabolic stability translates directlyinto an increased in vivo half-life or lower dosages, which under mostcircumstances would represent a preferred embodiment of the presentinvention. An isotope-labeled compound of the formula I can usually beprepared by carrying out the procedures disclosed in the synthesisschemes and the related description, in the example part and in thepreparation part in the present text, replacing a non-isotope-labeledreactant by a readily available isotope-labeled reactant. Compounds ofthe invention may be substituted by ¹⁸F, for use as PET imaging agents.

Deuterium (²H) can also be incorporated into a compound of the formula Ifor the purpose in order to manipulate the oxidative metabolism of thecompound by way of the primary kinetic isotope effect. The primarykinetic isotope effect is a change of the rate for a chemical reactionthat results from exchange of isotopic nuclei, which in turn is causedby the change in ground state energies necessary for covalent bondformation after this isotopic exchange. Exchange of a heavier isotopeusually results in a lowering of the ground state energy for a chemicalbond and thus causes a reduction in the rate in rate-limiting bondbreakage. If the bond breakage occurs in or in the vicinity of asaddle-point region along the coordinate of a multi-product reaction,the product distribution ratios can be altered substantially. Forexplanation: if deuterium is bonded to a carbon atom at anon-exchangeable position, rate differences of k_(M)/k_(D)=2-7 aretypical. If this rate difference is successfully applied to a corn-poundof the formula I that is susceptible to oxidation, the profile of thiscompound in vivo can be drastically modified and result in improvedpharmacokinetic properties.

When discovering and developing therapeutic agents, the person skilledin the art is able to optimize pharmacokinetic parameters whileretaining desirable in vitro properties. It is reasonable to assume thatmany compounds with poor pharmacokinetic profiles are susceptible tooxidative metabolism. In vitro liver microsomal assays currentlyavailable provide valuable information on the course of oxidativemetabolism of this type, which in turn permits the rational design ofdeuterated compounds of the formula I with improved stability throughresistance to such oxidative metabolism. Significant improvements in thepharmacokinetic profiles of compounds of the formula I are therebyobtained, and can be expressed quantitatively in terms of increases inthe in vivo half-life (t/2), concen-tra-tion at maximum therapeuticeffect (C_(max)), area under the dose response curve (AUC), and F; andin terms of reduced clearance, dose and materials costs.

The following is intended to illustrate the above: a compound of theformula I which has multiple potential sites of attack for oxidativemetabolism, for example benzylic hydrogen atoms and hydrogen atomsbonded to a nitrogen atom, is prepared as a series of analogues in whichvarious combinations of hydrogen atoms are replaced by deuterium atoms,so that some, most or all of these hydrogen atoms have been replaced bydeuterium atoms. Half-life determinations enable favorable and accuratedetermination of the extent of the extent to which the improvement inresistance to oxidative metabolism has improved. In this way, it isdetermined that the half-life of the parent compound can be extended byup to 100% as the result of deuterium-hydrogen exchange of this type.

Deuterium-hydrogen exchange in a compound of the formula I can also beused to achieve a favorable modification of the metabolite spectrum ofthe starting compound in order to diminish or eliminate undesired toxicmetabolites. For example, if a toxic metabolite arises through oxidativecarbon-hydrogen (C—H) bond cleavage, it can reasonably be assumed thatthe deuterated analogue will greatly diminish or eliminate production ofthe unwanted metabolite, even if the particular oxidation is not arate-determining step. Further information on the state of the art withrespect to deuterium-hydrogen exchange may be found, for example inHanzlik et al., J. Org. Chem. 55, 3992-3997, 1990, Reider et al., J.Org. Chem. 52, 3326-3334, 1987, Foster, Adv. Drug Res. 14, 1-40, 1985,Gillette et al, Biochemistry 33(10) 2927-2937, 1994, and Jarman et al.Carcinogenesis 16(4), 683-688, 1993.

As used herein, the term “modulator” is defined as a compound that bindsto and/or inhibits the target with measurable affinity. In certainembodiments, a modulator has an IC₅₀ and/or binding constant of lessabout 50 μM. In certain embodiments, a modulator has an IC₅₀ and/orbinding constant of less than about 5 μM. In certain embodiments, amodulator has an IC₅₀ and/or binding constant of between about 1 toabout 5 μM. In certain embodiments, a modulator has an IC₅₀ and/orbinding constant of less than about 1 μM. In certain embodiments, amodulator has an IC₅₀ and/or binding constant of between about 500 toabout 1000 nM. In certain embodiments, a modulator has an IC₅₀ and/orbinding constant of less than about 500 nM. In certain embodiments, amodulator has an IC₅₀ and/or binding constant of between about 100 toabout 500 nM. In certain embodiments, a modulator has an IC₅₀ and/orbinding constant of less than about 100 nM. In certain embodiments, amodulator has an IC₅₀ and/or binding constant of between about 10 toabout 100 nM. In certain embodiments, a modulator has an IC₅₀ and/orbinding constant of less than about 10 nM.

The terms “measurable affinity” and “measurably inhibit,” as usedherein, means a measurable change in P2X7 activity between a samplecomprising a compound of the present invention, or composition thereof,and P2X7, and an equivalent sample comprising P2X7, in the absence ofsaid compound, or composition thereof.

Combinations of substituents and variables envisioned by this inventionare only those that result in the formation of stable compounds. Theterm “stable”, as used herein, refers to compounds which possessstability sufficient to allow manufacture and which maintains theintegrity of the compound for a sufficient period of time to be usefulfor the purposes detailed herein (e.g., therapeutic or prophylacticadministration to a subject).

The recitation of a listing of chemical groups in any definition of avariable herein includes definitions of that variable as any singlegroup or combination of listed groups. The recitation of an embodimentfor a variable herein includes that embodiment as any single embodimentor in combination with any other embodiments or portions thereof.

3. Description of Exemplary Compounds

According to one aspect, the present invention provides a compound offormula I,

or a pharmaceutically acceptable salt thereof, wherein:

-   R¹ is hydrogen, C₁ 6 aliphatic, C₅ 10 aryl, a 3-8 membered saturated    or partially unsaturated carbocyclic ring, a 3-7 membered    heterocylic ring having 1-4 heteroatoms independently selected from    nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaryl    ring having 1-4 heteroatoms independently selected from nitrogen,    oxygen, or sulfur, a fused 7-10 membered bicyclic saturated,    partially unsaturated ring, aryl, or heteroaryl ring; each of which    is optionally substituted by 1-5 of R^(A); or R¹ is —OR, —SR, —CN,    —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂, —NRC(O)R,    —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂;-   each R^(A) is independently —R, halogen, -haloalkyl, -hydroxyalkyl,    —OR, —SR, —CN, —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂,    —NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂;-   wherein when R¹ is a 3-7 membered heterocylic ring having 1-4    nitrogen, wherein one nitrogen is attached to the quinoline ring,    then R^(A) is —R, halogen, -haloalkyl, -hydroxyalkyl, —SR, —CN,    —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂, —NRC(O)R,    —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂;-   wherein when R¹ is a 3-7 membered heterocylic ring having 1-4    nitrogen, wherein one nitrogen is attached to the quinoline ring,    and R^(A) is —OR, then at least one R² is halogen;-   Z is O, S, SO₂, SO, C(O), CO₂, C(O)N(R), NRC(O), NRC(O)N(R), NRSO₂,    or N(R);-   Ring A is a 3-8 membered saturated or partially unsaturated    carbocyclic ring, or a 3-7 membered heterocylic ring having 1-4    heteroatoms independently selected from nitrogen, oxygen, or sulfur;-   each R² is independently —R, halogen, -haloalkyl, —OR, —SR, —CN,    —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂, —NRC(O)R,    —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂; or two R² groups on the same atom    are taken together with the atom to which they are attached to form    a C₃₋₁₀ aryl, a 3-8 membered saturated or partially unsaturated    carbocyclic ring, a 3-7 membered heterocylic ring having 1-4    heteroatoms independently selected from nitrogen, oxygen, or sulfur,    or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms    independently selected from nitrogen, oxygen, or sulfur; each of    which is optionally substituted;-   each R is independently hydrogen, C₁₋₆ aliphatic, C₃₋₁₀ aryl, a 3-8    membered saturated or partially unsaturated carbocyclic ring, a 3-7    membered heterocylic ring having 1-4 heteroatoms independently    selected from nitrogen, oxygen, or sulfur, or a 5-6 membered    monocyclic heteroaryl ring having 1-4 heteroatoms independently    selected from nitrogen, oxygen, or sulfur; each of which is    optionally substituted; or-   two R groups on the same atom are taken together with the atom to    which they are attached to form a C₃₋₁₀ aryl, a 3-8 membered    saturated or partially unsaturated carbocyclic ring, a 3-7 membered    heterocylic ring having 1-4 heteroatoms independently selected from    nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl    ring having 1-4 heteroatoms independently selected from nitrogen,    oxygen, or sulfur; each of which is optionally substituted;-   m is 0, 1, or 2; and-   n is 1, 2, 3, 4, or 5;-   wherein, at least one of R^(A) or R² is halogen or haloalkyl, or at    least one R² is —OR; and-   wherein, the following compounds are excluded:-   6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide;-   6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3R)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide;-   6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-(4-hydroxypiperidin-1-yl]quinoline-5-carboxamide;    and-   6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-(3-hydroxy-3-methylpyrrolidin-1-yl]quinoline-5-carboxamide.

In certain embodiments, at least one of R^(A) or R² is halogen. Incertain embodiments, at least one of R^(A) or R² is F. In certainembodiments, at least one of R² is OH.

In certain embodiments, R¹ is hydrogen.

In certain embodiments, R¹ is C₁₋₆ aliphatic which is optionallysubstituted by 1-5 of R^(A). In certain embodiments, R¹ is C₁₋₆ alkyl.In certain embodiments, R¹ is C₁₋₆ alkenyl. In certain embodiments, R¹is C₁₋₆ alkynyl.

In certain embodiments, R¹ is methyl, ethyl, n-propyl, i-propyl,n-butyl, s-butyl, t-butyl, straight chain or branched pentyl, straightchain or branched hexyl, each of which is optionally substituted by 1-5of R^(A). In certain embodiments, R¹ is ethenyl, n-propenyl, i-propenyl,n-butenyl, s-butenyl, t-butenyl, straight chain or branched pentenyl,straight chain or branched hexenyl, each of which is optionallysubstituted by 1-5 of R^(A). In certain embodiments, R¹ is ethynyl,n-propynyl, i-propynyl, n-butynyl, s-butynyl, t-butynyl, straight chainor branched pentynyl, straight chain or branched hexynyl, each of whichis optionally substituted by 1-5 of R^(A).

In certain embodiments, R¹ is

In certain embodiments, R¹ is C₅₋₁₀ aryl, a 3-8 membered saturated orpartially unsaturated carbocyclic ring, a 3-7 membered heterocylic ringhaving 1-4 heteroatoms independently selected from nitrogen, oxygen, orsulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatomsindependently selected from nitrogen, oxygen, or sulfur, a fused 7-10membered bicyclic saturated, partially unsaturated ring, aryl, orheteroaryl ring; each of which is optionally substituted by 1-5 ofR^(A).

In certain embodiments, R¹ is phenyl, naphthyl, cyclopropyl, cyclobutyl,cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl,[3.3.0]bicyclooctanyl, [4.3.0]bicyclononanyl, [4.4.0]bicyclodecanyl,[2.2.2]bicyclooctanyl, fluorenyl, indanyl, tetrahydronaphthyl,acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl,benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl,benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl,carbazolyl, NH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl,decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl,dihydrofuro[2,3-b]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl,imidazolinyl, imidazolyl, 1H-indazolyl, indolenyl, indolinyl,indolizinyl, indolyl, 3H-indolyl, isoindolinyl, isoindolenyl,isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl,isoquinolinyl, isothiazolyl, isoxazolyl, morpholinyl, naphthyridinyl,octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl,1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl,oxazolyl, oxazolidinyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl,phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl,piperazinyl, piperidinyl, pteridinyl, purinyl, pyranyl, pyrazinyl,pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridooxazole,pyridoimidazole, pyridothiazole, pyridinyl, pyridyl, pyrimidinyl,pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, quinazolinyl,quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl,tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl,6H-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl,1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl,thienyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl,triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl,1,3,4-triazolyl, oxetanyl, azetidinyl, or xanthenyl; each of which isoptionally substituted by 1-5 of R^(A).

In certain embodiments, R¹ is

In certain embodiments, R¹ is

In certain embodiments, R¹ is —OR, —SR, —CN, —NO₂, —SO₂R, —SOR, —C(O)R,—CO₂R, —C(O)N(R)₂, —NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂. Incertain embodiments, R¹ is —OR, —SR, —SO₂R, —SOR, —NRC(O)R,—NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂. In certain embodiments, R¹ is—NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂.

In certain embodiments, R¹ is —N(R)₂.

In certain embodiments, R¹ is

In certain embodiments, R¹ is —OR.

In certain embodiments, R¹ is

In certain embodiments, each R^(A) is independently H.

In certain embodiments, each R^(A) is independently —R, halogen,-haloalkyl, —OR, —SR, —CN, —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂,—NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂.

In certain embodiments, each R^(A) is independently

In certain embodiments, Z is C(O), CO₂, C(O)N(R), NRC(O), NRC(O)N(R),NRSO₂, or N(R). In certain embodiments, Z is C(O), CO₂, or C(O)N(R).

In certain embodiments, Z is C(O).

In certain embodiments, Z is CO₂.

In certain embodiments, Z is C(O)N(R).

In certain embodiments, Z is C(O)NH.

In certain embodiments, Ring A is a 3-8 membered saturated or partiallyunsaturated carbocyclic ring. In certain embodiments, Ring A is a 3-7membered heterocylic ring having 1-4 heteroatoms independently selectedfrom nitrogen, oxygen, or sulfur.

In certain embodiments, Ring A is cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cycloheptyl, morpholinyl, piperazinyl, piperidinyl,pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl,oxetanyl, or azetidinyl.

In certain embodiments, Ring A is cyclohexyl. In certain embodiments,Ring A is cycloheptyl.

In certain embodiments, Ring A is

In certain embodiments, each R² is independently H.

In certain embodiments, each R² is independently —R, halogen, or —OR. Incertain embodiments, each R² is independently C₁₋₆ aliphatic, halogen,or —OR. In certain embodiments, each R² is independently methyl, ethyl,n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, straight chain orbranched pentyl, straight chain or branched hexyl, F, Cl, Br, I, CF₃, orOH.

In certain embodiments, each R² is independently methyl, F, CF₃, or OH.

In certain embodiments, two R² groups on the same atom are takentogether with the atom to which they are attached to form a C₃₋₁₀ aryl,a 3-8 membered saturated or partially unsaturated carbocyclic ring, a3-7 membered heterocylic ring having 1-4 heteroatoms independentlyselected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclicheteroaryl ring having 1-4 heteroatoms independently selected fromnitrogen, oxygen, or sulfur; each of which is optionally substituted.

In certain embodiments, the two R² groups on the same atom are takentogether with the atom to which they are attached to form a cyclopropyl,cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl ring.

In certain embodiments, m is 0. In certain embodiments, m is 1. Incertain embodiments, m is 2.

In certain embodiments, each of R¹, R², R^(A), Z, ring A, m, and n, isas defined above and described in embodiments, classes and subclassesabove and herein, singly or in combination.

In certain embodiments, the present invention provides a compound offormula II,

or a pharmaceutically acceptable salt thereof, wherein each of R¹, R²,Z, m, and n is as defined above and described in embodiments, classesand subclasses above and herein, singly or in combination.

In certain embodiments, the present invention provides a compound offormula III:

or a pharmaceutically acceptable salt thereof, wherein each of R¹, R²,and n, is as defined above and described in embodiments, classes andsubclasses above and herein, singly or in combination.

In certain embodiments, the present invention provides a compound offormula IV:

or a pharmaceutically acceptable salt thereof, wherein each of R¹, R²,and n, is as defined above and described in embodiments, classes andsubclasses above and herein, singly or in combination.

In certain embodiments, the present invention provides a compound offormula V:

or a pharmaceutically acceptable salt thereof, wherein each of R¹, R²,and n, is as defined above and described in embodiments, classes andsubclasses above and herein, singly or in combination.

In certain embodiments, the invention provides a compound selected fromTable 1:

TABLE 1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

In some embodiments, the present invention provides a compound selectedfrom those depicted above, or a pharmaceutically acceptable saltthereof.

Various structural depictions may show a heteroatom without an attachedgroup, radical, charge, or counterion. Those of ordinary skill in theart are aware that such depictions are meant to indicate that theheteroatom is attached to hydrogen

is understood to be

In certain embodiments, the compounds of the invention were synthesizedin accordance with Schemes below. More specific examples of compoundsmade utilizing the Schemes are provided in the Examples below.

4. Uses, Formulation and Administration

Pharmaceutically Acceptable Compositions

According to another embodiment, the invention provides a compositioncomprising a compound of this invention or a pharmaceutically acceptablederivative thereof and a pharmaceutically acceptable carrier, adjuvant,or vehicle. The amount of compound in compositions of this invention issuch that is effective to measurably modulate P2X7 in a biologicalsample or in a patient. In certain embodiments, the amount of compoundin compositions of this invention is such that is effective tomeasurably modulate P2X7 in a biological sample or in a patient. Incertain embodiments, a composition of this invention is formulated foradministration to a patient in need of such composition.

The term “patient” or “subject”, as used herein, means an animal,preferably a mammal, and most preferably a human.

The term “pharmaceutically acceptable carrier, adjuvant, or vehicle”refers to a non-toxic carrier, adjuvant, or vehicle that does notdestroy the pharmacological activity of the compound with which it isformulated. Pharmaceutically acceptable carriers, adjuvants or vehiclesthat are used in the compositions of this invention include, but are notlimited to, ion exchangers, alumina, aluminum stearate, lecithin, serumproteins, such as human serum albumin, buffer substances such asphosphates, glycine, sorbic acid, potassium sorbate, partial glyceridemixtures of saturated vegetable fatty acids, water, salts orelectrolytes, such as protamine sulfate, disodium hydrogen phosphate,potassium hydrogen phosphate, sodium chloride, zinc salts, colloidalsilica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-basedsubstances, polyethylene glycol, sodium carboxymethylcellulose,polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers,polyethylene glycol and wool fat.

A “pharmaceutically acceptable derivative” means any non-toxic salt,ester, salt of an ester or other derivative of a compound of thisinvention that, upon administration to a recipient, is capable ofproviding, either directly or indirectly, a compound of this inventionor an inhibitorily active metabolite or residue thereof.

Compositions of the present invention are administered orally,parenterally, by inhalation spray, topically, rectally, nasally,buccally, vaginally or via an implanted reservoir. The term “parenteral”as used herein includes subcutaneous, intravenous, intramuscular,intra-articular, intra-synovial, intrasternal, intrathecal,intrahepatic, intralesional and intracranial injection or infusiontechniques. Preferably, the compositions are administered orally,intraperitoneally or intravenously. Sterile injectable forms of thecompositions of this invention include aqueous or oleaginous suspension.These suspensions are formulated according to techniques known in theart using suitable dispersing or wetting agents and suspending agents.The sterile injectable preparation is also be a sterile injectablesolution or suspension in a non-toxic parenterally acceptable diluent orsolvent, for example as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that are employed are water, Ringer'ssolution and isotonic sodium chloride solution. In addition, sterile,fixed oils are conventionally employed as a solvent or suspendingmedium.

For this purpose, any bland fixed oil employed includes synthetic mono-or diglycerides. Fatty acids, such as oleic acid and its glyceridederivatives are useful in the preparation of injectables, as are naturalpharmaceutically-acceptable oils, such as olive oil or castor oil,especially in their polyoxyethylated versions. These oil solutions orsuspensions also contain a long-chain alcohol diluent or dispersant,such as carboxymethyl cellulose or similar dispersing agents that arecommonly used in the formulation of pharmaceutically acceptable dosageforms including emulsions and suspensions. Other commonly usedsurfactants, such as Tweens, Spans and other emulsifying agents orbioavailability enhancers which are commonly used in the manufacture ofpharmaceutically acceptable solid, liquid, or other dosage forms arealso be used for the purposes of formulation.

Pharmaceutically acceptable compositions of this invention are orallyadministered in any orally acceptable dosage form. Exemplary oral dosageforms are capsules, tablets, aqueous suspensions or solutions. In thecase of tablets for oral use, carriers commonly used include lactose andcorn starch. Lubricating agents, such as magnesium stearate, are alsotypically added. For oral administration in a capsule form, usefuldiluents include lactose and dried cornstarch. When aqueous suspensionsare required for oral use, the active ingredient is combined withemulsifying and suspending agents. If desired, certain sweetening,flavoring or coloring agents are optionally also added.

Alternatively, pharmaceutically acceptable compositions of thisinvention are administered in the form of suppositories for rectaladministration. These can be prepared by mixing the agent with asuitable non-irritating excipient that is solid at room temperature butliquid at rectal temperature and therefore will melt in the rectum torelease the drug. Such materials include cocoa butter, beeswax andpolyethylene glycols.

Pharmaceutically acceptable compositions of this invention are alsoadministered topically, especially when the target of treatment includesareas or organs readily accessible by topical application, includingdiseases of the eye, the skin, or the lower intestinal tract. Suitabletopical formulations are readily prepared for each of these areas ororgans.

Topical application for the lower intestinal tract can be effected in arectal suppository formulation (see above) or in a suitable enemaformulation. Topically-transdermal patches are also used.

For topical applications, provided pharmaceutically acceptablecompositions are formulated in a suitable ointment containing the activecomponent suspended or dissolved in one or more carriers. Exemplarycarriers for topical administration of compounds of this are mineraloil, liquid petrolatum, white petrolatum, propylene glycol,polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.Alternatively, provided pharmaceutically acceptable compositions can beformulated in a suitable lotion or cream containing the activecomponents suspended or dissolved in one or more pharmaceuticallyacceptable carriers. Suitable carriers include, but are not limited to,mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax,cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

Pharmaceutically acceptable compositions of this invention areoptionally administered by nasal aerosol or inhalation. Suchcompositions are prepared according to techniques well-known in the artof pharmaceutical formulation and are prepared as solutions in saline,employing benzyl alcohol or other suitable preservatives, absorptionpromoters to enhance bioavailability, fluorocarbons, and/or otherconventional solubilizing or dispersing agents.

Most preferably, pharmaceutically acceptable compositions of thisinvention are formulated for oral administration. Such formulations maybe administered with or without food. In some embodiments,pharmaceutically acceptable compositions of this invention areadministered without food. In other embodiments, pharmaceuticallyacceptable compositions of this invention are administered with food.

The amount of compounds of the present invention that are optionallycombined with the carrier materials to produce a composition in a singledosage form will vary depending upon the host treated, the particularmode of administration. Preferably, provided compositions should beformulated so that a dosage of between 0.01-100 mg/kg body weight/day ofthe compound can be administered to a patient receiving thesecompositions.

It should also be understood that a specific dosage and treatmentregimen for any particular patient will depend upon a variety offactors, including the activity of the specific compound employed, theage, body weight, general health, sex, diet, time of administration,rate of excretion, drug combination, and the judgment of the treatingphysician and the severity of the particular disease being treated. Theamount of a compound of the present invention in the composition willalso depend upon the particular compound in the composition.

Uses of Compounds and Pharmaceutically Acceptable Compositions

In certain embodiments, the invention provides a method for antagonizingP2X7 in a positive manner in a patient or in a biological samplecomprising the step of administering to said patient or contacting saidbiological sample with a compound according to the invention.

In certain embodiments, the invention is directed to the use ofcompounds of the invention and/or physiologically acceptable saltsthereof, for antagonizing P2X7. The compounds are characterized by sucha high affinity to P2X7, which ensures a reliable binding and preferablyantagonization of P2X7. In certain embodiments, the substances aremono-specific in order to guarantee an exclusive and directedrecognition with the single P2X7 target. In the context of the presentinvention, the term “recognition”—without being limited thereto—relatesto any type of interaction between the specific compounds and thetarget, particularly covalent or non-covalent binding or association,such as a covalent bond, hydrophobic/hydrophilic interactions, van derWaals forces, ion pairs, hydrogen bonds, ligand-receptor interactions,and the like. Such association may also encompass the presence of othermolecules such as peptides, proteins or nucleotide sequences. Thepresent receptor/ligand-interaction is characterized by high affinity,high selectivity and minimal or even lacking cross-reactivity to othertarget molecules to exclude unhealthy and harmful impacts to the treatedsubject.

In certain embodiments, the present invention relates to a method forantagonizing P2X7 with at least one compound of formula (I) according tothe invention and/or physiologically acceptable salts thereof, underconditions such that said P2X7 receptor is antagonized. In certainembodiments, the system is a cellular system. In other embodiments, thesystem is an in-vitro translation which is based on the proteinsynthesis without living cells. The cellular system is defined to be anysubject provided that the subject comprises cells. Hence, the cellularsystem can be selected from the group of single cells, cell cultures,tissues, organs and animals. In certain embodiments, the method forantagonizing P2X7 is performed in-vitro. The prior teaching of thepresent specification concerning the compounds of formula (I), includingany embodiments thereof, is valid and applicable without restrictions tothe compounds according to formula (I) and their salts when used in themethod for antagonizing P2X7. The prior teaching of the presentspecification concerning the compounds of formula (I), including anyembodiments thereof, is valid and applicable without restrictions to thecompounds according to formula (I) and their salts when used in themethod for antagonizing P2X7.

In certain embodiments, the compounds according to the invention exhibitan advantageous biological activity, which is easily demonstrated incell culture-based assays, for example assays as described herein or inprior art (cf. e.g. WO 2002/09706, which is incorporated herein byreference). In such assays, the compounds according to the inventionpreferably exhibit and cause an agonistic effect.

In certain embodiments, the invention provides a method for preventing,treating or ameliorating in a subject a disease, disorder, or conditionthat is causally related to the aberrant activity of P2X7 receptor,which comprises administering to the subject a therapeutically effectiveamount of a compound of any formulae herein, or a pharmaceuticallyacceptable salt thereof. In certain embodiments, the disease or disorderis an autoimmune, inflammatory or cardiovascular disease or disorder.

In certain embodiments, the disease or disorder is a neurodegenerativedisease or disorder, including Parkinson's disease, multiple sclerosis(MS); Alzheimer's disease, diseases and disorders which are mediated byor result in neuroinflammation such as, for example traumatic braininjury, and encephalitis; centrally-mediated neuropsychiatric diseasesand disorders such as, for example depression mania, bipolar disease,anxiety, schizophrenia, eating disorders, sleep disorders and cognitiondisorders; epilepsy and seizure disorders; prostate, bladder and boweldysfunction such as, for example urinary incontinence, urinaryhesitancy, rectal hypersensitivity, fecal incontinence, benign prostatichypertrophy and inflammatory bowel disease; respiratory and airwaydisease and disorders such as, for example, allergic rhinitis, asthmaand reactive airway disease and chronic obstructive pulmonary disease;diseases and disorders which are mediated by or result in inflammationsuch as, for example rheumatoid arthritis and osteoarthritis, myocardialinfarction, various autoimmune diseases and disorders, uveitis andatherosclerosis; itch/pruritus such as, for example psoriasis; obesity;lipid disorders; cancer; blood pressure; spinal cord injury; and renaldisorders.

In certain embodiments, the disease or disorder is pain, includingacute, inflammatory and neuropathic pain, chronic pain, dental pain andheadache including migraine, cluster headache and tension headache.

In certain embodiments, the disease or disorder is rheumatoid arthritis,osteoarthritis, psoriasis, allergic dermatitis, asthma,hyperresponsiveness of the airway, chronic obstructive pulmonary disease(COPD), bronchitis, septic shock, glomerulonephritis, irritable boweldisease, Crohn's disease, ulcerative colitis, atherosclerosis, growthand metastases of malignant cells, myoblastic leukaemia, diabetes,neurodegenerative disease, Alzheimer's disease, multiple sclerosis,meningitis, osteoporosis, burn injury, ischaemic heart disease, stroke,peripheral vascular disease, varicose veins, glaucoma, bipolar disorder,and neuropathic pain conditions such as diabetic neuropathy,post-herpatic neuralgia, low back pain, chemotherapy-induced neuropathicpain, fibromyalgia and spinal cord injury pain.

In certain embodiments, the present invention is used when the use ofcompounds which inhibit the P2X7 receptor are expected to improvepathological conditions. Such cases include, for example, prevention andtherapy of swelling, exacerbation of pain and bone metabolism inrheumatoid arthritis, prevention and therapy of inflammatory boweldiseases, chronic obstructive pulmonary disease (COPD) andosteoarthritis, prevention and therapy of inflammatory pain and cancerpain and IL-1β-associated diseases such as Crohn's disease, emphysema,acute respiratory distress syndrome, adult respiratory distresssyndrome, asthma, bronchitis, chronic pulmonary inflammatory diseases,silicosis, pulmonary sarcoidosis, allergic reactions, allergic contacthypersensitivity, eczema, contact dermatitis, psoriasis, sunburn,cancer, tissue ulceration, restenosis, periodontal disease,epidermolysis bullosa, osteoporosis, bone resorption disease, looseningof artificial joint implants, atherosclerosis, aortic aneurysm,congestive heart failure, myocardial infarction, stroke, cerebralischemia, head trauma, neurotrauma, spinal cord injury,neurodegenerative disorder, Alzheimer's disease, Parkinson's disease,migraine, depression, peripheral neuropathy, pain, cerebral amyloidangiopathy, nootropic or cognition enhancement, amyotrophic lateralsclerosis, multiple sclerosis, ocular angiogenesis, corneal injury,macular degeneration, corneal scarring, scleritis, abnormal woundhealing, burns, autoimmune diseases, Huntington's disease, diabetes,AIDS, cachexia, sepsis, septic shock, endotoxin shock, conjunctivitisshock, gram-negative sepsis, toxic shock syndrome, cerebral malaria,cardiac and renal reperfusion injury, thrombosis, glomerulonephritis,graft-versus-host reaction, homograft rejection, organ transplanttoxicity, ulcerative colitis or muscle degeneration.

In certain embodiments, the present invention encompasses a method oftreating a patient suffering from a mood disorder, including thosesuffering from a treatment resistant form of depression, comprisingadministering a therapeutically effective amount of a modulator of P2X7receptor activity to a subject suffering from said affective disorder.It is understood that the mood disorder may be one among many of thedisorders affecting mood and behavior. For example, mood disorderscomprise depressive disorder (that includes major depressive disorder,dysthymic disorder), bipolar disorder (includes bipolar I disorder,bipolar II disorder, cyclothymic disorder), mood disorder due to ageneral medical condition and substance-induced mood disorder (AmericanPsychiatric Association: Diagnostic and Statistical Manual of MentalDisorders (DSM-IV-TR), Fourth Edition, Text Revision. Washington, D.C.,American Psychiatric Association, pages 345-428, 2000.). In certainembodiments, the disorder is a depressive disorder. The presentinvention also encompasses a method of treating a patient suffering froman anxiety disorder. Anxiety disorders include: panic attack,agoraphobia, specific phobia, social phobia, obsessive-compulsivedisorder, posttraumatic stress disorder, acute stress disorder, andgeneralized anxiety disorder.

In certain embodiments, the disease or disorder is pain, selected frompain associated with postmastectomy pain syndrome, stump pain, phantomlimb pain, oral neuropathic pain, Charcot's pain, toothache, venomoussnake bite, spider bite, insect sting, postherpetic neuralgia, diabeticneuropathy, reflex sympathetic dystrophy, trigeminal neuralgia,osteoarthritis, rheumatoid arthritis, fibromyalgis, Guillain-Barresyndrome, meralgia paresthetica, burning-mouth syndrome, bilateralperipheral neuropathy, causalgia, sciatic neuritis, peripheral neuritis,polyneuritis, segmental neuritis, Gombault's neuritis, neuronitis,cervicobrachial neuralgia, cranial neuralgia, egniculate neuralgia,glossopharyngial neuralgia, migranous neuralgia, idiopathic neuralgia,intercostals neuralgia, mammary neuralgia, mandibular joint neuralgia,Morton's neuralgia, nasociliary neuralgia, occipital neuralgia, redneuralgia, Sluder's neuralgia splenopalatine neuralgia, supraorbitalneuralgia, vidian neuralgia, sinus headache, tension headache, labor,childbirth, intestinal gas, menstruation, cancer, and trauma.

In certain embodiments, the disease or disorder is associated withinflammation, including rheumatoid arthritis, osteoarthritis, uveitis,asthma, myocardial infarction, traumatic brain injury; septic shock,atherosclerosis, chronic pulmonary obstructive disease (COPD), acutespinal cord injury, inflammatory bowel disease and immune dysfunction.

In certain embodiments, the disease or disorder is associated with painresponses or imbalances in the maintenance of basal activity of sensorynerves. The amine compounds of the invention have use as analgesics forthe treatment of pain of various geneses or etiology, for example acute,inflammatory pain (such as pain associated with osteoarthritis andrheumatoid arthritis); various neuropathic pain syndromes (such aspost-herpetic neuralgia, trigeminal neuralgia, reflex sympatheticdystrophy, diabetic neuropathy, Guillian Barre syndrome, fibromyalgia,phantom limb pain, post-masectomy pain, peripheral neuropathy, HIVneuropathy, and chemotherapy-induced and other iatrogenic neuropathies);visceral pain, (such as that associated with gastroesophageal reflexdisease, irritable bowel syndrome, inflammatory bowel disease,pancreatitis, and various gynecological and urological disorders),dental pain and headache (such as migraine, cluster headache and tensionheadache).

In certain embodiments, the disease or disorder is arthritis, uveitis,asthma, myocardial infarction, traumatic brain injury, acute spinal cordinjury, or inflammatory bowel disease.

In certain embodiments, the disease or disorder is MS.

In certain embodiments, the disease or disorder is Parkinson's disease.

In certain embodiments, the disease or disorder is rheumatoid arthritis.

In certain embodiments, the disease or disorder is traumatic braininjury.

In certain embodiments, the disease or disorder is pain.

In other embodiments, the invention provides compounds of the inventionfor use as a pharmaceutical especially in the treatment or prevention ofthe aforementioned conditions and diseases. Also provided herein is theuse of the present compounds in the manufacture of a medicament for thetreatment or prevention of one of the aforementioned conditions anddiseases. The present invention also provides the use of a compound ofthe invention or a pharmaceutically acceptable salt thereof for themanufacture of a medicament for the treatment of conditions or diseasesselected from P2X7 receptor mediated conditions or diseases.

When used to prevent the onset of a P2X7 related disease/disorder, thecompounds of this invention will be administered to a patient at riskfor developing the condition, typically on the advice and under thesupervision of a physician, at the dosage levels described above.Patients at risk for developing a particular condition generally includethose that have a family history of the condition, or those who havebeen identified by genetic testing or screening to be particularlysusceptible to developing the condition.

The invention further relates to combination therapies wherein acompound of the invention, or a pharmaceutically acceptable saltthereof, or a pharmaceutical composition or formulation comprising acompound of the invention, is administered concurrently or sequentiallyor as a combined preparation with another therapeutic agent or agents,for the treatment of one or more of the conditions listed.

A compound of Formula (I) of the present invention can be administeredas sole active agent or can be adminstered in combination with otheragents. These agents include non-steroidal anti-inflammatory drug(NSAIDS) such as celecoxib, rofecoxib, cimicoxib, etoricoxib,lumiracoxib, valdecoxib, deracoxib,N-(2-cyclohexyloxynitrophenyl)methane sulphonamide, COX189, ABT963,JTE-522, GW-406381, LAS-34475, CS-706, PAC-10649, SVT-2016, GW-644784,tenidap, acetylsalicylic acid (aspirin), amoxiprin, benorilate, cholinemagnesium salicylate, diflunisal, faislamine, methyl salicylate,magnesium salicylate, salicyl salicylate (salsalatee), diclofenac,aceclofenac, acemetacin, bromfenac, etodolac, indometacin, nabumetone,sulindac, tolmetin, ibuprofen, carprofen, fenbufen, fenoprofen,flurbiprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin,tiaprofenic acid, suprofen, mefenamic acid, meclofenamic acid,phenylbutazone, azapropazone, metamizole, oxyphenbutazone,sulfinpyrazone, piroxicam, lornoxicam, meloxicam, tenoxicam, nimesulide,licofelone, or paracetamol.

A compound of Formula (I) of the present invention can be combined withagents such as TNFα inhibitors such as anti-TNF monoclonal antibodies(such as Remicade, CDP-870 and D2E7) and TNF receptor immunoglobulinmolecules (such as Enbrel), low dose methotrexate, lefunomide;ciclesonide; hydroxychloroquine, d-penicillamine, auranofin orparenteral or oral gold.

A compound of Formula (I) of the present invention can also beadministered in combination with an inhibitor of proTNFalpha convertaseenzyme (TACE) such as3-Amino-N-hydroxy-a-(2-methylpropyl)-3-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]-2-oxo-1-pyrrolidineacetamide,2(S),3(S)-Piperidinedicarboxamide,N3-hydroxy-1-methyl-N2-[4-[(2-methyl-4-quinolinyl)methoxy]phenyl],3-Thiomorpholinecarboxamide,4-[[4-(2-butynyloxyl)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl, 5-Hexenoicacid,3-[(hydroxyamino)carbonyl]-2-(2-methylpropyl)-6-phenyl-,2-(2-methylpropyl)-2-(methylsulfonyl)hydrazide,(2R,3S,5E), 2-Piperidinecarboxamide,N,5-dihydroxy-1-[[4-(1-naphthalenylmethoxyl)phenyl]sulfonyl]-, (2R,5R),Pentanamide,3-(formylhydroxyamino)-4-methyl-2-(2-methylpropyl)-N-[(1S,2S)-2-methyl-1-[(2-pyridinylamino)carbonyl]butyl]-,(2R,3S),2-Propenamide,N-hydroxy-3-[3-[[(4-methoxyphenyl)sulfonyl](1-methylethyl)amino]phenyl]-3-(3-pyridinyl)-,(2E), Benzamide,N-(2,4-dioxo-1,3,7-triazaspiro[4.4]non-9-yl)-4-[(2-methyl-4-quinolinyl)methoxy],Benzamide,N-[(1-acetyl-4-piperidinyl)(2,5-dioxo-4-imidazolidinyl)methyl]-4-[(2-methyl-4-quinolinyl)methoxy],or 2,4-Imidazolidinedione,5-methyl-5-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl].

A compound of Formula (I) of the present invention can also beadministered in combination with a corticosteroid such as budesonide,corticosterone, cortisol, cortisone acetate, prednisone, prednisolone,methylprednisolone, dexamethasone, betamethasone, triamcinolone,beclometasone, fludrocortisone acetate, deoxycorticosterone acetate(doca), or aldosterone.

A compound of Formula (I) of the present invention can further beadministered in combination with a b2-adrenergic receptor agonist suchas formoterol, salbutamol (albuterol), levalbuterol, terbutaline,pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate,salmeterol, bambuterol, or clenbuterol.

A compound of Formula (I) of the present invention can further beadministered in combination with an antidepressant drug such assertraline, escitalopram, fluoxetine, bupropion, paroxetine,venlafaxine, trazodone, amitriptyline, citalopram, duloxetine,mirtazapine, nortriptyline, imipramine, or lithium.

A compound of Formula (I) of the present invention can further beadministered in combination with an antipsychotic drug such aschlorpromazine, fluphenazine, perphenazine, prochlorperazine,thioridazine, trifluoperazine, mesoridazine, promazine, triflupromazine,levomepromazine, promethazine, chlorprothixene, flupenthixol,thiothixene, zuclopenthixol, haloperidol, droperidol, pimozide,melperone, benperidol, triperidol, clozapine, olanzapine, risperidone,quetiapine, ziprasidone, amisulpride, paliperidone, bifeprunox, oraripiprazole.

A compound of Formula (I) of the present invention can also beadministered in combination with a leukotriene biosynthesis inhibitor,5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein(FLAP) antagonist, for example, zileuton; ABT-761; fenleuton; tepoxalin;nicaraven; VIA-2291; etalocib; ketoprofen, Abt-79175; Abt-85761;N-(5-substituted) thiophene-2-alkylsulfonamides; TDT-070; licofelone;PEP-03; tenoxicam; 2,6-di-tert-butylphenol hydrazones;methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661;pyridinyl-substituted 2-cyanonaphthalene compounds such as L-739-010;2-cyanoquinoline compounds such as L-746-530; indole and quinolinecompounds such as MK-591, MK-886, and BAY×1005.

A compound of Formula (I) of the present invention can be administeredin combination with a receptor antagonists for leukotrienes LTB4, LTC4,LTD4, and LTE, for example, phenothiazin-3-ones such as L-651.392;amidino compounds such as CGS-25019c; benzoxalamines such as ontezolast;benzenecarboximidamides such as BIIL 284/260; and compounds such aszafirlukast, ablukast, montelukast, praniukast, verlukast (MK-679),RG-12525, Ro-245913, iralukast (CGP 45715A), BAY×7195, and masilukast.

A compound of Formula (I) of the present invention can also beadministered in combination with a PDE4 inhibitor including inhibitorsof the isoform PDE4D.

A compound of Formula (I) of the present invention can also beadministered in combination with a antihistaminic H1 receptorantagonists including cetirizine, loratadine, desloratadine,fexofenadine, astemizole, azelastine, and chlorpheniramine. A compoundof Formula (I) of the present invention can further be administered incombination with a gastroprotective H2 receptor antagonist.

A compound of Formula (I) of the present invention can yet further beadministered in combination with an a1- and a2-adrenoceptor agonistvasoconstrictor sympathomimetic agent, including propylhexedrine,phenylephrine, phenylpropanolamine, pseudoephedrine, naphazolinehydrochloride, oxymetazoline hydrochloride, tetrahydrozolinehydrochloride, xylometazoline hydrochloride, and ethylnorepinephrinehydrochloride.

A compound of Formula (I) of the present invention can be administeredin combination with anticholinergic agents including ipratropiumbromide; tiotropium bromide; oxitropium bromide; pirenzepine; andtelenzepine. The present invention still further relates to thecombination of a compound of the invention together with a b1- tob4-adrenoceptor agonists including metaproterenol, isoproterenol,isoprenaline, albuterol, salbutamol, formoterol, salmeterol,terbutaline, orciprenaline, bitolterol mesylate, and pirbuterol; ormethylxanthanines including theophylline and aminophylline; sodiumcromoglycate; or muscarinic receptor (M1, M2, and M3) antagonist.

A compound of Formula (I) of the present invention can be administeredin combination with an insulin-like growth factor type I (IGF-1)mimetic.

A compound of Formula (I) of the present invention can be administeredin combination with an inhaled glucocorticoid with reduced systemic sideeffects, including, prednisone, prednisolone, flunisolide, triamcinoloneacetonide, beclomethasone dipropionate, budesonide, fluticasonepropionate, and mometasone furoate.

A compound of Formula (I) of the present invention can be administeredin combination with (a) tryptase inhibitors; (b) platelet activatingfactor (PAF) antagonists; (c) interleukin converting enzyme (ICE)inhibitors; (d) IMPDH inhibitors; (e) adhesion molecule inhibitorsincluding VLA-4 antagonists; (f) cathepsins; (g) MAP kinase inhibitors;(h) glucose-6 phosphate dehydrogenase inhibitors; (i) kinin-B1- andB2-receptor antagonists; j) anti-gout agents, e.g., colchicine; (k)xanthine oxidase inhibitors, e.g., allopurinol; (1) uricosuric agents,e.g., probenecid, sulfinpyrazone, and benzbromarone; (m) growth hormonesecretagogues; (n) transforming growth factor (TGFBβ; (o)platelet-derived growth factor (PDGF); (p) fibroblast growth factor,e.g., basic fibroblast growth factor (bFGF); (q) granulocyte macrophagecolony stimulating factor (GM-CSF); (r) capsaicin cream; (s) TachykininNK1 and NK3 receptor antagonists such as NKP-608C; SB-233412(talnetant); and D-4418; and (t) elastase inhibitors such as UT-77 andZD-0892.

A compound of Formula (I) of the present invention can be administeredin combination with an inhibitor of matrix metalloproteases (MMPs),i.e., the stromelysins, the collagenases, and the gelatinases, as wellas aggrecanase; especially collagenase-1 (MMP-1), collagenase-2 (MMP-8),collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-10),and stromelysin-3 (MMP-11).

A compound of Formula (I) of the present invention can be administeredin combination with anticancer agents such as endostatin and angiostatinor cytotoxic drugs such as adriamycin, daunomycin, cis-platinum,etoposide, taxol, taxotere and farnesyl transferase inhibitors, VEGFinhibitors, COX-2 inhibitors and antimetabolites such as methotrexateantineoplastic agents, especially antimitotic drugs including the vincaalkaloids such as vinblastine and vincristine.

A compound of Formula (I) of the present invention can be administeredin combination with antiviral agents such as Viracept, AZT, aciclovirand famciclovir, and antisepsis compounds such as Valant.

A compound of Formula (I) of the present invention can be administeredin combination with cardiovascular agents such as calcium channelblockers, lipid lowering agents such as stating, fibrates,beta-blockers, ACE inhibitors, Angiotensin-2 receptor antagonists andplatelet aggregation inhibitors.

A compound of Formula (I) of the present invention can be administeredin combination with CNS agents such as antidepressants (such assertraline), anti-Parkinsonian drugs (such as deprenyl, L-dopa, Requip,Mirapex, MAOB inhibitors such as selegine and rasagiline, comPinhibitors such as Tasmar, A-2 inhibitors, dopamine reuptake inhibitors,NMDA antagonists, Nicotine agonists, Dopamine agonists and inhibitors ofneuronal nitric oxide synthase), and anti-Alzheimer's drugs such asdonepezil, tacrine, COX-2 inhibitors, propentofylline or metrifonate.

A compound of Formula (I) of the present invention can be administeredin combination with osteoporosis agents such as roloxifene, droloxifene,lasofoxifene or fosomax and immunosuppressant agents such as FK-506,rapamycin, cyclosporine, azathioprine, and methotrexate.

In certain embodiments, the compounds of the invention may be combinedwith agents listed below.

Non-steroidal anti-inflammatory agents (hereinafter NSAIDs) includingnon-selective cyclo-oxygenase COX-1/COX-2 inhibitors whether appliedtopically or systemically (such as piroxicam, diclofenac, propionicacids such as naproxen, flurbiprofen, fenoprofen, ketoprofen andibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac,azapropazone, pyrazolones such as phenylbutazone, salicylates such asaspirin); selective COX-2 inhibitors (such as meloxicam, celecoxib,rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib);cyclo-oxygenase inhibiting nitric oxide donors (CINODs);glucocorticosteroids (whether administered by topical, oral,intramuscular, intravenous, or intra-articular routes); methotrexate;leflunomide; hydroxychloroquine; d-penicillamine; auranofin or otherparenteral or oral gold preparations; analgesics; diacerein;intra-articular therapies such as hyaluronic acid derivatives; andnutritional supplements such as glucosamine.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, together with a cytokine or agonist or antagonist of cytokinefunction, (including agents which act on cytokine signalling pathwayssuch as modulators of the SOCS system) including alpha-, beta-, andgamma-interferons; insulin-like growth factor type I (IGF-1);interleukins (IL) including IL1 to 17, and interleukin antagonists orinhibitors such as anakinra; tumour necrosis factor alpha (TNF-α)inhibitors such as anti-TNF monoclonal antibodies (for exampleinfliximab; adalimumab, and CDP-870) and TNF receptor antagonistsincluding immunoglobulin molecules (such as etanercept) andlow-molecular-weight agents such as pentoxyfylline.

In addition the invention relates to a combination of a compound of theinvention, or a pharmaceutically acceptable salt thereof, with amonoclonal antibody targeting B-Lymphocytes (such as CD20 (rituximab),MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax I1-15).

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, with a modulator of chemokine receptor function such as anantagonist of CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCR10 andCCR11 (for the C—C family); CXCR1, CXCR2, CXCR3, CXCR4 and CXCR5 (forthe C—X—C family) and CX3CR1 for the C—X3-C family.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, with aninhibitor of matrix metalloprotease (MMPs), i.e., the stromelysins, thecollagenases, and the gelatinases, as well as aggrecanase; especiallycollagenase-1 (MMP-1), collagenase-2 (MMP-8), collagenase-3 (MMP-13),stromelysin-1 (MMP-3), stromelysin-2 (MMP-10), and stromelysin-3(MMP-11) and MMP-9 and MMP-12, including agents such as doxycycline.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO)inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist suchas; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761;a N-(5-substituted)-thiophene-2-alkylsulfonamide;2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such asZeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted2-cyanonaphthalene compound such as L-739,010; a 2-cyanoquinolinecompound such as L-746,530; or an indole or quinoline compound such asMK-591, MK-886, and BAY×1005.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, and areceptor antagonist for leukotrienes (LT) B4, LTC4, LTD4, and LTE4.Selected from the group consisting of the phenothiazin-3-1s such asL-651,392; amidino compounds such as CGS-25019c; benzoxalamines such asontazolast; benzenecarboximidamides such as BIIL 284/260; and compoundssuch as zafirlukast, ablukast, montelukast, pranlukast, verlukast(MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY×7195.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and a phosphodiesterase (PDE) inhibitor such as amethylxanthanine including theophylline and aminophylline; a selectivePDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of theisoform PDE4D, or an inhibitor of PDE5.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, and ahistamine type 1 receptor antagonist such as cetirizine, loratadine,desloratadine, fexofenadine, acrivastine, terfenadine, astemizole,azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, ormizolastine; applied orally, topically or parenterally.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and a proton pump inhibitor (such as omeprazole) or agastroprotective histamine type 2 receptor antagonist.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, and anantagonist of the histamine type 4 receptor.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and an alpha-1/alpha-2 adrenoceptor agonist vasoconstrictorsympathomimetic agent, such as propylhexedrine, phenylephrine,phenylpropanolamine, ephedrine, pseudoephedrine, naphazolinehydrochloride, oxymetazoline hydrochloride, tetrahydrozolinehydrochloride, xylometazoline hydrochloride, tramazoline hydrochlorideor ethylnorepinephrine hydrochloride.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, and ananticholinergic agents including muscarinic receptor (M1, M2, and M3)antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropiumbromide, tiotropium bromide, oxitropium bromide, pirenzepine ortelenzepine.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and a beta-adrenoceptor agonist (including beta receptorsubtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol,terbutaline, orciprenaline, bitolterol mesylate, or pirbuterol, or achiral enantiomer thereof.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, and achromone, such as sodium cromoglycate or nedocromil sodium.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, with a glucocorticoid, such as flunisolide, triamcinoloneacetonide, beclomethasone dipropionate, budesonide, fluticasonepropionate, ciclesonide or mometasone furoate.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, with anagent that modulates a nuclear hormone receptor such as PPARs, forexample rosiglitazone.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof withgabapentin, lidoderm, pregablin and equivalents and pharmaceuticallyactive isomer(s) and metabolite(s) thereof.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof withcelecoxib, etoricoxib, lumiracoxib, rofecoxib, valdecoxib, diclofenac,loxoprofen, naproxen, paracetamol and equivalents and pharmaceuticallyactive isomer(s) and metabolite(s) thereof.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, together with an immunoglobulin (Ig) or Ig preparation or anantagonist or antibody modulating Ig function such as anti-IgE (forexample omalizumab).

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, andanother systemic or topically-applied anti-inflammatory agent, such asthalidomide or a derivative thereof, a retinoid, dithranol orcalcipotriol.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and combinations of aminosalicylates and sulfapyridine such assulfasalazine, mesalazine, balsalazide, and olsalazine; andimmunomodulatory agents such as the thiopurines, and corticosteroidssuch as budesonide.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof,together with an antibacterial agent such as a penicillin derivative, atetracycline, a macrolide, a beta-lactam, a fluoroquinolone,metronidazole, an inhaled aminoglycoside; an antiviral agent includingacyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir,amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; aprotease inhibitor such as indinavir, nelfinavir, ritonavir, andsaquinavir; a nucleoside reverse transcriptase inhibitor such asdidanosine, lamivudine, stavudine, zalcitabine or zidovudine; or anon-nucleoside reverse transcriptase inhibitor such as nevirapine orefavirenz.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and a cardiovascular agent such as a calcium channel blocker, abeta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE)inhibitor, an angiotensin-2 receptor antagonist; a lipid lowering agentsuch as a statin or a fibrate; a modulator of blood cell morphology suchas pentoxyfylline; thrombolytic, or an anticoagulant such as a plateletaggregation inhibitor.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof, and aCNS agent such as an antidepressant (such as sertraline), ananti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole,pramipexole, a MAOB inhibitor such as selegine and rasagiline, a comPinhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptakeinhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist oran inhibitor of neuronal nitric oxide synthase), or an anti-Alzheimer'sdrug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor,propentofylline or metrifonate.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, and an agent for the treatment of acute or chronic pain, suchas a centrally or peripherally-acting analgesic (for example an opioidor derivative thereof), carbamazepine, gabapentin, pregabalin,phenyloin, sodium valproate, amitryptiline or other anti-depressantagent-s, paracetamol, CB 1 agonist, muscarinic agonist, TRPV-1antagonist, mGluR5 agonist or a non-steroidal anti-inflammatory agent.

The present invention further relates to the combination of a compoundof the invention, or a pharmaceutically acceptable salt thereof,together with a parenterally or topically-applied (including inhaled)local anaesthetic agent such as lignocaine or a derivative thereof.

A compound of the present invention, or a pharmaceutically acceptablesalt thereof, can also be used in combination with an anti-osteoporosisagent including a hormonal agent such as raloxifene, or a biphosphonatesuch as alendronate.

The present invention still further relates to the combination of acompound of the invention, or a pharmaceutically acceptable saltthereof, together with a: (i) tryptase inhibitor; (ii) plateletactivating factor (PAF) antagonist; (iii) interleukin converting enzyme(ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitorsincluding VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor suchas an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, forexample Gefitinib or Imatinib mesylate), a serine/threonine kinase (suchas an inhibitor of a MAP kinase such as p38, JNK, protein kinase A, B orC, or IKK), or a kinase involved in cell cycle regulation (such as acylin dependent kinase); (viii) glucose-6 phosphate dehydrogenaseinhibitor; (ix) kinin-B1- or B2-receptor antagonist; (x) anti-goutagent, for example colchicine; (xi) xanthine oxidase inhibitor, forexample allopurinol; (xii) uricosuric agent, for example probenecid,sulfinpyrazone or benzbromarone; (xiii) growth hormone secretagogue;(xiv) transforming growth factor (TGFβ); (xv) platelet-derived growthfactor (PDGF); (xvi) fibroblast growth factor for example basicfibroblast growth factor (bFGF); (xvii) granulocyte macrophage colonystimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) tachykininNK1 or NK3 receptor antagonist such as NKP-608C, SB-233412 (talnetant)or D-4418; (xx) elastase inhibitor such as UT-77 or ZD-0892; (xxi)TNF-alpha converting enzyme inhibitor (TACE); (xxii) induced nitricoxide synthase (iNOS) inhibitor; (xxiii) chemoattractantreceptor-homologous molecule expressed on TH2 cells, (such as a CRTH2antagonist); (xxiv) inhibitor of P38; (xxv) agent modulating thefunction of Toll-like receptors (TLR), or (xxvi) inhibitor oftranscription factor activation such as NFkB, API, or STATS.

A compound of the invention, or a pharmaceutically acceptable saltthereof, can also be used in combination with an existing therapeuticagent for the treatment of cancer, for example suitable agents include:

(i) an antiproliferative/antineoplastic drug or a combination thereof,as used in medical oncology, such as an alkylating agent (for examplecis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan,chlorambucil, busulphan or a nitrosourea); an antimetabolite (forexample an antifolate such as a fluoropyrimidine like 5-fluorouracil ortegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea,gemcitabine or paclitaxel); an antitumour antibiotic (for example ananthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin,epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); anantimitotic agent (for example a vinca alkaloid such as vincristine,vinblastine, vindesine or vinorelbine, or a taxoid such as taxol ortaxotere); or a topoisomerase inhibitor (for example anepipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecanor a camptothecin); (ii) a cytostatic agent such as an antioestrogen(for example tamoxifen, toremifene, raloxifene, droloxifene oriodoxyfene), an oestrogen receptor down regulator (for examplefulvestrant), an antiandrogen (for example bicalutamide, flutamide,nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist(for example goserelin, leuprorelin or buserelin), a progestogen (forexample megestrol acetate), an aromatase inhibitor (for example asanastrozole, letrozole, vorazole or exemestane) or an inhibitor of5α-reductase such as finasteride; (iii) an agent which inhibits cancercell invasion (for example a metalloproteinase inhibitor like marimastator an inhibitor of urokinase plasminogen activator receptor function);(iv) an inhibitor of growth factor function, for example: a growthfactor antibody (for example the anti-erbb2 antibody trastuzumab, or theanti-erbb1 antibody cetuximab [C225]), a farnesyl transferase inhibitor,a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, aninhibitor of the epidermal growth factor family (for example an EGFRfamily tyrosine kinase inhibitor such asN-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine(gefitinib, AZD1839),N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine(erlotinib, OSI-774) or6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine(CI-1033)), an inhibitor of the platelet-derived growth factor family,or an inhibitor of the hepatocyte growth factor family; (v) anantiangiogenic agent such as one which inhibits the effects of vascularendothelial growth factor (for example the anti-vascular endothelialcell growth factor antibody bevacizumab, linomide, an inhibitor ofintegrin αvβ3 function or an angiostatin); (vi) a vascular damagingagent such as combretastatin A4; (vii) an agent used in antisensetherapy, for example one directed to one of the targets listed above,such as ISIS 2503, an anti-ras antisense; (viii) an agent used in a genetherapy approach, for example approaches to replace aberrant genes suchas aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzymepro-drug therapy) approaches such as those using cytosine deaminase,thymidine kinase or a bacterial nitroreductase enzyme and approaches toincrease patient tolerance to chemotherapy or radiotherapy such asmulti-drug resistance gene therapy; or (ix) an agent used in animmunotherapeutic approach, for example ex-vivo and in-vivo approachesto increase the immunogenicity of patient tumour cells, such astransfection with cytokines such as interleukin 2, interleukin 4 orgranulocyte-macrophage colony stimulating factor, approaches to decreaseT-cell anergy, approaches using transfected immune cells such ascytokine-transfected dendritic cells, approaches usingcytokine-transfected tumour cell lines and approaches usinganti-idiotypic antibodies.

The method of the invention can be performed either in-vitro or in-vivo.The susceptibility of a particular cell to treatment with the compoundsaccording to the invention can be particularly determined by in-vitrotests, whether in the course of research or clinical application.Typically, a culture of the cell is combined with a compound accordingto the invention at various concentrations for a period of time which issufficient to allow the active agents to antagonize P2X7 activity,usually between about one hour and one week. In-vitro treatment can becarried out using cultivated cells from a biopsy sample or cell line.

The host or subject can belong to any mammalian species, for example aprimate species, particularly humans; rodents, including mice, rats andhamsters; rabbits; horses, cows, dogs, cats, etc. Animal models are ofinterest for experimental investigations, providing a model fortreatment of human disease.

For identification of a signal transduction pathway and for detection ofinteractions between various signal transduction pathways, suitablemodels or model systems have been developed, for example cell culturemodels and models of transgenic animals. For the determination ofcertain stages in the signal transduction cascade, interacting compoundscan be utilized in order to modulate the signal. The compounds accordingto the invention can also be used as reagents for testing P2X7-dependentsignal transduction pathways in animals and/or cell culture models or inthe clinical diseases mentioned in this application.

The use according to the previous paragraphs of the specification may beeither performed in-vitro or in-vivo models. The modulation can bemonitored by the techniques described in the course of the presentspecification. In certain embodiments, the in-vitro use is preferablyapplied to samples of humans suffering from P2X7-related disorders.Testing of several specific compounds and/or derivatives thereof makesthe selection of that active ingredient possible that is best suited forthe treatment of the human subject. The in-vivo dose rate of the chosenderivative is advantageously pre-adjusted to the P2X7 susceptibilityand/or severity of disease of the respective subject with regard to thein-vitro data. Therefore, the therapeutic efficacy is remarkablyenhanced. Moreover, the subsequent teaching of the present specificationconcerning the use of the compounds according to formula (I) and itsderivatives for the production of a medicament for the prophylactic ortherapeutic treatment and/or monitoring is considered as valid andapplicable without restrictions to the use of the compound for theantagonism of P2X7 activity if expedient.

The invention also relates to the use of compounds according to formula(I) and/or physiologically acceptable salts thereof for the prophylacticor therapeutic treatment and/or monitoring of diseases that are caused,mediated and/or propagated by P2X7 activity. Furthermore, the inventionrelates to the use of compounds according to formula (I) and/orphysiologically acceptable salts thereof for the production of amedicament for the prophylactic or therapeutic treatment and/ormonitoring of diseases that are caused, mediated and/or propagated byP2X7 activity. In certain embodiments, the invention provides the use ofa compound according to formula I or physiologically acceptable saltsthereof, for the production of a medicament for the prophylactic ortherapeutic treatment of a P2X7-mediated disorder.

Compounds of formula (I) and/or a physiologically acceptable saltthereof can furthermore be employed as intermediate for the preparationof further medicament active ingredients. The medicament is preferablyprepared in a non-chemical manner, e.g. by combining the activeingredient with at least one solid, fluid and/or semi-fluid carrier orexcipient, and optionally in conjunction with a single or more otheractive substances in an appropriate dosage form.

The compounds of formula (I) according to the invention can beadministered before or following an onset of disease once or severaltimes acting as therapy. The aforementioned compounds and medicalproducts of the inventive use are particularly used for the therapeutictreatment. A therapeutically relevant effect relieves to some extent oneor more symptoms of a disorder, or returns to normality, eitherpartially or completely, one or more physiological or biochemicalparameters associated with or causative of a disease or pathologicalcondition. Monitoring is considered as a kind of treatment provided thatthe compounds are administered in distinct intervals, e.g. in order tobooster the response and eradicate the pathogens and/or symptoms of thedisease completely. Either the identical compound or different compoundscan be applied. The methods of the invention can also be used toreducing the likelihood of developing a disorder or even prevent theinitiation of disorders associated with P2X7 activity in advance or totreat the arising and continuing symptoms.

In the meaning of the invention, prophylactic treatment is advisable ifthe subject possesses any preconditions for the aforementionedphysiological or pathological conditions, such as a familialdisposition, a genetic defect, or a previously passed disease.

The invention furthermore relates to a medicament comprising at leastone compound according to the invention and/or pharmaceutically usablederivatives, salts, solvates and stereoisomers thereof, includingmixtures thereof in all ratios. In certain embodiments, the inventionrelates to a medicament comprising at least one compound according tothe invention and/or physiologically acceptable salts thereof.

A “medicament” in the meaning of the invention is any agent in the fieldof medicine, which comprises one or more compounds of formula (I) orpreparations thereof (e.g. a pharmaceutical composition orpharmaceutical formulation) and can be used in prophylaxis, therapy,follow-up or aftercare of patients who suffer from diseases, which areassociated with P2X7 activity, in such a way that a pathogenicmodification of their overall condition or of the condition ofparticular regions of the organism could establish at least temporarily.

In another aspect, the invention provides for a kit consisting ofseparate packs of an effective amount of a compound according to theinvention and/or pharmaceutically acceptable salts, derivatives,solvates and stereoisomers thereof, including mixtures thereof in allratios, and optionally, an effective amount of a further activeingredient. The kit comprises suitable containers, such as boxes,individual bottles, bags or ampoules. The kit may, for example, compriseseparate ampoules, each containing an effective amount of a compoundaccording to the invention and/or pharmaceutically acceptable salts,derivatives, solvates and stereoisomers thereof, including mixturesthereof in all ratios, and an effective amount of a further activeingredient in dissolved or lyophilized form.

As used herein, the terms “treatment,” “treat,” and “treating” refer toreversing, alleviating, delaying the onset of, or inhibiting theprogress of a disease or disorder, or one or more symptoms thereof, asdescribed herein. In some embodiments, treatment is administered afterone or more symptoms have developed. In other embodiments, treatment isadministered in the absence of symptoms. For example, treatment isadministered to a susceptible individual prior to the onset of symptoms(e.g., in light of a history of symptoms and/or in light of genetic orother susceptibility factors). Treatment is also continued aftersymptoms have resolved, for example to prevent or delay theirrecurrence.

The compounds and compositions, according to the method of the presentinvention, are administered using any amount and any route ofadministration effective for treating or lessening the severity of adisorder provided above. The exact amount required will vary fromsubject to subject, depending on the species, age, and general conditionof the subject, the severity of the infection, the particular agent, itsmode of administration, and the like. Compounds of the invention arepreferably formulated in dosage unit form for ease of administration anduniformity of dosage. The expression “dosage unit form” as used hereinrefers to a physically discrete unit of agent appropriate for thepatient to be treated. It will be understood, however, that the totaldaily usage of the compounds and compositions of the present inventionwill be decided by the attending physician within the scope of soundmedical judgment. The specific effective dose level for any particularpatient or organism will depend upon a variety of factors including thedisorder being treated and the severity of the disorder; the activity ofthe specific compound employed; the specific composition employed; theage, body weight, general health, sex and diet of the patient; the timeof administration, route of administration, and rate of excretion of thespecific compound employed; the duration of the treatment; drugs used incombination or coincidental with the specific compound employed, andlike factors well known in the medical arts.

Pharmaceutically acceptable compositions of this invention can beadministered to humans and other animals orally, rectally, parenterally,intracisternally, intravaginally, intraperitoneally, topically (as bypowders, ointments, or drops), bucally, as an oral or nasal spray, orthe like, depending on the severity of the infection being treated. Incertain embodiments, the compounds of the invention are administeredorally or parenterally at dosage levels of about 0.01 mg/kg to about 100mg/kg and preferably from about 1 mg/kg to about 50 mg/kg, of subjectbody weight per day, one or more times a day, to obtain the desiredtherapeutic effect.

Liquid dosage forms for oral administration include, but are not limitedto, pharmaceutically acceptable emulsions, microemulsions, solutions,suspensions, syrups and elixirs. In addition to the active compounds,the liquid dosage forms optionally contain inert diluents commonly usedin the art such as, for example, water or other solvents, solubilizingagents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethylcarbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butylene glycol, dimethylformamide, oils (in particular,cottonseed, groundnut, corn, germ, olive, castor, and sesame oils),glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fattyacid esters of sorbitan, and mixtures thereof. Besides inert diluents,the oral compositions can also include adjuvants such as wetting agents,emulsifying and suspending agents, sweetening, flavoring, and perfumingagents.

Injectable preparations, for example, sterile injectable aqueous oroleaginous suspensions are formulated according to the known art usingsuitable dispersing or wetting agents and suspending agents. The sterileinjectable preparation are also a sterile injectable solution,suspension or emulsion in a nontoxic parenterally acceptable diluent orsolvent, for example, as a solution in 1,3-butanediol. Among theacceptable vehicles and solvents that may be employed are water,Ringer's solution, U.S.P. and isotonic sodium chloride solution. Inaddition, sterile, fixed oils are conventionally employed as a solventor suspending medium. For this purpose any bland fixed oil can beemployed including synthetic mono- or diglycerides. In addition, fattyacids such as oleic acid are used in the preparation of injectables.

Injectable formulations can be sterilized, for example, by filtrationthrough a bacterial-retaining filter, or by incorporating sterilizingagents in the form of sterile solid compositions which can be dissolvedor dispersed in sterile water or other sterile injectable medium priorto use.

In order to prolong the effect of a compound of the present invention,it is often desirable to slow the absorption of the compound fromsubcutaneous or intramuscular injection. This is accomplished by the useof a liquid suspension of crystalline or amorphous material with poorwater solubility. The rate of absorption of the compound then dependsupon its rate of dissolution that, in turn, may depend upon crystal sizeand crystalline form. Alternatively, delayed absorption of aparenterally administered compound form is accomplished by dissolving orsuspending the compound in an oil vehicle. Injectable depot forms aremade by forming microencapsule matrices of the compound in biodegradablepolymers such as polylactide-polyglycolide. Depending upon the ratio ofcompound to polymer and the nature of the particular polymer employed,the rate of compound release can be controlled. Examples of otherbiodegradable polymers include poly(orthoesters) and poly(anhydrides).Depot injectable formulations are also prepared by entrapping thecompound in liposomes or microemulsions that are compatible with bodytissues.

Compositions for rectal or vaginal administration are preferablysuppositories which can be prepared by mixing the compounds of thisinvention with suitable non-irritating excipients or carriers such ascocoa butter, polyethylene glycol or a suppository wax which are solidat ambient temperature but liquid at body temperature and therefore meltin the rectum or vaginal cavity and release the active compound.

Solid dosage forms for oral administration include capsules, tablets,pills, powders, and granules. In such solid dosage forms, the activecompound is mixed with at least one inert, pharmaceutically acceptableexcipient or carrier such as sodium citrate or dicalcium phosphateand/or a) fillers or extenders such as starches, lactose, sucrose,glucose, mannitol, and silicic acid, b) binders such as, for example,carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone,sucrose, and acacia, c) humectants such as glycerol, d) disintegratingagents such as agar-agar, calcium carbonate, potato or tapioca starch,alginic acid, certain silicates, and sodium carbonate, e) solutionretarding agents such as paraffin, f) absorption accelerators such asquaternary ammonium compounds, g) wetting agents such as, for example,cetyl alcohol and glycerol monostearate, h) absorbents such as kaolinand bentonite clay, and i) lubricants such as talc, calcium stearate,magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate,and mixtures thereof. In the case of capsules, tablets and pills, thedosage form also optionally comprises buffering agents.

Solid compositions of a similar type are also employed as fillers insoft and hard-filled gelatin capsules using such excipients as lactoseor milk sugar as well as high molecular weight polyethylene glycols andthe like. The solid dosage forms of tablets, dragees, capsules, pills,and granules can be prepared with coatings and shells such as entericcoatings and other coatings well known in the pharmaceutical formulatingart. They optionally contain opacifying agents and can also be of acomposition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions that can be usedinclude polymeric substances and waxes. Solid compositions of a similartype are also employed as fillers in soft and hard-filled gelatincapsules using such excipients as lactose or milk sugar as well as highmolecular weight polethylene glycols and the like.

The active compounds can also be in micro-encapsulated form with one ormore excipients as noted above. The solid dosage forms of tablets,dragees, capsules, pills, and granules can be prepared with coatings andshells such as enteric coatings, release controlling coatings and othercoatings well known in the pharmaceutical formulating art. In such soliddosage forms the active compound may be admixed with at least one inertdiluent such as sucrose, lactose or starch. Such dosage forms alsocomprise, as is normal practice, additional substances other than inertdiluents, e.g., tableting lubricants and other tableting aids such amagnesium stearate and microcrystalline cellulose. In the case ofcapsules, tablets and pills, the dosage forms optionally also comprisebuffering agents. They optionally contain opacifying agents and can alsobe of a composition that they release the active ingredient(s) only, orpreferentially, in a certain part of the intestinal tract, optionally,in a delayed manner. Examples of embedding compositions that can be usedinclude polymeric substances and waxes.

Dosage forms for topical or transdermal administration of a compound ofthis invention include ointments, pastes, creams, lotions, gels,powders, solutions, sprays, inhalants or patches. The active componentis admixed under sterile conditions with a pharmaceutically acceptablecarrier and any needed preservatives or buffers as required. Ophthalmicformulation, ear drops, and eye drops are also contemplated as beingwithin the scope of this invention. Additionally, the present inventioncontemplates the use of transdermal patches, which have the addedadvantage of providing controlled delivery of a compound to the body.Such dosage forms can be made by dissolving or dispensing the compoundin the proper medium. Absorption enhancers can also be used to increasethe flux of the compound across the skin. The rate can be controlled byeither providing a rate controlling membrane or by dispersing thecompound in a polymer matrix or gel.

The compounds of the invention can also be utilized as commercialresearch reagents for various medical research and diagnostic uses. Suchuses can include but are not limited to: use as a calibration standardfor quantifying the activities of candidate P2X7 antagonists in avariety of functional assays; use as blocking reagents in randomcompound screening, i.e. in looking for new families of P2X7 receptorligands, the compounds can be used to block recovery of the presentlyclaimed P2X7 compounds; use in the co-crystallization with P2X7receptor, i.e. the compounds of the present invention will allowformation of crystals of the compound bound to P2X7, enabling thedetermination of receptor/compound structure by x-ray crystallography;other research and diagnostic applications, etc.; use in assays asprobes for determining the expression of P2X7 on the surface of cells;and developing assays for detecting compounds which bind to the samesite as the P2X7 binding ligands.

The compounds of formula (I), their salts, isomers, tautomers,enantiomeric forms, diastereomers, racemates, derivatives, prodrugsand/or metabolites are characterized by a high specificity andstability, low manufacturing costs and convenient handling. Thesefeatures form the basis for a reproducible action, wherein the lack ofcross-reactivity is included, and for a reliable and safe interactionwith the target structure.

The term “biological sample”, as used herein, includes, withoutlimitation, cell cultures or extracts thereof; biopsied materialobtained from a mammal or extracts thereof; and blood, saliva, urine,feces, semen, tears, or other body fluids or extracts thereof.

Antagonism of P2X7 activity in a biological sample is useful for avariety of purposes that are known to one of skill in the art. Examplesof such purposes include, but are not limited to, blood transfusion,organ transplantation, biological specimen storage, and biologicalassays.

EXEMPLIFICATION

As depicted in the Examples below, in certain exemplary embodiments,compounds are prepared according to the following general procedures. Itwill be appreciated that, although the general methods depict thesynthesis of certain compounds of the present invention, the followinggeneral methods, and other methods known to one of ordinary skill in theart, can be applied to all compounds and subclasses and species of eachof these compounds, as described herein.

Compound numbers utilized in the Examples below correspond to compoundnumbers set forth supra.

¹H NMR was recorded on a Bruker 400 MHz spectrometer, using residualsignal of deuterated solvent as internal reference. Chemical shifts (δ)are reported in ppm relative to the residual solvent signal (δ=2.49 ppmfor 1H NMR in DMSO-d6). 1H NMR data are reported as follows: chemicalshift (multiplicity, coupling constants, and number of hydrogens).Multiplicity is abbreviated as follows: s (singlet), d (doublet), t(triplet), q (quartet), m (multiplet), br (broad).

LCMS-Analysis was performed under the following conditions:

Method A (Rapid LC): A Shimadzu Shim-pack XR-ODS, 3.0×30 mm, 2.2 μm, wasused at a temperature of 50° C. and at a flow rate of 1.5 mL/min, 2 uLinjection, mobile phase: (A) water with 0.1% formic acid and 1%acetonitrile, mobile phase (B) methanol with 0.1% formic acid; retentiontime given in minutes. Method details: (I) runs on a Binary Pump G1312Bwith UV/Vis diode array detector G1315C and Agilent 6130 massspectrometer in positive and negative ion electrospray mode withUV-detection at 220 and 254 nm with a gradient of 15-95% (B) in a 2.2min linear gradient (II) hold for 0.8 min at 95% (B) (III) decrease from95-15% (B) in a 0.1 min linear gradient (IV) hold for 0.29 min at 15%(B).

Method B: A: 0.1% TFA in H₂O, B: 0.1% TFA in ACN:

Runtime: 6.5 min

Flow Rate: 1.0 mL/min

Gradient: 5-95% B in 4.5 min, wavelength 254 and 215 nM.

Column: Waters Sunfire C18, 3.0×50 mm, 3.5 um, +ve mode

Mass Scan: 100-900 Da

Synthesis of Intermediates

Intermediate 1:2,6-Dichloro-N-((4,4-difluorocyclohexyl)methyl)quinoline-5-carboxamide

Step 1: 5-Bromo-2,6-dichloroquinoline

A mixture of 2,6-dichloroquinoline (5.0 g, 25.4 mmol) and aluminiumtrichloride (10.0 g, 76.1 mmol) was heated to 120° C. with stirringunder a nitrogen atmosphere. Bromine (4.81 g, 30.48 mmol, 1.54 mL) wasadded dropwise over 0.5 h, and the mixture was then stirred at 120° C.for 1 hour before being cooled to room temperature. A MeOH/water mixture(50 mL, 1:1) was then slowly added and the mixture was concentrated invacuum. Dichloromethane (500 mL) and water (250 mL) were added, theorganic layers were separated and the aqueous fraction was extractedwith dichloromethane (2×50 mL). The combined organic extracts werewashed with saturated aqueous sodium hydrogen carbonate (150 mL) beforebeing dried, filtered and concentrated. Purification by columnchromatography on silica gel (petroleum ether: EtOAc=10:1) gave5-bromo-2,6-dichloroquinoline (5.7 g, 82%) as a solid. m/z: 275.2 [M+H]⁺

Step 2: 2,6-Dichloroquinoline-5-carboxylic acid

To a stirred mixture of 5-bromo-2,6-dichloroquinoline (5.7 g, 20.7 mmol)in THF (100 mL) was added isopropyl magnesium chloride (10.5 mL, 20.9mmol, 2.0M in THF) at 0° C. over 1 hour, and then CO₂ was bubbledthrough the reaction mixture, which was kept at 0° C. for 60 min. Themixture was poured into water and extracted with ethyl acetate. Theaqueous layer was acidified with hydrochloric acid (2M) to pH 2˜3 andthe resulting solid was collected by filtration. The solid was washedwith water and dried to afford 2,6-dichloroquinoline-5-carboxylic acid(2.1 g, 42%) as a white solid. m/z: 242.02 [M+H]⁺

Step 3:2,6-Dichloro-N-((4,4-difluorocyclohexyl)methyl)quinoline-5-carboxamide

A mixture of 2,6-dichloro-quinoline-5-carboxylic acid (1500.00 mg; 6.20mmol; 1.00 eq.), (4,4-difluoro-cyclohexyl)-methylamine (1380.48 mg; 7.44mmol; 1.20 eq.), (3-dimethylamino-propyl)-ethyl-carbodiimidehydrochloride (1425.53 mg; 7.44 mmol; 1.20 eq.) (EDCI),benzotriazol-1-ol (1004.81 mg; 7.44 mmol; 1.20 eq.) (HOBt) andethyl-diisopropyl-amine (2402.70 mg; 18.59 mmol; 3.00 eq.) in DMF (10.0mL) was stirred at room temperature overnight. The mixture was pouredinto water, the solid was collected by filtration and washed with ethylacetate, then dried over. The product,2,6-dichloro-N-((4,4-difluorocyclohexyl)methyl)quinoline-5-carboxamide(1.78 g, 77% yield) was used for the next reaction without furtherpurification. m/z: 374 [M+H]⁺

Intermediate 2:2,6-Dichloro-N-((3,3-difluorocyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 2 was synthesized according to the procedure describedfor intermediate 1 using (3,3-difluoro-cyclohexyl)-methylaminehydrochloride instead of (4,4-difluoro-cyclohexyl)-methylamine. m/z: 374[M+H]⁺

Intermediate 3:2,6-Dichloro-N-((3,3-difluoro-1-hydroxycyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 3 was synthesized according to the procedure describedfor intermediate 1 using (3,3-difluoro-hydroxycyclohexyl)-methylaminehydrochloride instead of (4,4-difluoro-cyclohexyl)-methylamine. m/z: 390[M+H]⁺

Intermediate 4:2,6-Dichloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 4 was synthesized according to the procedure describedfor intermediate 1 using (4,4-difluoro-1-hydroxycyclohexyl)-methylaminehydrochloride instead of (4,4-difluoro-cyclohexyl)-methylamine. m/z: 390[M+H]⁺

Intermediate 5:2,6-Dichloro-N-(1-hydroxy-3-methylcyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 5 was synthesized according to the procedure describedfor intermediate 1 using (1-hydroxy-3-methylcyclohexyl)-methylamineinstead of (4,4-difluoro-cyclohexyl)-methylamine. m/z: 368 [M+H]⁺

Intermediate 6:2,6-Dichloro-N-((1R,3R)-1-hydroxy-3-methylcyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 6 was synthesized according to the procedure describedfor intermediate 1 using((1R,3R)-1-hydroxy-3-methylcyclohexyl)-methylamine instead of(4,4-difluoro-cyclohexyl)-methylamine. m/z: 368 [M+H]⁺

Intermediate 7:2,6-Dichloro-N-((1S,3S)-1-hydroxy-3-methylcyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 7 was synthesized according to the procedure describedfor intermediate 1 using((1S,3S)-1-hydroxy-3-methylcyclohexyl)-methylamine instead of(4,4-difluoro-cyclohexyl)-methylamine. m/z: 368 [M+H]⁺

Intermediate 8:2,6-Dichloro-N-(4,4-difluoro-1-hydroxy-3-methylcyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 8 was synthesized according to the procedure describedfor intermediate 1 using(4,4-difluoro-1-hydroxy-3-methylcyclohexyl)-methylamine hydrochlorideinstead of (4,4-difluoro-cyclohexyl)-methylamine. m/z: 404 [M+H]⁺

Intermediate 9:2,6-Dichloro-N-(1-hydroxy-3-trifluoromethylcyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 9 was synthesized according to the procedure describedfor intermediate 1 using(1-hydroxy-3-trifluoromethylcyclohexyl)-methylamine hydrochlorideinstead of (4,4-difluoro-cyclohexyl)-methylamine. m/z: 422 [M+H]⁺

Intermediate 10:2,6-Dichloro-N-(1-hydroxy-3-cyclopropylcyclohexyl)methyl)quinoline-5-carboxamide

The intermediate 10 was synthesized according to the procedure describedin intermediate 1 using (1-hydroxy-3-cyclopropylcyclohexyl)-methylaminehydrochloride instead of (4,4-difluoro-cyclohexyl)-methylamine. m/z: 380[M+H]⁺

Example 1 6-Chloro-2-(3,3-difluoro-azetidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (74)

In a microwave vial 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (100 mg, 0.27 mmol),3,3-difluoro-azetidine hydrochloride (347.07 mg, 2.68 mmol) and DIPEA(519.43 mg, 4.02 mmol) in ACN (1.5 mL) was heated at 120° C. for 2 hoursunder microwave irradiation. After cooling to room temperature, themixture was concentrated and purified through reverse phase HPLC toprovide the desired product (68 mg, 59%) as a solid. ¹H NMR (400 MHz,DMSO-d₆) δ ppm 8.75 (1H), 7.88 (1H), 6.69 (1H), 4.54 (4H), 3.24 (t,J=6.24 Hz, 2H), 2.04 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 3H), 1.27-1.30(m, 2H). m/z: 430 [M+H]

Example 23-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-ylamino}-propionicacid ethyl ester (81)

The title compound was synthesized according to the procedure describedin example 1 by heating 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIEPA and 3-Amino-propionic acidethyl ester hydrochloride in DMSO at 140° C. ¹H NMR (400 MHz, DMSO-d₆) δ4.16 (s, 1H), 4.00 (t, J=13.2 Hz, 2H), 3.78 (t, J=7.60 Hz, 2H), 3.28 (d,J=6.04 Hz, 2H), 8.81 (s, 1H), 7.68-7.77 (m, 2H), 6.93-7.02 (m, 1H),4.05-4.10 (m, 2H), 3.68-3.80 (m, 2H), 3.23 (t, J=6.03 Hz, 2H), 2.01-2.03(m, 2H), 1.73-1.88 (m, 5H), 1.22-2.27 (m, 2H), 1.15-1.19 (m, 3H). m/z:454.0 [M+H]⁺

Example 33-{6-Chloro-5-[(4,4-difluorocyclohexylmethyl)-carbamoyl]-quinolin-2-ylamino}-propionicacid (83)

To a solution of3-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-ylamino}-propionicacid ethyl ester (80 mg, 0.17 mmol, 1.00 eq) in THF (8.00 mL, 100 V) andWater (2.00 mL, 25 V) was added Lithium Hydroxide Monohydrate (14.72 mg,0.35 mmol, 2.00 eq). The reaction mixture was stirred for overnight atroom temperature. The reaction mixture was concentrated under vacuum.The aqueous solution was adjusted to pH 2 and then extracted with ethylacetate and combined organic layer was collected and dried overanhydrous sodium sulphate, filtered, concentrated under vacuum. Thecrude was purified by preparative HPLC to afford the title compound (35mg, 0.08 mmol, 45.3%) as a off-white solid. ¹H NMR (400 MHz, DMSO-d₆): δ8.69 (t, J=6.01 Hz, 1H), 7.60 (d, J=9.22 Hz, 1H), 7.46-7.52 (m, 2H),7.31-7.33 (m, 1H), 6.84 (d, J=9.24 Hz, 1H), 3.57 (q, J=6.43 Hz, 2H),3.22 (t, J=6.40 Hz, 2H), 2.54-2.57 (m, 2H), 2.03-2.00 (m, 2H), 1.72-1.89(m, 5H), 1.22-1.31 (m, 2H). m/z: 426.0 [M+H]⁺

Example 4 6-Chloro-2-(2-dimethylcarbamoyl-ethylamino)-quinoline-5-carboxylic acid (4,4-difluoro-cyclohexyl methyl)-amide (82)

To a stirred solution of3-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-ylamino}-propionicacid (100 mg, 0.22 mmol, 1.00 eq) in DMF (2.00 mL, 20.00 V) were addeddiisopropyl-ethyl amine (0.15 mL, 0.89 mmol, 4.00 eq) andbenzotriazol-1-ol (54.48 mg, 0.33 mmol, 1.50 eq) and stirred for 1 h atroom temperature under nitrogen atmosphere. After 1 h, to the reactionmixture was added dimethyl-amine (22.05 mg, 0.27 mmol, 1.20 eq) and thereaction mixture was stirred overnight at room temperature undernitrogen atmosphere. The crude was diluted with ethyl acetate (50 mL)and washed with water (2×25 mL), brine (2×25 mL). The combined organiclayer was collected, dried over anhydrous sodium sulphate, filtered andconcentrated under vacuum. The crude was purified by silica gelchromatography to afford. The title compound (11.00 mg, 0.02 mmol,10.4%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.69-8.70 (m, 1H),7.59 (d, J=8.81 Hz, 1H), 7.46-7.51 (m, 2H), 7.27 (s, 1H), 6.84 (d,J=9.61 Hz, 1H), 3.59-3.60 (m, 2H), 3.21-3.24 (m, 2H), 2.97 (s, 3H), 2.83(s, 3H), 2.60-2.63 (m, 2H), 2.01-2.03 (m, 2H), 1.73-1.85 (m, 5H),1.23-1.28 (m, 2H). m/z: 453.3 [M+H]⁺

Example 5 6-Chloro-2-(2-methoxy-ethylamino)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (68)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and 2-Methoxy-ethylamine. ¹H NMR(400 MHz, DMSO-d₆): δ 8.70 (t, J=5.81 Hz, 1H), 7.59 (d, J=9.21 Hz, 1H),7.45-7.50 (m, 2H), 7.32 (t, J=5.32 Hz, 1H), 6.88 (d, J=9.21 Hz, 1H),3.55-3.54 (m, 2H), 3.51-3.52 (m, 2H), 3.28 (s, 3H), 3.22 (t, J=6.31 Hz,2H), 2.01-2.03 (m, 2H), 1.73-1.85 (m, 5H), 1.22-1.31 (m, 2H). m/z: 412.0[M+H]⁺

Example 6 6-Chloro-2-(3-methoxy-propylamino)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (77)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and 3-methoxy-propylamine. ¹H NMR(400 MHz, DMSO-d₆) δ ppm 8.70 (t, J=5.8 Hz, 1H), 7.59 (d, J=9.2 Hz, 1H),7.47-7.50 (m, 2H), 7.24 (t, J=5.4 Hz, 1H), 6.82 (d, J=9.2 Hz, 1H),3.39-3.42 (m, 4H), 3.20-3.22 (m, 5H), 2.01-2.03 (m, 2H), 1.73-1.85 (m,7H), 1.22-1.31 (m, 2H). m/z: 426.0 [M+H]⁺

Example 7 6-Chloro-2-(2-hydroxy-ethylamino)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (66)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and 2-amino-ethanol. ¹H NMR (400MHz, DMSO-d₆): δ 8.70 (t, J=5.81 Hz, 1H), 7.59 (d, J=9.21 Hz, 1H), 7.47(s, 2H), 7.27 (t, J=5.21 Hz, 1H), 6.87 (d, J=9.21 Hz, 1H), 4.79-4.81 (m,1H), 3.55-3.59 (m, 2H), 3.44-3.48 (m, 2H), 3.22-3.23 (m, 2H), 1.98-2.03(m, 2H), 1.73-1.85 (m, 5H), 1.22-1.31 (m, 2H). m/z: 398.3 [M+H]⁺

Example 8 6-Chloro-2-(3-hydroxy-propylamino)-quinoline-5-carboxylic acid(4,4-difluoro-cyclo hexyl methyl)-amide (60)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and 3-amino-propan-1-ol. ¹H NMR(400 MHz, DMSO-d₆): δ 8.70 (t, J=5.81 Hz, 1H), 7.59 (d, J=9.12 Hz, 1H),7.47-7.50 (m, 2H), 7.24 (t, J=5.41 Hz, 1H), 6.82 (d, J=9.21 Hz, 1H),4.58-4.60 (m, 1H), 3.46-3.51 (m, 2H), 3.39-3.44 (m, 2H), 3.20-3.23 (m,2H), 2.00-2.03 (m, 2H), 1.82-1.85 (m, 3H), 1.68-1.76 (m, 4H), 1.22-1.31(m, 2H). m/z: 412.2 [M+H]⁺

Example 9 6-Chloro-2-(2-methoxy-ethoxy)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (70)

To a stirred solution of 60% NaH (38.28 mg, 2.0 eq) in THF (5.00 mL,25.00 V) at 0° C. was added 2-methoxy-ethanol (54.74 mg, 0.72 mmol, 1.50eq) and stirred for 30 min. Then 2,6-dichloro-quinoline-5-carboxylicacid (4,4-difluorocyclohexylmethyl)-amide (200 mg, 0.48 mmol, 1.00 eq)was added to reaction mixture at 0 OC and stirred at RT for 12 h. Thereaction was quenched with ice water and extracted with ethyl acetate.The organic layer was dried over anhydrous Na₂SO₄ and evaporated todryness. The crude product was purified by column chromatography toafford. The title compound as (46 mg, 0.1 mmol, 22.3%) as a off-whitesolid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.74 (t, J=5.6 Hz, 1H), 7.73 (d,J=9.61 Hz, 1H), 7.49-7.55 (m, 2H), 7.17 (d, J=9.62 Hz, 1H), 3.23 (t,J=6.41 Hz, 2H), 3.15 (s, 6H), 1.99-2.05 (m, 2H), 1.75-1.85 (m, 5H),1.22-1.28 (m, 2H). m/z: 413.0 [M+H]⁺

Example 10 6-Chloro-2-(3-methoxy-propoxy)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (69)

The title compound was synthesized according to the procedure describedin example 9 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro cyclohexyl methyl)-amide and 3-methoxy-propan-1-ol. ¹H NMR(400 MHz, DMSO-d₆): δ 8.79-8.82 (m, 1H), 7.95 (d, J=9.11 Hz, 1H), 7.79(d, J=9.01 Hz, 1H), 7.70 (d, J=9.01 Hz, 1H), 7.12 (d, J=9.12 Hz, 1H),4.45 (t, J=13.2 Hz, 2H), 3.49 (t, J=12.61 Hz, 2H), 3.25 (s, 5H),1.97-2.04 (m, 4H), 1.80-1.86 (m, 3H), 1.73-1.76 (m, 2H), 1.23-1.32 (m,2H). m/z: 427.0 [M+H]⁺

Example 11 6-Chloro-2-(3-methoxy-propoxy)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexyl methyl)-amide (62)

The title compound was synthesized according to the procedure describedin example 9 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide and3-methoxy-propan-1-ol. ¹H NMR (400 MHz, DMSO-d₆): δ 8.74 (t, J=6.01 Hz,1H), 8.03 (d, J=9.61 Hz, 1H), 7.77-7.80 (m, 1H), 7.69-7.71 (m, 1H), 7.10(d, J=9.21 Hz, 1H), 4.68 (s, 1H), 4.45 (t, J=6.41 Hz, 2H), 3.47-3.50 (m,2H), 3.38-3.39 (m, 2H), 3.25 (s, 3H), 2.01-2.04 (m, 4H), 1.90-2.00 (m,2H), 1.67-1.72 (m, 4H). m/z: 443.2 [M+H]⁺

Example 12 6-Chloro-2-(3-hydroxy-prop-1-ynyl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclo hexylmethyl)-amide (19)

To a solution of 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (500 mg, 1.24 mmol, 1.00 eq) indegassed 1,4-dioxane (2.50 mL, 5.00 V), prop-2-yn-1-ol (0.09 mL, 1.49mmol, 1.20 eq) Et₃N (0.52 mL, 3.71 mmol, 3.00 eq),Bis(triphenylphosphine)palladium (II) dichloride (34.86 mg, 0.05 mmol,0.04 eq) and copper (I) iodide (4.81 mg, 0.02 mmol, 0.02 eq) were added.The reaction mixture was heated at 90° C. for 1 h. The reaction mixturewas diluted with dichloromethane and filtered through celite. Thefiltrate was concentrated and subjected to column chromatography toafford the title compound (0.38 g, 0.94 mmol, 75.7%) as a off-whitesolid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.87 (t, J=5.92 Hz, 1H), 8.09 (d,J=8.61 Hz, 1H), 8.01 (d, J=9.01 Hz, 1H), 7.86 (d, J=9.11 Hz, 1H), 7.68(d, J=8.72 Hz, 1H), 5.53 (t, J=6.13 Hz, 1H), 4.39 (d, J=6.01 Hz, 2H),3.27 (t, J=6.32 Hz, 2H), 1.98-2.04 (m, 2H), 1.74-1.86 (m, 5H), 1.24-1.33(m, 2H). m/z: 393.2 [M+H]⁺

Example 13 6-Chloro-2-(3-hydroxy-propyl)-quinoline-5-carboxylic acid(4,4-Difluorocyclohexyl methyl)-amide (64)

To a solution of6-chloro-2-(3-hydroxy-prop-1-ynyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (0.25 g, 0.62 mmol, 1.00 eq) inmethanol (5 mL, 20 V) were added trimethylsilane (0.65 mL, 6.23 mmol, 10eq) and followed by palladium on carbon (10% w/w) (0.07 g, 0.06 mmol,0.10 eq) at 0 OC. The reaction mixture was stirred for 0.5 h. After thecompletion of the reaction as evidenced by TLC, the reaction mixture wasconcentrated under vacuum. The reaction mixture was diluted with ethylacetate (20 mL) and extracted with water (20 mL) and brine solution (20mL). The organic layer was separated and dried over Na₂SO₄ andconcentrated under vacuum. The crude product was further purified bycolumn chromatography to afford the title compound (0.08 g, 0.18 mmol,29.0%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.82 (t, J=5.83Hz, 1H), 7.96-8.01 (m, 2H), 7.76 (d, J=9.01 Hz, 1H), 7.55 (d, J=8.72 Hz,1H), 4.58 (t, J=6.22 Hz, 1H), 3.46 (t, J=6.41 Hz, 2H), 3.27 (t, J=6.22Hz, 2H), 2.95 (t, J=7.62 Hz, 2H), 2.02-2.04 (m, 2H), 1.74-1.93 (m, 7H),1.29-1.33 (m, 2H). m/z: 397.2 [M+H]⁺

Example 146-Chloro-2-((R)-3-hydroxymethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (12)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(R)-pyrrolidin-3-ylmethanol. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75 (1H),7.48 (2H), 6.69 (1H), 4.72 (1H), 3.66 (m, 2H), 3.49 (m, 2H), 3.32 (m,2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H),1.27-1.30 (m, 2H). m/z: 438 [M+H]

Example 156-Chloro-2-((S)-3-hydroxymethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (29)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and (S)-pyrrolidin-3-ylmethanol. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75 (1H), 7.48 (2H), 6.69(1H), 4.72 (1H), 3.66 (m, 2H), 3.49 (m, 2H), 3.32 (m, 2H), 2.44 (m, 2H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.30 (m, 2H). m/z:438 [M+H]

Example 16 2-(azetidin-1-yl)-6-Chloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (49)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and azetidine. ¹H NMR (400MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.88 (1H), 6.69 (1H), 4.49 (m, 4H), 3.24(m, 2H), 2.40 (m, 2H), 2.04 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 3H),1.27-1.30 (m, 2H). m/z: 394 [M+H].

Example 176-Chloro-2-((R)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (33)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75 (1H), 7.48(2H), 6.69 (1H), 5.43-5.56 (1H), 3.89 (m, 2H), 3.70 (m, 1H), 3.55 (m,1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76(m, 5H), 1.27-1.32 (m, 2H). m/z: 426 [M+H]

Example 186-Chloro-2-((S)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (41)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75 (1H), 7.48(2H), 6.69 (1H), 5.43-5.56 (1H), 3.89 (m, 2H), 3.70 (m, 1H), 3.55 (m,1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76(m, 5H), 1.27-1.32 (m, 2H). m/z: 426 [M+H]

Example 196-Chloro-2-(3-difluoromethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (59)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and3-Difluoromethyl-pyrrolidine hydrochloride. ¹H NMR (400 MHz, DMSO-d₆): δ8.75 (t, J=5.81 Hz, 1H), 7.75 (dd, J=9.31, Hz, 1H), 7.51-7.58 (m, 2H),7.01 (d, J=9.01 Hz, 1H), 6.05-6.34 (m, 1H), 3.67-3.76 (m, 2H), 3.51-3.57(m, 2H), 3.22-3.24 (m, 2H), 2.84-2.93 (m, 1H), 2.13-2.21 (m, 1H),1.99-2.06 (m, 3H), 1.73-1.86 (m, 5H), 1.23-1.32 (m, 2H). m/z: 458.2[M+H]⁺

Example 206-Chloro-2-(3-methylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (17)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and methyl-pyrrolidin-3-yl-amine.¹H NMR (400 MHz, DMSO-d₆): δ 8.73-8.76 (m, 1H), 7.70-7.73 (m, 1H),7.48-7.54 (m, 2H), 6.94-6.96 (m, 1H), 3.53-3.56 (m, 3H), 3.22-3.29 (m,4H), 2.31-2.34 (m, 5H), 2.01-2.13 (m, 3H), 1.73-1.86 (m, 6H), 1.23-1.32(m, 2H). m/z: 458.2 [M+H]⁺

Example 216-Chloro-2-((S)-3-methylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (99)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(S)-3-methylaminopyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75 (1H),7.48 (2H), 6.69 (1H), 3.66 (m, 2H), 3.49 (m, 2H), 3.32 (m, 2H), 2.36 (s,3H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.30 (m, 2H).m/z: 437 [M+H]

Example 226-Chloro-2-((R)-3-methylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (100)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(R)-3-methylaminopyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75 (1H),7.48 (2H), 6.69 (1H), 3.66 (m, 2H), 3.49 (m, 2H), 3.32 (m, 2H), 2.36 (s,3H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.30 (m, 2H).m/z: 437 [M+H]

Example 232-(3-Acetylamino-pyrrolidin-1-yl)-6-chloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (67)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and N-pyrrolidin-3-yl-acetamidewith DMSO as a solvent. ¹H NMR (400 MHz, DMSO-d₆): δ 8.73-8.76 (m, 1H),8.17-8.18 (m, 1H), 7.72-7.75 (m, 1H), 7.49-7.56 (m, 2H), 6.96-6.99 (m,1H), 4.34-4.35 (m, 1H), 3.71-3.76 (m, 1H), 3.59-3.63 (m, 2H), 3.38-3.40(m, 1H), 3.22-3.25 (m, 2H), 2.15-2.20 (m, 1H), 2.01-2.07 (m, 2H),1.73-1.94 (m, 9H), 1.29-1.32 (m, 2H). m/z: 465.2 [M+H]⁺

Example 24 6-Chloro-2-(3-hydroxy-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclo hexylmethyl)-amide (57)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and pyrrolidin-3-ol. ¹H NMR (400MHz, DMSO-d₆): δ 8.74 (t, J=5.62 Hz, 1H), 7.72 (d, J=9.61 Hz, 1H), 7.52(dd, J=9.21, 8.20 Hz, 2H), 6.96 (d, J=9.23 Hz, 1H), 4.97-5.01 (m, 1H),3.55-3.61 (m, 4H), 3.22-3.25 (m, 2H), 2.02-2.04 (m, 3H), 1.73-1.94 (m,6H), 1.15-1.32 (m, 2H). m/z: 424.2 [M+H]⁺

Example 25 6-Chloro-2-(3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylicacid (3,3-difluoro-cyclohexylmethyl)-amide (39)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide, DIPEA and 3-fluoropyrrolidine. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.75 (m, 1H), 7.55 (2H), 7.05(1H), 5.43-5.56 (1H), 3.89 (m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m,2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H),1.27-1.32 (m, 2H). m/z: 426 [M+H]

Example 266-Chloro-2-((S)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide (3)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.75(m, 1H), 7.55 (2H), 7.05 (1H), 5.43-5.56 (1H), 3.89 (m, 2H), 3.70 (m,1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m,2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 426 [M+H]

Example 276-Chloro-2-((R)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide (1)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.75(m, 1H), 7.55 (2H), 7.05 (1H), 5.43-5.56 (1H), 3.89 (m, 2H), 3.70 (m,1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m,2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 426 [M+H]

Example 28 6-Chloro-2-(3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylicacid (3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (38)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m,1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.56 (s, 1H), 3.89 (m, 2H),3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H),1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 442 [M+H]

Example 296-Chloro-2-((S)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (36)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and(S)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.56 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 442 [M+H]

Example 306-Chloro-2-((R)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (37)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and(R)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.56 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 442 [M+H]

Example 31 2-(3-Aminopyrrolidin-1-yl)-6-chloro-quinoline-5-carboxylicacid (3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (32)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3-aminopyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m,1H), 7.58 (2H), 7.05 (1H), 4.61 (s, 1H), 4.01 (m, 2H), 3.80 (m, 2H),3.45 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H),1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 439 [M+H]

Example 32 6-Chloro-2-(3,3-difluoroazetidin-1-yl)-quinoline-5-carboxylicacid (3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (75)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3,3-difluoroazetidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.94(m, 1H), 7.66 (2H), 7.05 (1H), 4.57 (m, 4H), 3.49 (m, 2H), 2.44 (m, 2H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z:446 [M+H]

Example 33 2-(Azetidin-1-yl)-6-chloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (54)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and azetidine. ¹HNMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.84 (m, 1H), 7.56 (2H), 6.85(1H), 4.57 (m, 1H), 4.11 (m, 4H), 3.49 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 410 [M+H]

Example 346-Chloro-2-(3-hydroxymethylpyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide (35)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide, DIPEA andpyrrolidin-3-ylmethanol. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.72 (1H), 7.75(m, 1H), 7.55 (2H), 7.05 (1H), 4.73 (1H), 3.65 (m, 2H), 3.50 (m, 3H),3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m,5H), 1.27-1.32 (m, 2H). m/z: 438 [M+H]

Example 356-Chloro-2-(3-hydroxyethyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide (63)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide, DIPEA and pyrrolidin-3-ylethanol.¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.72 (m, 1H), 7.75 (1H), 7.48 (2H), 6.96(1H), 4.48 (1H), 3.79 (m, 1H), 3.66 (m, 1H), 3.49 (m, 2H), 3.34 (m, 1H),3.23 (m, 2H), 3.09 (m, 1H), 2.44 (m, 1H), 2.12 (m, 1H), 2.06 (m, 2H),1.85 (m, 2H), 1.77 (m, 2H), 1.60 (m, 4H), 1.27-1.30 (m, 2H). m/z: 452[M+H]

Example 366-Chloro-2-((R)-3-hydroxyethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (11)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(R)-pyrrolidin-3-ylethanol. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.71 (m,1H), 7.75 (1H), 7.48 (2H), 6.96 (1H), 4.52 (1H), 3.79 (m, 1H), 3.66 (m,1H), 3.49 (m, 2H), 3.34 (m, 1H), 3.23 (m, 2H), 3.09 (m, 1H), 2.44 (m,1H), 2.12 (m, 1H), 2.06 (m, 2H), 1.85 (m, 2H), 1.77 (m, 2H), 1.60 (m,4H), 1.27-1.30 (m, 2H). m/z: 452 [M+H]

Example 376-Chloro-2-((S)-3-hydroxyethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (26)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(S)-pyrrolidin-3-ylethanol. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.71 (m,1H), 7.75 (1H), 7.48 (2H), 6.96 (1H), 4.52 (1H), 3.79 (m, 1H), 3.66 (m,1H), 3.49 (m, 2H), 3.34 (m, 1H), 3.23 (m, 2H), 3.09 (m, 1H), 2.44 (m,1H), 2.12 (m, 1H), 2.06 (m, 2H), 1.85 (m, 2H), 1.77 (m, 2H), 1.60 (m,4H), 1.27-1.30 (m, 2H). m/z: 452 [M+H]

Example 386-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (30)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and3-pyrrolidinyl-pyrrolidine dihydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δppm 7.75 (1H), 7.48 (2H), 6.69 (1H), 3.89 (m, 1H), 3.70 (m, 1H), 3.45(m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H), 2.15 (m, 1H), 2.06(m, 2H), 1.85 (m, 3H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 478[M+H]

Example 396-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide (34)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-cyclohexylmethyl)-amide, DIPEA and3-pyrrolidinyl-pyrrolidine dihydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δppm 7.75 (1H), 7.48 (2H), 6.69 (1H), 3.89 (m, 1H), 3.70 (m, 1H), 3.45(m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H), 2.15 (m, 1H), 2.06(m, 2H), 1.85 (m, 3H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 478[M+H]

Example 406-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide (27)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3-pyrrolidinyl-pyrrolidine dihydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δppm 7.75 (1H), 7.48 (2H), 6.69 (1H), 4.59 (s, 1H), 3.89 (m, 1H), 3.70(m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H), 2.15(m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m, 5H), 1.27-1.32 (m,2H). m/z: 494 [M+H]

Example 41 6-Chloro-2-pyrrolidin-1-yl-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (16)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-Dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexyl methyl)-amide and pyrrolidine. ¹HNMR (400 MHz, DMSO-d₆): δ 8.50 (t, J=6.01 Hz, 1H), 7.80 (d, J=9.21 Hz,1H), 7.47-7.54 (m, 2H), 6.96 (d, J=9.22 Hz, 1H), 4.16 (s, 1H), 3.51-3.53(m, 4H), 3.26-3.28 (m, 2H), 1.97-1.98 (m, 4H), 1.71-1.73 (m, 1H),1.45-1.61 (m, 6H), 1.00-1.07 (m, 1H), 0.83-0.84 (m, 3H), 0.73-0.74 (m,1H). m/z: 402.2 [M+H]⁺

Example 42 6-Chloro-2-pyrrolidin-1-yl-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (2)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-Dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexyl methyl)-amide and pyrrolidine. ¹HNMR (400 MHz, DMSO-d₆): δ 8.50 (t, J=6.01 Hz, 1H), 7.80 (d, J=9.22 Hz,1H), 7.47-7.54 (m, 2H), 6.96 (d, J=9.21 Hz, 1H), 4.16 (s, 1H), 3.51-3.53(m, 4H), 3.26-3.28 (m, 2H), 1.97-1.98 (m, 4H), 1.71-1.73 (m, 1H),1.45-1.61 (m, 6H), 1.00-1.07 (m, 1H), 0.83-0.84 (m, 3H), 0.73-0.79 (m,1H). m/z: 402.2 [M+H]⁺

Example 43 6-Chloro-2-(3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (5)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m,1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m, 2H),3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H),1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H). m/z:420 [M+H]

Example 446-Chloro-2-(3-(R)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (8)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-ds) 6 ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H).m/z: 420 [M+H]

Example 456-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (9)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H).m/z: 420 [M+H]

Example 466-Chloro-2-((R)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide (23)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and(R)—N,N-dimethylpyrrolidin-3-amine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.73(m, 1H), 7.85 (1H), 7.48 (m, 2H), 6.69 (1H), 4.66 (s, 1H), 3.89 (m, 1H),3.70 (m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H),2.22 (s, 6H), 2.15 (m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m,5H). m/z: 467 [M+H]

Example 476-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexylmethyl)-amide (88)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA andN,N-dimethylpyrrolidin-3-amine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,1H), 0.83 (d, 3H). m/z: 446 [M+H]

Example 486-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (6)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H), 3.80 (t,1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t, 1H), 0.83(d, 3H). m/z: 446 [M+H]

Example 496-Chloro-2-((S)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (1-hydroxy-3-methyl-cyclohexylmethyl)-amide (87)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(S)—N,N-dimethylpyrrolidin-3-amine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,1H), 0.83 (d, 3H). m/z: 446 [M+H]

Example 516-Chloro-2-((S)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (4)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and((S)—N,N-dimethylpyrrolidin-3-amine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t,2H), 3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s,6H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07(t, 1H), 0.83 (d, 3H). m/z: 446 [M+H]

Example 526-Chloro-2-((R)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (22)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(R)—N,N-dimethylpyrrolidin-3-amine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,1H), 0.83 (d, 3H). m/z: 446 [M+H]

Example 536-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (13)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-pyrrolidinyl-pyrrolidine dihydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δppm 8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00(t, 2H), 3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06(m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t, 1H),0.83 (d, 3H). m/z: 472 [M+H]

Example 546-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide (28)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA andN,N-dimethylpyrrolidin-3-amine. 1H NMR (400 MHz, DMSO-d₆) δ ppm 8.73 (m,1H), 7.85 (1H), 7.48 (m, 2H), 6.69 (1H), 4.66 (s, 1H), 3.89 (m, 1H),3.70 (m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H),2.22 (s, 6H), 2.15 (m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m,5H). m/z: 467 [M+H]

Example 556-Chloro-2-((S)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide (20)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and(S)—N,N-dimethylpyrrolidin-3-amine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.73(m, 1H), 7.85 (1H), 7.48 (m, 2H), 6.69 (1H), 4.66 (s, 1H), 3.89 (m, 1H),3.70 (m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H),2.22 (s, 6H), 2.15 (m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m,5H). m/z: 467 [M+H]

Example 566-Chloro-2-(3,3-difluoro-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide (91)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-Dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclo hexyl methyl)-amide, and3,3-Difluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.68-8.71 (bs,1H), 7.89 (d, J=9.2 Hz, 1H), 7.55-7.62 (m, 2H), 7.03 (d, J=9.3 Hz, 1H),4.67 (s, 1H), 3.96-4.03 (m, 2H), 3.76-3.80 (m, 2H), 3.37-3.39 (m, 2H),2.54-2.61 (m, 2H), 1.88-2.08 (m, 4H), 1.68-1.76 (m, 4H). m/z: 460.2[M+H]⁺

Example 576-Chloro-2-(3,3-difluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (46)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3,3-difluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 4.61 (s, 1H), 4.01 (m, 2H), 3.80 (m, 2H),3.45 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H),1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 460 [M+H]

Example 586-Chloro-2-(3,3-difluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((R)-3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (24)

The title compound was separated from6-Chloro-2-(3,3-difluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide through the chiralcolumn. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m, 1H), 7.58(2H), 7.05 (1H), 4.61 (s, 1H), 4.01 (m, 2H), 3.80 (m, 2H), 3.45 (m, 1H),3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m,5H), 1.27-1.32 (m, 2H). m/z: 460 [M+H]

Example 596-Chloro-2-(3,3-difluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((S)-3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (80)

The title compound was separated from6-Chloro-2-(3,3-difluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide through the chiralcolumn. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m, 1H), 7.58(2H), 7.05 (1H), 4.61 (s, 1H), 4.01 (m, 2H), 3.80 (m, 2H), 3.45 (m, 1H),3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m,5H), 1.27-1.32 (m, 2H). m/z: 460 [M+H]

Example 606-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexylmethyl)-amide (89)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H).m/z: 420 [M+H]

Example 616-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexylmethyl)-amide (90)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H).m/z: 420 [M+H]

Example 626-Chloro-2-((S)-3-hydroxymethyl-ethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (98)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and(S)-3-hydroxymethyl-ethyl-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm7.75 (1H), 7.48 (2H), 6.69 (1H), 4.72 (1H), 3.66 (m, 2H), 3.49 (m, 2H),3.32 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m,5H), 1.27-1.30 (m, 2H). m/z: 466 [M+H]

Example 636-Chloro-2-(3,3-difluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexylmethyl)-amide (97)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3,3-difluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 3.89 (m, 2H), 3.70 (m, 1H),3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H),1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H). m/z: 438 [M+H]

Example 646-Chloro-2-(3,3-difluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (10)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3,3-difluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H), 3.80 (t, 1H),3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H),1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H). m/z: 438 [M+H]

Example 656-Chloro-2-(3,3-difluoro-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (86)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-Dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and3,3-difluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆): δ 8.54 (t, J=6.01Hz, 1H), 7.89 (d, J=9.32 Hz, 1H), 7.54-7.61 (m, 2H), 7.04 (d, J=9.21 Hz,1H), 4.16 (s, 1H), 3.96-4.03 (m, 2H), 3.45 (t, J=5.00 Hz, 2H), 3.27-3.28(m, 2H), 2.56-2.59 (m, 3H), 1.73-1.75 (m, 1H), 1.52-1.61 (m, 4H),1.46-1.47 (m, 1H), 1.34-1.38 (m, 1H), 1.18-1.19 (m, 1H), 0.84-0.87 (m,4H). m/z: 438.2 [M+H]⁺

Example 666-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexylmethyl)-amide (96)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-pyrrolidin-yl-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 3.89 (m, 2H), 3.70 (m,1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m,2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H), 0.77 (m, 1H).m/z: 472 [M+H]

Example 67 6-Chloro-2-(3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylicacid (1-hydroxy-3-methyl-cyclohexylmethyl)-amide (95)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m,1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m, 2H),3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H),1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H). m/z:420 [M+H]

Example 686-Chloro-2-((R)-3-hydroxymethyl-ethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (101)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and(R)-3-hydroxymethyl-ethyl-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm7.75 (1H), 7.48 (2H), 6.69 (1H), 4.72 (1H), 3.66 (m, 2H), 3.49 (m, 2H),3.32 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m,5H), 1.27-1.30 (m, 2H). m/z: 466 [M+H]

Example 696-Chloro-2-(3-(1-hydroxyethyl)-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (102)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3-hydroxyethyl-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75 (1H),7.48 (2H), 6.69 (1H), 4.62 (m, 1H), 3.71-3.66 (m, 2H), 3.49 (m, 2H),3.32 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m,5H), 1.30 (m, 2H), 1.13 (m, 3H). m/z: 452 [M+H]

Example 706-Chloro-2-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (103)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and4-fluoro-2-hydroxymethyl-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm7.75 (1H), 7.48 (2H), 6.69 (1H), 5.33-5.52 (1H), 4.31 (m, 1H), 3.89 (m,1H), 3.70 (m, 3H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 456 [M+H]

Example 716-Chloro-2-(3-hydroxy-methyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (85)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-(1-hydroxy-methyl)-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.47 (s, 1H), 4.14 (s, 1H),3.65 (m, 2H), 3.45 (m, 3H), 3.28 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H),1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.15 (m, 1H), 1.03 (m, 1H), 0.83 (d,3H), 0.74 (m, 1H). m/z: 432 [M+H]

Example 726-Chloro-2-(3-hydroxymethyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl cyclo hexylmethyl)-amide (84)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid2,6-Dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and3-(1-hydroxy-methyl)-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆): δ 8.49 (t,J=6.16 Hz, 1H), 7.80 (d, J=9.28 Hz, 1H), 7.53-7.47 (m, 2H), 6.94 (d,J=9.32 Hz, 1H), 4.73-4.72 (m, 1H), 4.15 (s, 1H), 3.64-3.49 (m, 2H),3.47-3.41 (m, 3H), 2.42 (s, 1H), 2.05-2.03 (m, 1H), 1.79-1.60 (m, 2H),1.60-1.47 (m, 5H), 1.29-1.28 (m, 1H), 1.18-1.17 (m, 1H), 0.84-0.82 (m,3H), 0.75-0.75 (m, 1H) m/z: 432.2 [M+H]⁺

Example 736-Chloro-2-(4-fluoro-2-hydroxymethyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (104)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and4-fluoro-2-(hydroxymethyl) pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 5.07 (m,1H), 4.31 (m, 1H), 4.16 (s, 1H), 3.89 (m, 1H), 3.70 (m, 2H), 3.55 (m,1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76(m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H), 0.74 (m, 1H). m/z: 450 [M+H]

Example 746-Chloro-2-(3-(1-hydroxyethyl)-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (105)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-(1-hydroxyethyl)-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.69 (m, 1H), 4.16 (s, 1H),3.89 (m, 1H), 3.70 (m, 2H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.15 (m, 3H), 1.03 (m,1H), 0.83 (d, 3H), 0.74 (m, 1H). m/z: 446 [M+H]

Example 756-Chloro-2-((R)-3-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (106)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-(1-hydroxy-1-methyl-ethyl)-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆)δ ppm 8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.40 (s, 1H), 4.14(s, 1H), 3.74 (m, 1H), 3.65 (m, 1H), 3.36 (m, 2H), 3.28 (m, 2H), 2.44(m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.15 (m, 6H),1.03 (m, 1H), 0.83 (d, 3H), 0.74 (m, 1H). m/z: 460 [M+H]

Example 766-Chloro-2-((S)-3-(1-hydroxy-1-methyl-ethyl)-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (107)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-(1-hydroxy-1-methyl-ethyl)-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆)δ ppm 8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.40 (s, 1H), 4.14(s, 1H), 3.74 (m, 1H), 3.65 (m, 1H), 3.36 (m, 2H), 3.28 (m, 2H), 2.44(m, 2H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.15 (m, 6H),1.03 (m, 1H), 0.83 (d, 3H), 0.74 (m, 1H). m/z: 460 [M+H]

Example 776-Chloro-2-(3-diethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (108)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3-diethylaminopyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.56 (s, 1H), 3.89 (m, 1H), 3.70 (m,1H), 3.45 (m, 3H), 3.34 (m, 2H), 3.26 (m, 1H), 2.63 (m, 4H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 2H), 1.27-1.32 (m, 2H), 0.98 (m, 5H).m/z: 496 [M+H]

Example 786-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxy-cyclohexylmethyl)-amide (109)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide, DIPEA and3-pyrrolidin-yl-pyrrolidine dihydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δppm 7.75 (1H), 7.48 (2H), 6.69 (1H), 4.59 (s, 1H), 3.89 (m, 1H), 3.70(m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H), 2.15(m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m, 5H), 1.27-1.32 (m,2H). m/z: 494 [M+H]

Example 796-Chloro-2-(3-(2-hydroxyethyl)-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (110)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-(2-hydroxyethyl)-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.69 (m, 1H), 4.16 (s, 1H),3.89 (m, 1H), 3.70 (m, 2H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.15 (m, 3H), 1.03 (m,1H), 0.83 (d, 3H), 0.74 (m, 1H). m/z: 446 [M+H]

Example 806-Chloro-2-((S)-3-hydroxy-methyl-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (111)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-(hydroxymethyl)-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.47 (s, 1H), 4.14 (s, 1H),3.65 (m, 2H), 3.45 (m, 3H), 3.28 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H),1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.15 (m, 1H), 1.03 (m, 1H), 0.83 (d,3H), 0.74 (m, 1H). m/z: 432 [M+H]

Example 81 2-(Azetidin-1-yl)-6-chloro-quinoline-5-carboxylic acid((S)-3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (112)

The title compound was separated from6-Chloro-2-(azetidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide through the chiralcolumn. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.84 (m, 1H), 7.56(2H), 6.85 (1H), 4.57 (m, 1H), 4.11 (m, 4H), 3.49 (m, 2H), 2.44 (m, 2H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z:410 [M+H]

Example 82 2-(Azetidin-1-yl)-6-chloro-quinoline-5-carboxylic acid((R)-3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (113)

The title compound was separated from6-Chloro-2-(azetidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide through the chiralcolumn. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.84 (m, 1H), 7.56(2H), 6.85 (1H), 4.57 (m, 1H), 4.11 (m, 4H), 3.49 (m, 2H), 2.44 (m, 2H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z:410 [M+H]

Example 836-Chloro-2-((R)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (114)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(R)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75(1H), 7.48 (2H), 6.69 (1H), 3.66 (m, 2H), 3.49 (m, 2H), 3.32 (m, 2H),2.36 (s, 6H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.30(m, 2H). m/z: 451 [M+H]

Example 846-Chloro-2-((S)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide (115)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, DIPEA and(S)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 7.75(1H), 7.48 (2H), 6.69 (1H), 3.66 (m, 2H), 3.49 (m, 2H), 3.32 (m, 2H),2.36 (s, 6H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.30(m, 2H). m/z: 451 [M+H]

Example 856-Chloro-2-((R)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide (116)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.56 (s, 1H), 3.89(m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06(m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 442[M+H]

Example 866-Chloro-2-((S)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide (117)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.56 (s, 1H), 3.89(m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06(m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 2H). m/z: 442[M+H]

Example 876-Chloro-2-((S)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (160)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66 (s, 1H), 3.89(m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06(m, 2H), 1.85 (m, 2H), 1.74-1.56 (m, 1H), 1.27-1.32 (m, 1H), 1.00 (d,3H). m/z: 456 [M+H]

Example 886-Chloro-2-((R)-3-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (161)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66 (s, 1H), 3.89(m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06(m, 2H), 1.85 (m, 2H), 1.74-1.56 (m, 1H), 1.27-1.32 (m, 1H), 1.00 (d,3H). m/z: 456 [M+H]

Example 896-Chloro-2-((R)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (118)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66 (s, 1H),3.89 (m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H),2.26 (s, 6H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.56 (m, 1H), 1.27-1.32(m, 1H), 1.00 (d, 3H). m/z: 481 [M+H]

Example 906-Chloro-2-(3-(S)-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (119)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66 (s, 1H),3.89 (m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H),2.26 (s, 6H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.56 (m, 1H), 1.27-1.32(m, 1H), 1.00 (d, 3H). m/z: 481 [M+H]

Example 916-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (120)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66 (s, 1H), 3.89(m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.26(s, 6H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.56 (m, 1H), 1.27-1.32 (m,1H), 1.00 (d, 3H). m/z: 481 [M+H]

Example 926-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (121)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and3-pyrrolidin-yl-pyrrolidine dihydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δppm 8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66(s, 1H), 3.89 (m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.24(m, 2H), 2.06 (m, 4H), 1.85 (m, 2H), 1.74-1.56 (m, 3H), 1.27-1.32 (m,1H), 1.00 (d, 3H). m/z: 508 [M+H]

Example 936-Chloro-2-(3-difluoro-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (122)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and3,3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.24 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.56 (m, 1H), 1.27-1.32 (m, 1H), 1.00 (d, 3H).m/z: 474 [M+H]

Example 946-Chloro-2-(3-diethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (123)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, DIPEA and3-diethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.66 (s, 1H), 3.89(m, 2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.19 (m, 3H), 2.06(m, 2H), 1.85 (m, 3H), 1.74-1.56 (m, 1H), 1.27-1.32 (m, 1H), 1.00 (m,9H). m/z: 505 [M+H]

Example 956-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxy-cyclohexylmethyl)-amide (124)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxy-cyclohexylmethyl)-amide, DIPEA and3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.73 (m,1H), 7.85 (1H), 7.48 (m, 2H), 6.69 (1H), 4.66 (s, 1H), 3.89 (m, 1H),3.70 (m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H),2.22 (s, 6H), 2.15 (m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m,5H). m/z: 467 [M+H]

Example 966-Chloro-2-(3-(S)-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (3,3-difluoro-1-hydroxy-cyclohexylmethyl)-amide (125)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxy-cyclohexylmethyl)-amide, DIPEA and(S)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.73(m, 1H), 7.85 (1H), 7.48 (m, 2H), 6.69 (1H), 4.66 (s, 1H), 3.89 (m, 1H),3.70 (m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H),2.22 (s, 6H), 2.15 (m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m,5H). m/z: 467 [M+H]

Example 976-Chloro-2-(3-(R)-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (3,3-difluoro-1-hydroxy-cyclohexylmethyl)-amide (126)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxy-cyclohexylmethyl)-amide, DIPEA and(R)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.73(m, 1H), 7.85 (1H), 7.48 (m, 2H), 6.69 (1H), 4.66 (s, 1H), 3.89 (m, 1H),3.70 (m, 1H), 3.45 (m, 1H), 3.26 (m, 2H), 2.85 (m, 1H), 2.54 (m, 4H),2.22 (s, 6H), 2.15 (m, 1H), 2.06 (m, 2H), 1.85 (m, 3H), 1.74-1.76 (m,5H). m/z: 467 [M+H]

Example 986-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((R)-3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (127)

The title compound was separated from6-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide through the chiralcolumn. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m, 1H), 7.58(2H), 7.05 (1H), 5.57-5.44 (d, 1H), 4.58 (s, 1H), 3.98 (m, 2H), 3.80 (m,2H), 3.45 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m,2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H). m/z: 442 [M+H]

Example 996-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((S)-3,3-difluoro-1-hydroxycyclohexylmethyl)-amide (128)

The title compound was separated from6-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid(3,3-difluoro-1-hydroxycyclohexylmethyl)-amide through the chiralcolumn. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85 (m, 1H), 7.58(2H), 7.05 (1H), 5.57-5.44 (d, 1H), 4.58 (s, 1H), 3.98 (m, 2H), 3.80 (m,2H), 3.45 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m, 2H), 1.85 (m,2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H). m/z: 442 [M+H]

Example 1006-Chloro-2-(3-(R)-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (129)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,1H), 0.83 (d, 3H). m/z: 446 [M+H]

Example 1016-Chloro-2-(3-(S)-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (130)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,1H), 0.83 (d, 3H). m/z: 446 [M+H]

Example 1026-Chloro-2-(3-(S)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (131)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H).m/z: 420 [M+H]

Example 1036-Chloro-2-(3-(R)-fluoropyrrolidin-1-yl)-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (132)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoropyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (1H), 4.16 (s, 1H), 3.89 (m,2H), 3.70 (m, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27-1.32 (m, 1H), 0.83 (d, 3H).m/z: 420 [M+H]

Example 1046-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (133)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H), 3.80 (t,1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t, 1H), 0.83(d, 3H). m/z: 446 [M+H]

Example 1056-Chloro-2-(3-diethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (134)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-diethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H), 3.80 (t,1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t, 3H), 0.83(d, 3H). m/z: 474 [M+H]

Example 1066-Chloro-2-(3-ethyl-methyl-amino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (135)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-ethylmethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 3H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,3H), 0.83 (d, 3H). m/z: 460 [M+H]

Example 1076-Chloro-2-(3-isopropyl-methyl-amino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (136)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-isopropylmethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 3H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,4H), 0.83 (d, 3H). m/z: 474 [M+H]

Example 1086-Chloro-2-(3-cyclopropyl-methyl-amino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (137)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-cyclopropyl-methyl-amino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t,2H), 3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s,3H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07(t, 1H), 0.83 (d, 4H). m/z: 472 [M+H]

Example 1096-Chloro-2-(3-pyrrolidinyl-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (138)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-pyrrolidinyl-pyrrolidine dihydrochloride. ¹H NMR (400 MHz, DMSO-d₆) δppm 8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00(t, 2H), 3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.06(m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t, 1H),0.83 (d, 3H). m/z: 472 [M+H]

Example 1106-Chloro-2-(3-cyclopropyl-methyl-amino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (139)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-cyclopropyl-methyl-amino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t,2H), 3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s,3H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07(t, 1H), 0.83 (d, 4H). m/z: 472 [M+H]

Example 1116-Chloro-2-(3-ethyl-methyl-amino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (140)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-ethyl-methyl-amino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H),3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 3H),2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t,3H), 0.83 (d, 3H). m/z: 460 [M+H]

Example 1126-Chloro-2-(3-isopropyl-methyl-amino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (141)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-isopropyl-methyl-amino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm8.75 (1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t,2H), 3.80 (t, 1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s,3H), 2.06 (m, 2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07(t, 4H), 0.83 (d, 3H). m/z: 474 [M+H]

Example 1136-Chloro-2-(3-diethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (142)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3methyl-cyclohexylmethyl)-amide, DIPEA and3-diethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.16 (s, 1H), 4.00 (t, 2H), 3.80 (t,1H), 3.55 (m, 1H), 3.26 (m, 2H), 2.44 (m, 2H), 2.22 (s, 6H), 2.06 (m,2H), 1.85 (m, 2H), 1.74-1.76 (m, 5H), 1.27 (t, 1H), 1.07 (t, 3H), 0.83(d, 3H). m/z: 474 [M+H]

Example 1146-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide (143)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide, DIPEA and3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.76 (s, 1H), 3.83 (t, 1H), 3.75 (m,2H), 3.46 (m, 2H), 3.26 (m, 2H), 2.84 (m, 1H), 2.22 (s, 6H), 2.12 (m,2H), 1.85-1.72 (m, 4H), 1.27 (t, 1H), 1.07 (t, 1H), 0.83 (d, 3H). m/z:499 [M+H]

Example 1156-Chloro-2-((S)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide (144)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.76 (s, 1H), 3.83 (t, 1H),3.75 (m, 2H), 3.46 (m, 2H), 3.26 (m, 2H), 2.84 (m, 1H), 2.22 (s, 6H),2.12 (m, 2H), 1.85-1.72 (m, 4H), 1.27 (t, 1H), 1.07 (t, 1H), 0.83 (d,3H). m/z: 499 [M+H]

Example 1166-Chloro-2-((R)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide (145)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.76 (s, 1H), 3.83 (t, 1H),3.75 (m, 2H), 3.46 (m, 2H), 3.26 (m, 2H), 2.84 (m, 1H), 2.22 (s, 6H),2.12 (m, 2H), 1.85-1.72 (m, 4H), 1.27 (t, 1H), 1.07 (t, 1H), 0.83 (d,3H). m/z: 499 [M+H]

Example 1176-Chloro-2-((R)-3-fluoro-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide (146)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (d, 1H), 4.72 (s, 1H),3.80-3.58 (m, 3H), 3.26 (m, 2H), 2.59 (m, 1H), 2.22 (m, 1H), 2.08 (1H),1.85-1.72 (m, 2H), 1.50 (m, 1H), 1.33-1.20 (m, 3H). m/z: 474 [M+H]

Example 1186-Chloro-2-((S)-3-fluoro-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide (147)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (d, 1H), 4.72 (s, 1H),3.80-3.58 (m, 3H), 3.26 (m, 2H), 2.59 (m, 1H), 2.22 (m, 1H), 2.08 (1H),1.85-1.72 (m, 2H), 1.50 (m, 1H), 1.33-1.20 (m, 3H). m/z: 474 [M+H]

Example 119 6-Chloro-2-(3-fluoro-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide (148)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-trifluoromethyl-cyclohexylmethyl)-amide, DIPEA and3-fluoro-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H), 7.85(m, 1H), 7.58 (2H), 7.05 (1H), 5.43-5.56 (d, 1H), 4.72 (s, 1H),3.80-3.58 (m, 3H), 3.26 (m, 2H), 2.59 (m, 1H), 2.22 (m, 1H), 2.08 (1H),1.85-1.72 (m, 2H), 1.50 (m, 1H), 1.33-1.20 (m, 3H). m/z: 474 [M+H]

Example 1206-Chloro-2-(3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylic acid(1-hydroxy-3-cyclopropyl-cyclohexylmethyl)-amide (149)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-cyclopropyl-cyclohexylmethyl)-amide, DIPEA and3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75 (1H),7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.26 (s, 1H), 3.87 (t, 1H), 3.75 (m,2H), 3.56 (m, 1H), 3.49 (m, 1H), 3.36 (m, 2H), 3.24 (m, 2H), 2.84 (m,1H), 2.22 (s, 6H), 1.85 (m, 1H), 1.67 (m, 2H), 1.44-1.38 (m, 4H), 1.27(m, 2H), 0.30 (m, 2H), 0.23 (m, 2H). m/z: 458 [M+H]

Example 1216-Chloro-2-((S)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (1-hydroxy-3-cyclopropyl-cyclohexylmethyl)-amide (150)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-cyclopropyl-cyclohexylmethyl)-amide, DIPEA and(S)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.26 (s, 1H), 3.87 (t, 1H),3.75 (m, 2H), 3.56 (m, 1H), 3.49 (m, 1H), 3.36 (m, 2H), 3.24 (m, 2H),2.84 (m, 1H), 2.22 (s, 6H), 1.85 (m, 1H), 1.67 (m, 2H), 1.44-1.38 (m,4H), 1.27 (m, 2H), 0.30 (m, 2H), 0.23 (m, 2H). m/z: 458 [M+H]

Example 1226-Chloro-2-((R)-3-dimethylamino-pyrrolidin-1-yl)-quinoline-5-carboxylicacid (1-hydroxy-3-cyclopropyl-cyclohexylmethyl)-amide (151)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-cyclopropyl-cyclohexylmethyl)-amide, DIPEA and(R)-3-dimethylamino-pyrrolidine. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.75(1H), 7.85 (m, 1H), 7.58 (2H), 7.05 (1H), 4.26 (s, 1H), 3.87 (t, 1H),3.75 (m, 2H), 3.56 (m, 1H), 3.49 (m, 1H), 3.36 (m, 2H), 3.24 (m, 2H),2.84 (m, 1H), 2.22 (s, 6H), 1.85 (m, 1H), 1.67 (m, 2H), 1.44-1.38 (m,4H), 1.27 (m, 2H), 0.30 (m, 2H), 0.23 (m, 2H). m/z: 458 [M+H]

Example 1231-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-yl}-piperidine-3-carboxylicacid ethyl ester (55)

The title compound was synthesized according to the procedure describedin example 1 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-cyclopropyl-cyclohexylmethyl)-amide, andPiperidine-3-carboxylic acid ethyl ester. ¹H NMR (400 MHz, DMSO-d₆): δ8.73-8.75 (m, 1H), 7.74 (d, J=9.51 Hz, 1H), 7.51-7.56 (m, 2H), 7.35 (d,J=9.52 Hz, 1H), 4.42 (d, J=2.81 Hz, 1H), 4.04-4.12 (m, 3H), 3.36-3.38(m, 1H), 3.22-3.25 (m, 3H), 2.54-2.57 (m, 1H), 1.96-2.03 (m, 3H),1.69-1.85 (m, 7H), 1.51 (s, 1H), 1.25-1.29 (m, 2H), 1.16-1.19 (m, 3H).m/z: 494.3 [M+H]⁺

Example 1241-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-yl}-piperidine-3-carboxylicacid (79)

1-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-yl}-piperidine-3-carboxylicacid ethyl ester was hydrolysed to the desired product with 2.5 Maqueous sodium hydroxide. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.41 (s, 1H),8.72-8.75 (m, 1H), 7.73 (d, J=9.41 Hz, 1H), 7.50-7.56 (m, 2H), 7.35 (d,J=9.51 Hz, 1H), 4.48-4.51 (m, 1H), 4.18-4.21 (m, 1H), 3.15-3.25 (m, 4H),2.48-2.52 (m, 1H), 1.97-2.03 (m, 3H), 1.82-1.85 (m, 3H), 1.63-1.76 (m,4H), 1.45-1.51 (m, 1H), 1.27-1.31 (m, 2H). m/z: 466.3 [M+H]⁺

Example 125 6-Chloro-2-cyclopent-1-enyl-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (42)

2,6-Dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (300 mg, 0.74 mmol, 1.00 eq) in1,4-Dioxane (6 mL, 69.44 mmol, 20 V)/Water (2 mL, 111.02 mmol, 6.67 V)was taken in a microwave vial and to this were added Cesium fluoride(338.80 mg, 2.23 mmol, 3.00 eq) and2-Cyclopent-1-enyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (172.97 mg,0.89 mmol, 1.20 eq). The reaction mixture was purged with nitrogen for15 min and bis(triphenyl phosphine)palladium (II) dichloride (25.16 mg,0.04 mmol, 0.05 eq) was added and heated under microwave at 130 OC for 1h. The reaction mixture was concentrated and the crude obtained waspurified by flash column chromatography to afford the title compound (12mg, 0.03 mmol, 3.9%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.85(t, J=5.64 Hz, 1H), 7.95-7.98 (m, 3H), 7.75 (d, J=9.0 Hz, 1H), 6.88 (s,1H), 3.26-3.29 (m, 2H), 2.85-2.89 (m, 2H), 2.60 (s, 2H), 1.96-2.04 (m,4H), 1.81-1.86 (m, 3H), 1.74-1.77 (m, 2H), 1.23-1.33 (m, 2H). m/z: 405[M+H]⁺

Example 126 6-Chloro-2-cyclopentyl-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (43)

To a solution of 6-chloro-2-cyclopent-1-enyl-quinoline-5-carboxylic acid(4,4-difluoro-cyclo hexyl methyl)-amide (110.00 mg, 0.25 mmol, 1.00 eq)in methanol (15 mL, 136.36 V) was added palladium on carbon (10% w/w)(20 mg, 0.02 mmol, 0.08 eq) under argon atmosphere. Triethylsilane (0.40mL, 2.49 mmol, 10 eq) was added to the reaction mixture and stirred for30 min. The reaction mixture was filtered through a Celite bed and thefiltrate was concentrated to provide a crude product which was purifiedby preparative HPLC to afford the title compound (18 mg, 0.04 mmol,17.5%) as a white solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.80 (t, J=5.80Hz, 1H), 7.94-8.01 (m, 2H), 7.75 (d, J=9.01 Hz, 1H), 7.58 (d, J=8.72 Hz,1H), 3.39-3.40 (m, 1H), 3.27 (t, J=6.21 Hz, 2H), 2.02-2.11 (m, 4H),1.64-1.86 (m, 11H), 1.27-1.33 (m, 2H). m/z: 407 [M+H]⁺

Example 127 2,6-Di-cyclohex-1-enylquinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (40)

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide, cyclohexene-1-yl-boronic acid,cesium carbonate and tetrakis(triphenylphosphine)palladium (0). ¹H NMR(400 MHz, DMSO-d₆): δ 8.83 (t, J=5.9 Hz, 1H), 7.89-8.00 (m, 3H),7.73-7.76 (m, 1H), 6.91 (s, 1H), 3.27 (t, J=6.2 Hz, 2H), 2.65-2.66 (m,2H), 2.31-2.32 (m, 2H), 1.86-2.01 (m, 2H), 1.74-1.76 (m, 3H), 1.65-1.67(m, 6H), 1.27-1.30 (m, 2H). m/z: 419 [M+H]⁺

Example 128 6-Chloro-2-cyclohexyl-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (48)

The title compound was synthesized according to the procedure describedin example 126 using 6-chloro-2-cyclohex-1-enyl-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexyl methyl)-amide, palladium on carbon andtriethylsilane. ¹H NMR (400 MHz, DMSO-d₆): δ ppm 8.78-8.80 (m, 1H),7.96-7.95 (m, 1H), 7.76 (d, J=9.04 Hz, 1H), 7.59 (d, J=8.80 Hz, 1H),3.25-3.40 (m, 2H), 2.85-2.95 (m, 1H), 2.01-2.15 (m, 2H), 1.86-1.99 (m,10H), 1.55-1.60 (m, 2H), 1.40-1.45 (m, 2H), 1.23-1.26 (m, 3H). m/z: 421[M+H]⁺

Example 1296-Chloro-2-(3,6-dihydro-2H-pyran-4-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclo hexyl methyl)-amide (31)

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, cesium carbonate,4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyranand tetrakis(triphenylphosphine)palladium (0). ¹H NMR (400 MHz,DMSO-d₆): δ ppm 8.85 (t, J=6.00 Hz, 1H), 7.95-8.05 (m, 3H), 7.77 (d,J=9.00 Hz, 1H), 6.98 (s, 1H), 4.33-4.35 (m, 2H), 3.86 (t, J=5.48 Hz,2H), 3.26-3.28 (m, 2H), 2.66-2.70 (m, 2H), 2.00-2.07 (m, 2H), 1.74-1.87(m, 5H), 1.23-1.31 (m, 2H). m/z: 421 [M+H]⁺

Example 130 6-Chloro-2-(tetrahydro-pyran-4-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexyl methyl)-amide (47)

The title compound was synthesized according to the procedure describedin example 126 using6-chloro-2-(3,6-dihydro-2H-pyran-4-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, palladium on carbon andtriethylsilane. ¹H NMR (400 MHz, DMSO-d₆): δ 8.80 (t, J=5.92 Hz, 1H),7.97-8.04 (m, 2H), 7.77 (d, J=9.00 Hz, 1H), 7.62 (d, J=8.76 Hz, 1H),3.96-4.00 (m, 2H), 3.45-3.52 (m, 2H), 3.25-3.27 (m, 2H), 3.11-3.17 (m,1H), 2.01-2.04 (m, 2H), 1.80-1.90 (m, 7H), 1.74-1.77 (m, 2H), 1.23-1.33(m, 2H). m/z: 423 [M+H]⁺

Example 131 6-Chloro-2-cyclopentyl-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclo hexyl methyl)-amide (7)

Step 1. 6-Chloro-2-cyclopent-1-enyl-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, cesium carbonate,2-cyclopent-1-enyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane andtetrakis(triphenylphosphine)Palladium (0). ¹H NMR (400 MHz, DMSO-d₆): δ8.63 (t, J=5.91 Hz, 1H), 8.06 (d, J=8.91 Hz, 1H), 7.96 (dd, J=4.41, 8.91Hz, 2H), 7.73 (d, J=9.02 Hz, 1H), 6.89 (s, 1H), 4.18 (s, 1H), 3.29 (s,1H), 2.85-2.87 (m, 2H), 2.48-2.49 (m, 2H), 1.96-2.03 (m, 1H), 1.45-1.78(m, 6H), 1.28-1.32 (m, 5H).

Step 2: 6-Chloro-2-cyclopentyl-quinoline-5-carboxylic acid((1S,3S)-1-hydroxy-3-methyl-cyclo hexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 126 using 6-chloro-2-cyclopent-1-enyl-quinoline-5-carboxylicacid ((1S,3S)-1-hydroxy-3-methyl-cyclohexyl methyl)-amide. ¹H NMR (400MHz, DMSO-d₆): δ 8.59 (t, J=6.03 Hz, 1H), 8.10 (d, J=8.81 Hz, 1H), 7.95(d, J=9.23 Hz, 1H), 7.75 (d, J=8.81 Hz, 1H), 7.59 (d, J=8.81 Hz, 1H),3.37-3.39 (m, 1H), 3.29-3.30 (m, 2H), 2.06-2.08 (m, 2H), 1.67-1.87 (m,7H), 1.54-1.65 (m, 4H), 1.12-1.47 (m, 1H), 1.23-1.32 (m, 3H), 1.02-1.08(m, 1H), 0.83-0.85 (m, 3H) m/z: 401.2 [M+H]⁺

Example 132 6-Chloro-2-cyclopentyl-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide (15)

Step 1: 6-Chloro-2-cyclopent-1-enyl-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, cesium carbonate,2-cyclopent-1-enyl-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane andtetrakis(triphenylphosphine)Palladium (0). ¹H NMR (400 MHz, DMSO-d₆): δ8.63 (t, J=5.91 Hz, 1H), 8.06 (d, J=8.92 Hz, 1H), 7.96 (dd, J=4.43, 8.92Hz, 2H), 7.73 (d, J=9.01 Hz, 1H), 6.89 (s, 1H), 4.18 (s, 1H), 3.29 (s,1H), 2.85-2.87 (m, 2H), 2.48-2.49 (m, 2H), 1.96-2.03 (m, 1H), 1.45-1.78(m, 6H), 1.28-1.32 (m, 5H). m/z: 399.2 [M+H]⁺

Step 2: 6-Chloro-2-cyclopentyl-quinoline-5-carboxylic acid((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide

The title compound was synthesized according to the procedure describedin example 126 using 6-chloro-2-cyclopent-1-enyl-quinoline-5-carboxylicacid ((1R,3R)-1-hydroxy-3-methyl-cyclohexylmethyl)-amide, palladium oncarbon and triethylsilane. ¹H NMR (400 MHz, DMSO-d₆): δ 8.59 (t, J=6.01Hz, 1H), 8.10 (d, J=8.82 Hz, 1H), 7.96 (d, J=9.22 Hz, 1H), 7.75 (d,J=9.23 Hz, 1H), 7.59 (d, J=8.81 Hz, 1H), 3.35-3.39 (m, 1H), 3.29 (s,2H), 2.06-2.09 (m, 2H), 1.78-1.87 (m, 4H), 1.69-1.75 (m, 3H), 1.47-1.61(m, 4H), 1.47-1.48 (m, 1H), 1.23-1.29 (m, 1H), 1.03 (t, J=12.81 Hz, 1H),0.83-0.84 (m, 3H), 0.73-0.76 (m, 1H). m/z: 401.2 [M+H]⁺

Example 1336-Chloro-2-(3-dimethylaminocyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexyl methyl)-amide (152)

Step 1: 6-Chloro-2-(3-oxo-cyclopent-1-enyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, Cesium carbonate,3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-cyclopent-2-enone andtetrakis(triphenylphosphine)palladium (0). ¹H NMR (400 MHz, DMSO-d₆): δppm 8.89-8.92 (m, 1H), 8.12-8.24 (m, 2H), 7.88 (d, J=9.12 Hz, 1H), 7.11(d, J=3.43 Hz, 1H), 3.28-3.32 (m, 2H), 3.19-3.21 (m, 2H), 2.54-2.56 (m,2H), 1.98-2.05 (m, 2H), 1.75-1.87 (m, 4H), 1.15-1.34 (m, 2H). m/z: 423[M+H]⁺

Step 2: 6-Chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 126 using6-chloro-2-(3-oxo-cyclopent-1-enyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, palladium on carbon andtriethylsilane. m/z: 421 [M+H]⁺

Step 3. 6-Chloro-2-(3-dimethylaminocyclopentyl)-quinoline-5-carboxylicacid (4,4-difluoro-1-hydroxy-cyclohexyl methyl)-amide

To a stirred solution of6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexylmethyl)-amide (0.30 g, 0.28 mmol, 1.00eq) in DCM (15.00 ml, 50.00 V) were added Et₃N (0.09 g, 0.84 mmol, 3.00eq) and dimethylamine solution 2.0 M in THF (0.70 mL, 1.40 mmol, 5.00eq) at 0° C., and warmed to room temperature. The reaction mixture wasstirred at RT for 1 h and sodium triacetoxyborohydride (0.09 g, 0.42mmol, 1.50 eq) was added and the reaction mixture was stirred at RT for16 h and the solvent was removed under vacuum. The crude product waspurified by prep HPLC to provide6-chloro-2-(3-dimethylaminocyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexyl methyl)-amide (0.03 g, 0.06 mmol,22.3%, Brown solid). ¹H NMR (400 MHz, DMSO-d₆): δ 8.81 (t, J=5.82 Hz,1H), 8.01-7.96 (m, 2H), 7.76-7.74 (m, 1H), 7.60-7.56 (m, 1H), 7.56-3.28(m, 1H), 3.27-3.25 (m, 2H), 2.68-2.57 (m, 1H), 2.56-2.48 (m, 1H),2.25-2.16 (m, 1H), 2.15-2.07 (m, 6H), 2.06-1.96 (m, 5H), 1.96-1.90 (m,4H), 1.88-1.83 (m, 2H), 1.78-1.72 (m, 1H), 1.30-1.24 (m, 2H). m/z: 450.2[M+H]⁺

Example 1342-(3-Azetidin-1-yl-cyclopentyl)-6-chloro-quinoline-5-carboxylic acid(4,4-difluoro cyclohexylmethyl)-amide (153)

The title compound was synthesized according to the procedure describedin example 133 using6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, and azetidine hydrochloride. ¹HNMR (400 MHz, DMSO-d₆): δ 10.08 (m, 1H), 8.81 (t, J=4.41 Hz, 1H),8.06-8.03 (m, 1H), 8.00-7.96 (m, 1H), 7.81-7.77 (m, 1H), 7.62-7.58 (m,1H), 4.17-4.06 (m, 5H), 4.06-4.04 (m, 1H), 3.29-3.26 (m, 2H), 2.50-2.44(m, 5H), 2.07-2.03 (m, 3H), 1.90-1.84 (m, 7H), 1.78-1.74 (m, 1H),1.31-1.27 (m, 2H). m/z: 462.3 [M+H]⁺

Example 1356-Chloro-2-(3-pyrrolidin-1-yl-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluorocyclo hexyl methyl)-amide (154)

The title compound was synthesized according to the procedure describedin example 133 using6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, pyrrolidine, glacial acetic acidand sodium triacetoxyborohydride. ¹H NMR (400 MHz, DMSO-d₆): δ 8.80 (t,J=5.82 Hz, 1H), 8.01-7.95 (m, 2H), 7.76-7.74 (m, 1H), 7.61-7.56 (m, 1H),3.55-3.44 (m, 1H), 3.43-3.41 (m, 1H), 3.27 (t, J=6.2 Hz, 2H), 2.74-2.66(m, 1H), 2.64-2.50 (m, 1H), 2.27-2.24 (m, 1H), 2.10-1.99 (m, 5H),1.89-1.76 (m, 6H), 1.75-1.68 (m, 2H), 1.33-1.29 (m, 5H), 1.27-1.24 (m,2H). m/z: 476.2 [M+H]⁺

Example 136 6-Chloro-2-(3-hydroxy-cyclopentyl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexyl methyl)-amide (92)

To a stirred solution of6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide (30 mg, 0.07 mmol, 1.00 eq) in dryTHF (3 mL) was added NaBH₄ (5.34 mg, 0.14 mmol, 2.00 eq) at 0° C. andleft to stir at RT for 1 h. The reaction mixture was quenched with water(5 mL) and extracted with EtOAc (15 mL). The organic layer was washedwith brine, dried over Na₂SO₄, filtered and concentrated to afford crudeproduct which was purified using preparative HPLC to afford the titlecompound as (10.00 mg, 0.02 mmol, 32.9%) off-white gum. ¹H NMR (400 MHz,DMSO-d₆): δ 8.26-8.39 (bs, 1H), 7.98-8.20 (m, 1H), 7.53-7.72 (m, 2H),6.53-6.71 (m, 1H), 4.42 (d, J=5.52 Hz, 1H), 3.70 (d, J=3.83 Hz, 1H),3.48-3.51 (m, 2H), 2.08-2.37 (m, 6H), 1.69-2.05 (m, 8H), 1.26-1.49 (m,2H). m/z: 423 [M+H]⁺

Example 1376-Chloro-2-(3-dimethylamino-cyclopentyl)-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexyl methyl)-amide (155)

Step 1. 6-Chloro-2-(3-oxo-cyclopent-1-enyl)-quinoline-5-carboxylic acid(1-hydroxy-3-methylcyclo hexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexylmethyl)-amide, cesium carbonate,3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-cyclopent-2-enone and[1,1-bis(diphenylphosphino)ferrocene]dichloropalladium(II). ¹H NMR (400MHz, DMSO-d₆) δ ppm: 8.70 (t, J=6.04 Hz, 1H), 8.28-8.22 (m, 2H), 8.12(d, J=9.21 Hz, 1H), 7.86 (d, J=9.03 Hz, 1H), 7.13 (t, J=1.64 Hz, 1H),4.21 (s, 1H), 3.22-3.20 (m, 2H), 2.56-2.54 (m, 2H), 1.73 (t, J=3.41 Hz,1H), 1.62-1.56 (m, 4H), 1.48-1.45 (m, 1H), 1.32-1.25 (m, 1H), 1.06-1.00(m, 1H), 0.84 (d, J=6.63 Hz, 3H), 0.77-0.74 (m, 1H). m/z: 413.2 [M+H]⁺

Step 2. 6-Chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(1-hydroxy-3-methyl-cyclohexylmethyl)-amide

The title compound was synthesized according to the procedure describedin example 126 using6-chloro-2-(3-oxo-cyclopent-1-enyl)-quinoline-5-carboxylic acid(1-hydroxy-3-methylcyclo hexyl methyl)-amide, palladium on carbon andtriethylsilane.

Step 3. 6-Chloro-2-(3-dimethylamino-cyclopentyl)-quinoline-5-carboxylicacid (1-hydroxy-3-methyl-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 133 using6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(1-hydroxy-3-methylcyclohexyl methyl)-amide, and dimethylamine. ¹H NMR(400 MHz, DMSO-d₆) δ ppm (VTNMR: 80° C.): 8.26-8.24 (m, 1H), 8.11-8.09(m, 1H), 7.97-7.94 (m, 1H), 7.73-7.70 (m, 1H), 7.56-7.54 (m, 1H),3.87-3.85 (m, 1H), 3.46-3.33 (m, 3H), 2.77-2.49 (m, 1H), 2.25-1.34 (m,20H), 0.87-0.77 (m, 1H). m/z: 444.0 [M+H]⁺

Example 138 6-Chloro-2-(3-hydroxy-cyclopentyl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexyl methyl)-amide (94)

Step 1. 6-Chloro-2-(3-oxo-cyclopent-1-enyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclo hexyl methyl)-amide, cesium carbonate,3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-cyclopent-2-enone andtetrakis(triphenyl phosphine)palladium(0). ¹H NMR (400 MHz, DMSO-d₆) δppm 8.83-8.86 (bs, 1H), 8.27-8.29 (m, 1H), 8.22 (d, J=8.8 Hz, 1H),8.12-8.14 (m, 1H), 7.87 (d, J=9.1 Hz, 1H), 7.12 (s, 1H), 4.72 (s, 1H),3.42-3.44 (m, 2H), 3.20-3.22 (m, 2H), 2.55-2.57 (m, 2H), 2.07-2.10 (m,2H), 1.89-2.01 (m, 2H), 1.70-1.77 (m, 4H).

Step 2. 6-Chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide

The title compound was synthesized according to the procedure describedin example 126 using6-chloro-2-(3-oxo-cyclopent-1-enyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide, palladium on carbon andtriethylsilane. ¹H NMR (400 MHz, DMSO-d₆) δ ppm 8.74-8.77 (bs, 1H), 8.13(d, J=9.0 Hz, 1H), 7.96 (d, J=9.51 Hz, 1H), 7.76 (d, J=9.01 Hz, 1H),7.66 (d, J=8.81 Hz, 1H), 4.71 (s, 1H), 3.80-3.83 (m, 1H), 3.31-3.41 (m,2H), 2.60-2.72 (m, 2H), 2.41-2.50 (m, 1H), 2.31-2.40 (m, 2H), 2.00-2.12(m, 3H), 1.89-1.97 (m, 2H), 1.68-1.76 (m, 4H). m/z: 437.3 [M+H]⁺

Step 3. 6-Chloro-2-(3-hydroxy-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 136 using6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexyl methyl)-amide and NaBH₄. ¹H NMR (400MHz, DMSO-d₆): δ 88.72-8.76 (bs, 1H), 8.05-8.10 (m, 1H), 7.94 (d, J=9.51Hz, 1H), 7.72-7.76 (m, 1H), 7.54-7.63 (m, 1H), 4.68 (s, 2H), 4.25-4.26(m, 1H), 3.31-3.40 (m, 3H), 2.48-2.50 (m, 1H), 1.95-2.32 (m, 4H),1.81-1.92 (m, 3H), 1.72-1.79 (m, 2H), 1.63-1.71 (m, 5H). m/z: 439.2[M+H]⁺

Example 1396-Chloro-2-(3-dimethylaminocyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexyl methyl)-amide (156)

The title compound was synthesized according to the procedure describedin example 133 using6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexyl methyl)-amide, and dimethylamine. ¹HNMR (400 MHz, DMSO-d₆): δ 8.76 (d, J=6.2 Hz, 1H), 8.13 (t, J=5.6 Hz,1H), 8.11-7.96 (m, 1H), 7.79-7.77 (m, 2H), 7.59 (d, J=8.6 Hz, 1H),3.41-2.85 (m, 1H), 2.84-2.50 (m, 1H), 2.50-2.49 (m, 2H), 2.48-2.46 (m,6H), 2.25-2.07 (m, 1H), 2.01-1.91 (m, 4H), 1.90-1.85 (m, 5H), 1.73-1.69(m, 4H). m/z: 466.3 [M+H]⁺

Example 1402-(3-Azetidin-1-yl-cyclopentyl)-6-chloro-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxy-cyclohexylmethyl)-amide (157)

The title compound was synthesized according to the procedure describedin example 133 using6-chloro-2-(3-oxo-cyclopentyl)-quinoline-5-carboxylic acid(4,4-difluoro-1-hydroxycyclohexyl methyl)-amide, and azetidinehydrochloride in glacial acetic acid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.76(t, J=6.0 Hz, 1H), 8.11-8.06 (m, 1H), 7.97-7.94 (m, 1H), 7.76-7.73 (m,1H), 7.64-7.54 (m, 1H), 4.71 (s, 1H), 3.47-3.16 (m, 1H), 3.07-2.49 (m,4H), 2.23-2.02 (m, 1H), 2.01-1.95 (m, 6H), 1.90 (s, 6H), 1.64-1.59 (m,8H. m/z: 478.3 [M+H]⁺

Example 1414-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-yl}-3,6-dihydro-2H-pyridine-1-carboxylicacid tert-butyl ester (51)

The title compound was synthesized according to the procedure describedin example 125 using 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexylmethyl)-amide, cesium fluoride,4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylicacid tert-butyl ester and bis(triphenylphosphine)palladium(II)dichloride. ¹H NMR (400 MHz, DMSO-d₆): δ 8.85 (t, J=5.82 Hz, 1H),8.03-8.05 (m, 1H), 7.94-8.00 (m, 2H), 7.78 (d, J=9.01 Hz, 1H), 6.89 (s,1H), 4.12 (s, 2H), 3.57 (t, J=5.5 Hz, 2H), 3.28 (t, J=6.23 Hz, 2H), 2.73(s, 2H), 2.02-2.04 (m, 2H), 1.74-1.87 (m, 5H), 1.43 (s, 9H), 1.30-1.32(m, 2H). m/z: 519.0 [M+H]⁺

Example 1424-{6-Chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-yl}-piperidine-1-carboxylicacid tert-butyl ester (71)

The title compound was synthesized according to the procedure describedin example 126 using4-{6-chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-yl}-3,6-dihydro-2H-pyridine-1-carboxylicacid tert-butyl ester, palladium on carbon and triethylsilane. ¹H NMR(400 MHz, DMSO-d₆) δ ppm 8.80 (t, J=5.71 Hz, 1H), 8.00 (dd, J=10.82,9.12 Hz, 2H), 7.77 (d, J=9.04 Hz, 1H), 7.61 (d, J=8.80 Hz, 1H),4.07-4.10 (m, 2H), 3.05-3.11 (m, 2H), 2.87 (s, 3H), 2.01-2.04 (m, 2H),1.83-1.91 (m, 5H), 1.62-1.77 (m, 4H), 1.41 (s, 9H), 1.22-1.29 (m, 2H).m/z: 522.0 [M+H]⁺

Example 143 6-Chloro-2-piperidin-4-yl-quinoline-5-carboxylic acid(4,4-difluorocyclohexylmethyl)-amide (53)

To a stirred solution of4-{6-chloro-5-[(4,4-difluoro-cyclohexylmethyl)-carbamoyl]-quinolin-2-yl}-piperidine-1-carboxylicacid tert-butyl ester (50 mg, 0.09 mmol, 1.00 eq) in dichloromethane(5.00 mL, 77.14 mmol, 100 V) at 0 OC was added 4M HCl in dioxane (2 mL,8.00 mmol, 89.05 eq) dropwise under nitrogen. The reaction mixture wasstirred at RT for 2 h and the solvent was evaporated completely. Thecrude obtained was basified with 10% sodium bicarbonate solution and wasextracted with DCM. The organic layer was separated, dried over sodiumsulphate and concentrated under reduced pressure. The crude obtained waspurified by preparative HPLC to afford the title compound (10 mg, 0.02mmol, 24.5%) as a pale brown solid. ¹H NMR (400 MHz, DMSO-d₆): δ 8.79(t, J=5.91 Hz, 1H), 7.99 (dd, J=9.42, 9.0 Hz, 2H), 7.76 (d, J=9.03 Hz,1H), 7.58 (d, J=8.72 Hz, 1H), 3.43 (s, 1H), 3.25-3.29 (m, 2H), 3.03-3.06(m, 2H), 2.91-2.98 (m, 1H), 2.58-2.67 (m, 2H), 2.02-2.04 (m, 2H),1.64-1.84 (m, 9H), 1.23-1.30 (m, 2H). m/z: 422.0 [M+H]⁺

Example 144 6-Chloro-2-(1-methyl-piperidin-4-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexyl methyl)-amide (158)

Step 1.6-Chloro-2-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-quinoline-5-carboxylicacid (4,4-difluorocyclohexylmethyl)-amide

To a suspension of 2,6-dichloro-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (150 mg, 0.37 mmol, 1.00 eq) in1,4-Dioxane (4.00 mL, 26.67 V) and water (0.50 mL, 3.33 V) was degassedwith nitrogen for 15 minutes, then to this1-methyl-1,2,3,6-tetrahydropyridine-4-boronic acid pinacol ester (101.25mg, 0.44 mmol, 1.20 eq), cesium carbonate (362.17 mg, 1.10 mmol, 3.00eq) and [1,1-bis(diphenyl phosphino)ferrocene]dichloropalladium (II),complex with dichloromethane (30.15 mg, 0.04 mmol, 0.10 eq) were added,then the reaction mixture was heated in pressure tube at 100° C. for 5h. After completion of the reaction by TLC, the reaction mixture wascooled to room temperature, and filtered through celite, washed withethyl acetate, and the filtrate was concentrated under reduced pressureto provide the crude compound, which was purified by columnchromatography to afford the title compound (90 mg, 0.17 mmol, 47.5%) asa dark brown solid. m/z: 434.2 [M+H]⁺

Step 2. 6-Chloro-2-(1-methyl-piperidin-4-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 126 using6-chloro-2-(1-methyl-1,2,3,6-tetrahydro-pyridin-4-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide, palladium on carbon andtriethylsilane. ¹H NMR (400 MHz, DMSO-d₆) δ 8.80 (t, J=5.81 Hz, 1H),8.05 (d, J=8.72 Hz, 1H), 7.98 (d, J=9.01 Hz, 1H), 7.78 (d, J=9.01 Hz,1H), 7.61 (d, J=8.71 Hz, 1H), 3.27 (t, J=6.21 Hz, 4H), 3.04 (s, 1H),2.69 (s, 2H), 2.58 (s, 3H), 2.03 (s, 6H), 1.74-1.86 (m, 5H), 1.22-1.33(m, 2H). m/z: 436.0 [M+H]⁺

Example 1456-Chloro-2-(1-isopropyl-piperidin-4-yl)-quinoline-5-carboxylic acid(4,4-difluoro-cyclohexyl methyl)-amide (159)

Step 1.6-Chloro-2-(1-isopropyl-1,2,3,6-tetrahydro-pyridin-4-yl)-quinoline-5-carboxylicacid (4,4-di fluoro-cyclohexyl methyl)-amide

To a stirred solution of6-chloro-2-(1,2,3,6-tetrahydro-pyridin-4-yl)-quinoline-5-carboxylic acid(4,4-difluorocyclohexylmethyl)-amide (150.00 mg, 0.33 mmol, 1.00 eq) in1,2-dichloroethane (5.00 mL, 33.33 V) was added acetone (0.05 mL, 0.66mmol, 2.00 eq) and glacial acetic acid (0.04 mL, 0.66 mmol, 2.00 eq),then the reaction mixture was stirred at RT for 1 h and then cooled to0° C. Sodium cyanoborohydride (43.54 mg, 0.66 mmol, 2.00 eq) was addedand stirred at RT for 16 h. The solvent was removed and the crudeproduct was purified by flash column chromatography using to afford6-chloro-2-(1-isopropyl-1,2,3,6-tetrahydro-pyridin-4-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexyl methyl)-amide (100.00 mg, 0.21 mmol,62.5%, pale yellow solid). ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 8.83 (t,J=6.03 Hz, 1H), 8.00-7.96 (m, 3H), 7.76 (d, J=9.02 Hz, 1H), 6.91 (s,1H), 3.27 (t, J=6.12 Hz, 4H), 2.70-2.65 (m, 4H), 2.04-2.02 (m, 2H),1.86-1.74 (m, 5H), 1.33-1.17 (m, 2H), 1.05 (br s, 6H). m/z: 462.3 [M+H]⁺

Step 2. 6-Chloro-2-(1-isopropyl-piperidin-4-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexyl methyl)-amide

The title compound was synthesized according to the procedure describedin example 126 using6-chloro-2-(1-isopropyl-1,2,3,6-tetrahydro-pyridin-4-yl)-quinoline-5-carboxylicacid (4,4-difluoro-cyclohexylmethyl)-amide, palladium on carbon andtriethylsilane. ¹H NMR (400 MHz, DMSO-d₆) δ ppm: 8.79 (t, J=5.92 Hz,1H), 8.01 (d, J=8.71 Hz, 1H), 7.97 (dd, J=0.5, 9.02 Hz, 1H), 7.76 (d,J=9.02 Hz, 1H), 7.60 (d, J=8.81 Hz, 1H), 3.27 (t, J=6.23 Hz, 2H), 2.91(d, J=7.61 Hz, 3H), 2.82 (s, 1H), 2.25 (s, 2H), 2.03 (d, J=9.4 Hz, 2H),1.86-1.74 (m, 9H), 1.30-1.24 (m, 2H), 1.00 (d, J=5.8 Hz, 6H). m/z:464.20 [M+H]⁺

Example 146 IL-1β Release Assay

The activation of P2X7 by ATP leads to a fast transient activation ofcells resulting in influx of Ca²⁺ followed by conversion of pro-IL-1β toactive IL-1β. The functional activity of P2X7 compounds was measured bythe release of mature IL-1β in the culture medium of THP-1 cells,detected by sandwich ELISA. Cells were maintained in complete growthmedium (RPMI 1640+10% HI-FCS+2 mM L-glutamine+1×PS). Every 3 days, themedium was renewed by diluting the cells ⅓ to ¼ as cell density did notexceed 0.5 million cells per ml (seeding cell density @ 1×10⁵/ml). THP-1cells were harvested from the flask in 50 ml by centrifugation for 3 minat 100 g. The cells were resuspended to 2×10⁵ cells/ml in mediumsupplemented with 0.5 μM PMA and incubated. The cells were washed andresuspended to 1.5×10⁵ cells/ml in medium complemented with 10 ng/mlLPS, and the cells were primed for 4 h at 37° C., 5% CO₂. After additionof 20 μL of prediluted test compounds, blank, standard and controlreagents, cells were incubated for a further 20 min at 37° C. andstimulated with 0.8 mM BzATP for 30 minutes. The cells were centrifuged,supernatant was collected and the presence of mature IL-1β was detectedusing Dual human IL-1b kit following manufacturer's instruction. Thetetrahydrobenzodiazepine analogs effectively modulated the activity ofP2X7 in the cells as measured by the levels of pro-inflammatory cytokineIL-1β, which is released by the activation of P2X7 receptor.

Pore Permeation Assay

Agonist-induced pore formation was determined by measuring cellularuptake of YO PRO fluorescence dye in HEK293 transfected with human P2X7receptor. A HEK293 cell over expressing human P2X7 was harvested usingHQTase reagent to detach the cells from T75 cm flask. The harvestedcells are centrifuged @ 1200 rpm for 5 min at room temperature. Theviability of cells was determined by Trypan blue dye and the cells areplated @ 10,000 cell/well in 50 ul volume in a 384 W BD Poly lysinecoated plate and incubated overnight at 37 C. After overnightincubation, the culture medium was replaced with 35 ul/well assay buffer(5 mM KCl, 0.1 mM CaCl2, 5 mM Glucose, 10 mM HEPES buffer pH7.4containing 125 mM NaCl. The serial dilution of compounds was performedusing Bravo liquid handling instrument and the compounds were addedusing Bravo to the cell assay plate starting at 2.5 uM with threedilutions for 10 points. The positive control inhibitor compound wasadded to column 23. The plate was shaken slowly on a plate shaker for 10seconds. The cells were incubated with the compound for 20 minutes atroom temperature. After the incubation period, YO PRO dye (1 uM) alongwith BzATP (10 uM) were added to cells at 10 ul/well. The plate wascentrifuged at 1000 rpm for 5 seconds and incubated at room temperaturefor 30 minutes. The uptake of YO PRO dye into the cells was measuredusing Envision Fluorescence plate reader instrument (Perkin Elmer).

The data is interpreted according to the following:

E >1 μM;

D 500-999 nM;

C 101-500 nM;

B 10-100 nM;

A <10 nM.

Compound hP2X7 hTHP-1/IL-ib number IC50 IC50 1 A B 2 A 3 A C 4 A A 5 A B6 A B 7 A 8 A B 9 A B 10 A B 11 A C 12 A C 13 A A 14 A 15 A 16 A 17 A B18 A B 19 A B 20 B B 21 B B 22 B 23 B B 24 B B 25 B B 26 B C 27 B B 28 BB 29 B B 30 B B 31 B C 32 B B 33 B C 34 B B 35 B B 36 B B 37 B B 38 B B39 B B 40 B C 41 B B 42 B C 43 B 44 B B 45 B B 46 B B 47 B C 48 B C 49 BB 50 B C 51 B C 52 B C 53 B 54 B C 55 B E 56 B B 57 B 58 B C 59 B C 60 BC 61 B C 62 B C 63 B C 64 B C 65 B C 66 B B 67 B C 68 B D 69 B C 70 B C71 B 72 B 73 B C 74 C C 75 C C 76 C B 77 C 78 C B 79 C 80 C E 81 C 82 C83 E

Example 147 Pharmaceutical Preparations

(A) Injection vials: A solution of 100 g of an active ingredientaccording to the invention and 5 g of disodium hydrogen phosphate in 3 lof bidistilled water is adjusted to pH 6.5 using 2 N hydrochloric acid,sterile filtered, transferred into injection vials, is lyophilized understerile conditions and is sealed under sterile conditions. Eachinjection vial contains 5 mg of active ingredient.

(B) Suppositories: A mixture of 20 g of an active ingredient accordingto the invention is melted with 100 g of soy lecithin and 1400 g ofcocoa butter, is poured into moulds and is allowed to cool. Eachsuppository contains 20 mg of active ingredient.

(C) Solution: A solution is prepared from 1 g of an active ingredientaccording to the invention, 9.38 g of NaH₂PO₄.2H₂O, 28.48 g ofNa₂HPO₄.12H₂O and 0.1 g of benzalkonium chloride in 940 ml ofbidistilled water. The pH is adjusted to 6.8, and the solution is madeup to 1 l and sterilized by irradiation. This solution could be used inthe form of eye drops.

(D) Ointment: 500 mg of an active ingredient according to the inventionis mixed with 99.5 g of Vaseline under aseptic conditions.

(E) Tablets: A mixture of 1 kg of an active ingredient according to theinvention, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and0.1 kg of magnesium stearate is pressed to give tablets in aconventional manner in such a way that each tablet contains 10 mg ofactive ingredient.

(F) Coated tablets: Tablets are pressed analogously to Example E andsubsequently are coated in a conventional manner with a coating ofsucrose, potato starch, talc, tragacanth and dye.

(G) Capsules: 2 kg of an active ingredient according to the inventionare introduced into hard gelatin capsules in a conventional manner insuch a way that each capsule contains 20 mg of the active ingredient.

(H) Ampoules: A solution of 1 kg of an active ingredient according tothe invention in 60 l of bidistilled water is sterile filtered,transferred into ampoules, is lyophilized under sterile conditions andis sealed under sterile conditions. Each ampoule contains 10 mg ofactive ingredient.

(I) Inhalation spray: 14 g of an active ingredient according to theinvention are dissolved in 10 l of isotonic NaCl solution, and thesolution is transferred into commercially available spray containerswith a pump mechanism. The solution could be sprayed into the mouth ornose. One spray shot (about 0.1 ml) corresponds to a dose of about 0.14mg.

While a number of embodiments of this invention are described herein, itis apparent that the basic examples may be altered to provide otherembodiments that utilize the compounds and methods of this invention.Therefore, it will be appreciated that the scope of this invention is tobe defined by the appended claims rather than by the specificembodiments that have been represented by way of example.

We claim:
 1. A compound of formula I,

or a pharmaceutically acceptable salt thereof, wherein: R¹ is hydrogen, C₁₋₆ aliphatic, C₅₋₁₀ aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a fused 7-10 membered bicyclic saturated, partially unsaturated ring, aryl, or heteroaryl ring; each of which is optionally substituted by 1-5 of R^(A); or R¹ is —OR, —SR, —CN, —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂, —NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂; each R^(A) is independently —R, halogen, -haloalkyl, -hydroxyalkyl, —OR, —SR, —CN, —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂, —NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂; wherein when R¹ is a 3-7 membered heterocylic ring having 1-4 nitrogen, wherein one nitrogen is attached to the quinoline ring, then R^(A) is —R, halogen, -haloalkyl, -hydroxyalkyl, —SR, —CN, —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂, —NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂; wherein when R¹ is a 3-7 membered heterocylic ring having 1-4 nitrogen, wherein one nitrogen is attached to the quinoline ring, and R^(A) is —OR, then at least one R² is halogen; Z is O, S, SO₂, SO, C(O), CO₂, C(O)N(R), NRC(O), NRC(O)N(R), NRSO₂, or N(R); Ring A is a 3-8 membered saturated or partially unsaturated carbocyclic ring, or a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each R² is independently —R, halogen, -haloalkyl, —OR, —SR, —CN, —NO₂, —SO₂R, —SOR, —C(O)R, —CO₂R, —C(O)N(R)₂, —NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂; or two R² groups on the same atom are taken together with the atom to which they are attached to form a C₃₋₁₀ aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; each R is independently hydrogen, C₁₋₆ aliphatic, C₃₋₁₀ aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or two R groups on the same atom are taken together with the atom to which they are attached to form a C₃₋₁₀ aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; m is 0, 1, or 2; and n is 1, 2, 3, 4, or 5; wherein, at least one of R^(A) or R² is halogen or haloalkyl, or at least one R² is —OR; and wherein, the following compounds are excluded: 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3S)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-[(3R)-3-hydroxypyrrolidin-1-yl]quinoline-5-carboxamide; 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-(4-hydroxypiperidin-1-yl]quinoline-5-carboxamide; and 6-chloro-N-{[(1S,3S)-1-hydroxy-3-methylcyclohexyl]methyl}-2-(3-hydroxy-3-methylpyrrolidin-1-yl]quinoline-5-carboxamide.
 2. The compound of claim 1, wherein at least one of R^(A) or R² is F, or at least one of R² is OH.
 3. The compound of claim 1, wherein R¹ is hydrogen.
 4. The compound of claim 1, wherein R¹ is


5. The compound of claim 1, wherein R¹ is C₅₋₁₀ aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a fused 7-10 membered bicyclic saturated, partially unsaturated ring, aryl, or heteroaryl ring; each of which is optionally substituted by 1-5 of R^(A).
 6. The compound of claim 1, wherein R¹ is —OR, —SR, —SO₂R, —SOR, —NRC(O)R, —NRC(O)N(R)₂, —NRSO₂R, or —N(R)₂.
 7. The compound of claim 1, wherein Z is C(O)N(R).
 8. The compound of claim 1, wherein Ring A is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, morpholinyl, tetrahydropyranyl, piperazinyl, piperidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, oxetanyl, or azetidinyl.
 9. The compound of claim 1, wherein Ring A is cyclohexyl or cycloheptyl.
 10. The compound of claim 1, wherein each R² is independently H.
 11. The compound of claim 1, wherein each R² is independently methyl, F, CF₃, or OH.
 12. The compound of claim 1, of formula II,

or a pharmaceutically acceptable salt thereof.
 13. The compound of claim 1, of formula III:

or a pharmaceutically acceptable salt thereof.
 14. The compound of claim 1, selected from Table 1

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160


161.


15. A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.
 16. A method for modulating P2X7 activity in a subject or in a biological sample, comprising the step of administering to said subject or contacting said biological sample with a compound of claim 1 or a physiologically acceptable salt thereof.
 17. A process for manufacturing a compound of formula I, comprising the steps of: reacting a compound of formula A:

wherein Z, Ring A, R², n, and m are as defined in claim 1; with a compound of formula H—R¹; wherein R¹ is as defined in claim 1; to yield a compound of formula I. 